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Abstract 
Introduction: Pharmacogenomics is an approach to personalizing therapy to help patients 
achieve their therapeutic goals with the least possible adverse events. This approach relies 
on the knowledge derived from large genetic studies that involve diverse populations to 
guide the development of treatment algorithms. The underrepresentation of select 
populations or unique sub-populations in genetic-based research presents as a gap in 
knowledge to create comprehensive genetic-based treatment algorithms and a missed 
opportunity to address health disparities within those unique populations. A prime 
example is the Minnesota Hmong. The Hmong is an Asian sub-population minimally 
represented in clinical or genetic-based research with a high prevalence of gout and gout-
related comorbidities than non-Hmong.    
Methods: Using the principles of community-based participatory research and the 
establishment of the Hmong advisory board, assessment of the community’s perception of 
genetics and preparedness for engagement in research were conducted. Capitalizing on the 
findings from the first informational study, two Hmong genetic-based studies were 
conducted. The first study was to ascertain the frequency of select pharmacogenes and 
disease-risk genes in the Hmong, relative to non-Hmong. The second study was to 
quantify the effect of genetic variations within uric acid transportome and purine 
metabolizing genes on the pharmacokinetics and pharmacodynamics of allopurinol in 
Hmong adults with gout or hyperuricemia.  
 
 vi 
Results: The informational study results indicated that most Hmong are willing to 
participate in research to help themselves and the Hmong community. Some of the genetic 
perceptions in the Hmong were not scientifically grounded and some concerns about 
privacy were reported while the return of genetic results to participants had mixed 
responses. The first genetic-based study indicated that more than 80% of Hmong 
participants were willing to store their DNA for future analyses and share their DNA with 
other scientists. Pharmacogenes risk allele frequencies of CYP2C19, CYP2C9, VKORC1, 
and CYP4F2 were higher in the Hmong relative to Caucasian.  Disease risk allele 
frequencies of hyperuricemia and gout associated genes such as SLC2A9, SLC17A1, 
SLC22A11, SLC22A12, ABCG2, PDZK1, were also higher in the Hmong than Caucasian 
and Han-Chinese. The second genetic-based study indicated that the genetic variation 
within SLC22A12 (rs505803T>C) significantly affects the exposure to and the renal 
clearance of the active metabolite of allopurinol, oxipurinol. Additionally, the rs505802 
was also significantly associated with the overall response to allopurinol.   
Conclusions: Engaging the Hmong in genetic-based research is a step forward to advance 
precision medicine while addressing health disparities within the Hmong community. The 
prevalence of pharmacogenes within the Hmong suggest that the Hmong will require a 
lower starting dose of warfarin and unlikely to benefit from clopidogrel. The prevalence of 
hyperuricemia and gout associated risk alleles in the Hmong are consistent with the higher 
prevalence of gout in the Hmong. Finally, the rs505802 T>C within SLC22A12 gene 
could predict the overall response to allopurinol.   
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Chapter 1  
Review Article 
Perspectives on Health Disparities of Gout within the Minnesota Hmong and the 
Opportunities for Genetic-Based Investigational Studies 
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Chapter Overview 
The purpose of this chapter is to give a brief introduction to the history and culture 
of the Hmong. The chapter also highlights some key health disparities within the Hmong, 
primarily gout and gout-related comorbidities. Additionally, the chapter explores some 
barriers associated with engaging minorities in clinical and genetic-based research. 
Moreover, the chapter presents key principles for conducting clinical and genetic-based 
research in minority groups. The chapter concludes with an example of building a 
community engagement research group to ultimately reduce ongoing health disparities 
within the Minnesota Hmong and potential research opportunities within this unique 
population.   
The History and Demographics of the Hmong 
The Hmong are a distinct Asian ancestral group originated from the southern parts 
of China and migrated to mountainous areas of Laos, Thailand, Vietnam, and Cambodia. 
In spite of their continuous migration, many of the Hmong maintained their agrarian 
lifestyles in their respective geographical areas.1 During the Vietnam War, the Hmong 
became allies with the United States, which ultimately facilitated many Hmong refugees 
to resettle in the United States at the conclusion of the Vietnam War.2 The Hmong 
population in the US has grown since 1975 with a 40% increase from 2000 to 2010. Per 
the 2010 US Census, the Hmong number more than 260,000. The Hmong population is 
not equally distributed across the US, rather it is clustered in three major states. The three 
largest Hmong communities in the US, in a descending order, are California (91,224), 
Minnesota (66,181), and Wisconsin (49,240).  The metropolitan areas with the highest 
 3 
number of Hmong, in a descending order, are Minneapolis-Saint Paul, MN; Sacramento 
and Fresno, CA; and Milwaukee, WI. 3 
The Hmong society is kinship-based and places tremendous emphasis on lineage and 
clan ties for security and mutual assistance. Making a medical decision within the Hmong 
is a communal act rather than an individual choice.4 To illustrate, in medical crises or 
serious illness, the individual could travel long distances to consult with other members or 
the leader of the clan to make such a decision. In addition, the Hmong beliefs also play a 
major role in their health-related decisions. As an example, many of the Hmong are 
hesitant about the effectiveness of western medicine and tend to opt out of the western 
medicine because it contradicts with their beliefs.1 One of the predominant belief systems 
in the Hmong is the Animism (Shamanism) religion. The followers of this religion believe 
that illness or sickness of the body is due to a separation or loss of one’s soul. This belief 
system can in part explain the rationale of why a high percentage of Hmong tend to be 
reluctant to donate blood or undergo certain types of surgeries that can result in organ 
removal or loss. Nonetheless, engaging in soul calling worship is a major practice for 
healing among the Hmong who are experiencing an illness or disease. 2 However, these 
beliefs and practices tend to be greatly influenced by the elderly, newly arrived into the 
US, and the less educated.  Although the health belief system within the Hmong is on a 
continuum scale, this gradient within their belief system has substantially influenced the 
health of Hmong community, perception of medical care, and reception and engagement 
in clinical research.  
The Hmong also present with a high and differential prevalence of major disease 
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risk factors as well as certain disease states compared to other ethnic groups, mainly 
Caucasians.  Anecdotal reports and primary research suggest higher incidence of gout, 
obesity, diabetes, hypertension, hepatitis, and select types of cancer in the Hmong 
community compared to non-Hmong or non-Hispanic whites.2,5-7  Nonetheless, there is 
very limited systematically-collected information on the prevalence of these diseases in 
the US vs. their homeland and epidemiological research comparing the development of 
these diseases in their new environments vs. their native homeland. This lack of data could 
be attributed to the continuous migration lifestyle of the Hmong while living in their 
native lands, resettlements in refugee camps after the Vietnam War, and eventually 
immigrating to the US. In the absence of such data allows us to propose the role of two 
theorems that could explain the differential prevalence of those health conditions between 
Hmong and non-Hmong.  
The first theory is the Epigenetic Theory of Change, which involves the role of 
exposure to different environmental factors that could modulate the levels of expression of 
certain genes. Thus, the change of environment could ultimately modulate the person’s 
disease risk. The second theory is the Paradoxical Theory of Change by Gestalt, the 
change that occurs when one becomes what he is, not when he tries to become what he is 
not, may be relevant to the Hmong’s situation in that behavioral changes and acculturation 
due to change of environment could influence the person’s disease risk. By combining the 
two theorems, we suggest that adapting to a western diet and lifestyle could have an 
impact on the onset of the disease or unmask the individual’s propensity to develop certain 
diseases. However, data on the prevalence of these disease states in the Hmong’s 
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homeland is needed to cement this rationale. 
Gout Prevalence across Racial Groups 
Gout is the most common inflammatory arthritis and is caused by the deposition of 
monosodium urate crystals in the distal joints. The formation of monosodium urate 
crystals is generally preceded by chronic elevation of serum uric acid levels also known as 
hyperuricemia. The global prevalence of gout is roughly 0.1%.8 However, the accurate 
estimation of gout prevalence in certain countries or racial groups can greatly differ owing 
to variations in the methodologies used in in those studies.  These limitations include 
failure to qualify such estimates across sex, age bands, different case definition of gout 
and calendar year.  Those studies reporting the prevalence of gout relying on “self-report” 
are also prone to recall bias.  Furthermore, the classifications of race and ethnicity may 
also confound the interpretations of gout prevalence, especially in a high admixture 
population where self-report of race or ethnicity is imprecise. Irrespective of the 
inconsistency of the methodologies used in different studies, the Oceanian countries 
particularly with ethnic groups such as Taiwanese aboriginals and Maori remain to have 
the highest prevalence of gout reported in which some estimates in excess of 10%.9 The 
notable high prevalence of gout in these populations may be attributable to a cultural 
specific diet and lifestyle as well as genetic predispositions for hyperuricemia or gout.  
In Europe, Greece has the highest prevalence of gout with an estimate of 4.75% 
while the prevalence of gout in the UK is  2.49% of the entire population (Figure 1.1).10 In 
contrast, gout is reportedly rare in former Soviet Union regions, Guatemala, Iran, 
Malaysia, and Philippines. In North America, the prevalence of gout in the US was 
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estimated to be 3.9% of adults.11 Although not statistically significant, the data from the 
Third National Health and Nutrition Examination Survey (NHANES) 2007-2008 showed 
that blacks have a higher prevalence of gout with 5.0% compared to whites with 3.9%. In 
Japan, although lower relative to other populations, the prevalence of hyperuricemia and 
gout have been shown to be trending upward which parallels the upward trend in the 
utilization of urate lowering therapies. Specifically, the prevalence of gout among 
Japanese men has nearly doubled from 0.86% to 1.67% from 1969 to 2003.12,13 This 
dramatic increase of gout prevalence amongst Japanese should be also assessed in the 
context of other trends that could contribute to new onset of gout such as the increased 
prevalence of western diet and obesity. In fact, a 3 to 4-fold increase in obesity rates in 
Japanese women and men were reported from 1962 to 2002, which could greatly explain 
the twofold increase in gout prevalence. 14 
These upward trends across different populations are consistent with the global 
increase of hyperuricemia and gout. However, this increase of prevalence of these two 
conditions should not be considered independent of other comorbidities and dietary habits 
that all of which can significantly contribute to the development of hyperuricemia and 
gout. For example, the increase of prevalence of obesity, chronic kidney disease, 
hypertension, and the use of drugs that treat these conditions are important confounders 
for this global phenomenon. In addition, the global consumption of high fructose corn 
syrup and alcohol are also important contributors to this global prevalence of gout and 
hyperuricemia.15,16 The focus of this chapter, however, will concentrate on the impact of 
dietary and lifestyle choices on the risk of developing gout.  
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Gout Prevalence in Minnesota Hmong 
The prevalence of gout in the Minnesota Hmong was estimated by two methods.  
These included self-reported gout and physician-diagnosed gout. The self-reported gout 
prevalence among the Minnesota Hmong was estimated from two cross-sectional 
community surveys then compared to the national data provided by NHANES III. In 
addition, physician-diagnosed gout was also estimated from Hmong residents in the Twin 
Cities from 11 primary care clinics. Findings from self-reported gout among the 
Minnesota Hmong (Figure 1.2) indicated that there was a 2-fold higher prevalence than 
the average US population reported in the NHANES III (6.5 % vs. 2.9%; p <0.001). While 
Hmong women reported having gout at a rate like non-Hmong women (1.9%), Hmong 
men were significantly more than likely to report gout than non-Hmong counterparts 
(11.5% vs. 4.1%; p<0.001).17Similarly, physician-diagnosed gout indicated that Hmong 
men were more than twice as likely compared to non-Hmong men seen at the same 
primary care clinics (6.1% vs. 2.5%, p<0.001), while Hmong women were equally as 
likely to be diagnosed with gout as non-Hmong women (0.8 % vs. 0.7%; p=0.833).17   
Gout is generally associated with other comorbidities that underscore the importance 
of optimal management of gout. In general, patients with gout generally present with 
multiple comorbidities that could be directly associated with acutely elevated SUA such as 
uric acid kidney stone or uric acid nephropathy.18 Other conditions associated with 
chronically elevated SUA could include hypertension, dyslipidemia, obesity, kidney 
disease and metabolic syndrome.11,18-20 The mechanisms by which chronic hyperuricemia 
or gout affect the development of cardiovascular diseases have been linked to decreased 
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production of endothelial nitric oxide, activation of the renin-angiotensin-aldosterone 
system, decrease insulin sensitivity, increased intra-glomerular pressure and glomerular 
sclerosis.21-23  
The high prevalence of gout among the Minnesota Hmong is also associated with 
other clinical manifestations such as uric acid kidney stones. A retrospective chart review 
of Hmong adults in a large urology group practice in the Twin Cities, 86 Hmong patients 
with kidney stones were compared to 86 non-Hmong patients with kidney stone of similar 
age, sex. Out of the 86 Hmong kidney stone patients, 24% had staghorn calculi vs. 0% in 
the non-Hmong patients with kidney stones. The surgical management of these calculi 
required more invasive treatment such as percutaneous nephrolithotomy, nephrectomy 
compared to non-Hmong. The composition of kidney stones was available for 40 Hmong 
and 39 non-Hmong. Stones with 100% uric acid were found in 35% and 5% of stones of 
Hmong and non-Hmong, respectively (P<0.001). The study concluded that a Hmong 
patient coming to a urologic attention is likely to be younger with four-fold higher risk for 
a stone disease than a non-Hmong patient counterpart. In addition, Hmong patients with 
stones were five-fold higher to have uric acid calculi compared to non-Hmong patients.24 
Collectively, these observations highlight the health burden of gout and gout-related 
comorbidities on the Hmong while being also associated with high direct and indirect 
healthcare cost. 
Hmong Perceptions of Managing Chronic Diseases 
The health belief model including the theory of Reasoned Action provides a 
framework to identify the underlying basis for certain health related behaviors in minority 
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populations. According to Barret et al 25 Hmong patients in general do not want to hear 
about the risks or the negative outcomes associated with a long-term treatment or the 
negative outcomes associated with unmanaged chronic diseases. This health belief model 
could explain why Hmong patients are more likely to seek treatment of acute symptomatic 
illnesses as opposed to chronic disease. This health-related behavior could well support 
the anecdotal reports that Hmong patients with gout tend to have a lower adherence rate to 
and suboptimal use of allopurinol compared to Caucasians.26 Hmong patients with gout 
are more than likely to self-medicate to seek relief from acute gout flares rather than 
follow a plan that potentially “cures” gout. This tendency is common in many Hmong 
patients due to their perceived lack of efficacy of the current Western treatment 
approaches and the rise of complementary and alternative medicinal (CAM) approaches - 
especially in rheumatic and musculoskeletal diseases.27   
It is important that clinicians are cognizant of their patients’ use of CAM to tailor the 
best approach for managing that individual’s condition. The use of CAM has been 
attributed to several reasons that are worthy of elaboration.  These reasons are categorized 
into two domains. The first includes access to healthcare and timeliness to obtain 
symptoms resolution.  Relying on a clinician-controlled decision can be ineffective in 
times of new or acute onset of pain.  Consequently, having access to some treatment or 
therapy that promises timely relief may be in the best interest to the patient.27,28 The 
second domain includes patient’s autonomy and the holistic belief system. Many patients 
utilize CAM due to their health or spiritual belief system.27,28 Several factors that promote 
patient’s autonomy are seen by the patient’s ability to have access to a wealth of health 
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information through health-based apps, direct-to-consumers testing, online websites, 
social media and access to products that promise relief and comfort. Other reasons may 
include sub-optimal physician-patient relationship or mistrust in the western medicine due 
to certain cultural beliefs or a negative treatment experience with poor outcomes.1 
As an example, Lor et al 29 provided a closer look at the frequency and perception of 
herbal medicinal use among Hmong-American using a telephone-based survey. The 
method used to determine eligibility was the surname of 18 clans. Participants had to be 
18 or older and with a partial or Hmong descent. The study concluded that Hmong-
Americans of Sacramento, CA have a higher CAM use relative to other ethnic groups 
reported by the by 2002 National Health Interview Survey Alternative Medicine 
Supplement. In fact, out of 118 interviewed participants 77(65%) reported using medicinal 
herbs. Although the study had many limitations, the results provided are consistent with 
what has been previously reported on Hmong’s perception of western medicine.1 The use 
of medicinal herbs, however, seem to be associated with certain demographics. These 
factors include being a male, having less formal educational level, and being born outside 
the US. 29 The high utilization of herbal and nonwestern medicine among the Hmong 
represents a critical step towards providing optimal patient care. Specifically, the 
concomitant use of herbal or non-herbal supplements along with the risk of polypharmacy 
present a potential perfect storm of risk for major drug adverse events. Therefore, the 
knowledge of alternative medicine use among the Hmong can be important in managing 
patient therapy to avoid drug–drug interactions and drug-disease interactions while 
optimizing the therapeutic outcomes.  
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Dietary and Lifestyle Practices of the Hmong and Risk of Gout 
Diet and lifestyle are major risk factors for the development of gout.10,30-32 
Specifically, low- energy expenditure lifestyle and diet high in purine content in 
conjunction with declining kidney function represent an elevated risk for developing new 
onset of gout. Historically, the Hmong from Laos and other parts of China have been 
known for their agrarian lifestyles that allowed them to be physically active and rely on 
food resources that are either produced or raised in their local communities. Although the 
pace of adapting to western diet can vary in speed within the Hmong culture, the 
immigration to the US has evidently and significantly reduced the high-energy 
expenditure associated activities. This change in the lifestyle and adaption to a western 
diet could, in part, explain some of the findings presented in the surveys and interviews of 
the Hmong living in California.33 
Yang and Mills 33 conducted a survey of 248 Hmong participants living in Fresno, 
California to assess the pattern of tobacco smoking, alcohol consumption, and dietary 
practices within the Hmong. The study revealed that more than 63% of Hmong are either 
overweight or obese (BMI>25 kg/m2),33 which is a risk enhancer for numerous diseases 
including gout. From a social lifestyle perspective, the Hmong are less likely to 
excessively smoke tobacco or consume alcohol, which provides some protection against 
diseases that are caused by alcohol and tobacco use.33  Specially, high consumption of 
alcohol can increase uric acid and precipitate acute gout attack. On the other hand, 
cigarette smoking can reduce uric acid levels as well as the risk of gout. Thus, knowledge 
of social lifestyles may predict the risk of gout.   
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While the Hmong were reported as less likely to excessively consume alcohol, this 
report does not reflect the true estimate of community use of alcohol due to the seasonality 
and calendar year. Although Yang and Mill33 did not account for these variables in their 
dietary survey, personal communications with Hmong community members and Hmong 
key informants34,35 have highlighted two aspects to alcohol consumption within the 
Hmong community. First, Hmong social celebratory events (Hmong New Year, weddings) 
and funerals tend to include high amounts of alcohol consumption. Second, per the 
Hmong cultural norms, the invited guests to these events are expected to partake in the 
event by consuming the food and beverages offered to them. In fact, refusal to consume 
any of the food or beverages could be a sign of disrespect to the host. Therefore, it is 
possible to speculate that gout patients can easily become socially isolated from the 
Hmong community due to their gout as they cannot consume some food or alcohol 
provided to them during these events. This social burden on Hmong patients with gout 
may lead to other complications that could adversely affect individuals of a high kinship 
community.  
On the dietary side, the Hmong frequently consume a select food items daily such as 
regular rice (79%), chicken (44%), pork (20%) beef (19%), egg (16%) and fish (7%).33 On 
a weekly basis, the Hmong participants reported consuming beef (56%), pork (52%), 
chicken (47%), egg (45%) and fish (28%). The study also revealed that most Hmong do 
not consume fruits and vegetables daily but rather on a seasonal basis.33 For example, 
apples (8.5%), bananas (6.5%), oranges/tangerines (6.5%) and honeydews (3.2%) were 
reported to be consumed daily versus 45%, 48%, 48% and 54% on a seasonal basis, 
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respectively. The consumption of vegetables also paralleled the consumption of fruits by 
being less daily compared to seasonal basis. For example, sweet peas (2.4%), eggplants 
(1.6%), and cucumbers (2.4%) and cabbage (4.8%) were reported to be consumed daily 
versus 54%, 54%, 52%, and 39% on a seasonal basis, respectively.  The use of non-
alcoholic beverages, carbonated soda, and milk were also assessed in the survey. The 
study revealed that about 10% of the participants reported drinking cola drinks every day 
while those reported drinking orange juice and milk were 9% and 6%, respectively.33 The 
above observations of patterns of dietary and lifestyle choices (alcohol, smoking sedentary 
life) in the Hmong are consistent with a population at elevated risk for hyperuricemia and 
gout.10,32,36  Although not specifically compared with other ethnic groups, they represent 
findings that are consistent with others examining dietary patterns that influence uric acid 
levels and risk for gout.30,32,36-38 
For instance, YI-Tsen et al 39 identified three dietary patterns that can influence uric 
acid levels known as uric acid-prone pattern, fish and fried food pattern and vegetable 
and fruit pattern. Specifically, in Chinese adults within Taiwan, the serum uric acid of 
participants in the uric acid-prone pattern, (which included seafood, meat, alcoholic 
beverages, and organ meat) was significantly higher compared to participants within the 
vegetables and fruits pattern. In addition, serum uric acid levels trended significantly as 
the quartiles increased in the uric acid-prone pattern.   
Additionally, a prospective study evaluating relationship between diet and the risk of 
gout in Singapore Chinese population identified significate hazard ratios (HRs) of select 
diets with physician-diagnosed gout.30 For instance, comparing the first to fourth quantile 
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of total protein was associated with HR 1.27 [95% CI (1.12-1.44)] of gout. This 
significant trend was also consistent with the sources of protein such as poultry, fish, and 
shellfish with HRs 1.27, 1.16, and 1.16, respectively. On the other hand, the study 
identified that the consumption of soy food and non-soy legumes was significantly 
associated with reduced risk for developing gout with HRs of 0.86 and 0.83, respectively. 
Consequently, the high intake of purine rich protein in general and decreased intake 
of sources known to mitigate or reduce the risk of gout such as fruits, vegetables, orange 
juice, and milk all represent optimal conditions for developing gout. These dietary choices 
which happen to be documented as prevalent in the Hmong, would be expected to 
enhanced risk for developing gout. While diet and nutrition play key roles in the 
development of diabetes and obesity, they are also a prominent risk factors for the 
development of gout. The generational effects of migration, acculturation and assimilation 
of dietary intake and to the western lifestyles on Hmong include increasing obesity risk 
among second and third generation compared to those who have recently immigrated.40 
These findings were also reported in the National Longitudinal Study of Adolescent to 
Adult Health particularly among Asian American and similar studies.41-43 Therefore, 
Hmong diet and their unique risk of obesity seem to correlate with the increased risk of 
gout. Consequently, in-depth understanding of the inherent predisposition to elevated 
serum uric acid and gout in conjunction with the clinical pharmacology of lowering serum 
uric acid will provide comprehensive analyses of why the Hmong have a high prevalence 
of gout and pharmacological means to address a highly prevalent health condition within 
the Minnesota Hmong. In addition, an appreciation to role of diet and lifestyles may have 
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on the development of the disease in this unique population, can be used to optimally and 
comprehensively manage a disease of a growing prevalence within the Hmong.   
Hmong and Minorities in Clinical Genetics Research 
The recent advancements in technologies and the declining cost of genetic testing 
have driven an unprecedented growth of genomic discoveries in our recent memories. In 
the past decade alone, there has been an increase in genetic-based investigations, growing 
knowledge of the impact of human genetic variations on human health and the 
development of genetic-based guidelines for drug selection. This genetic revolution and 
the recognition of the importance of including large number of individuals from different 
ethnic and cultural backgrounds to donate biological samples has further advanced genetic 
research.44,45 
The multiethnic and racial representation including the Hmong in clinical trials 
and/or clinical genetic research remains limited due to challenges attributed to 
geographical, cultural, educational barriers as well as  mistrust experiences.1,34,35 Although 
a substantial effort has been placed to ameliorate these barriers to participate in research 
within select ethnic and racial groups, mainly African Americans, further work is needed 
to engage other populations in clinical research.46 One example is the Asian population. It 
is evident that within the Asian race there are many sub-populations that are culturally 
unique and present with different levels of risk  for developing select diseases.2 
Consequently, the practice of utilizing aggregate results pertaining to the broad 
categorization of “Asians” masks the potential differences which likely exist between 
subgroups within the Asian race. This imprecise approach leads to inaccurate 
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generalizations and undermines the full potential and value of personalized therapy.  
Currently, up to 75% of the Genome-Wide Association Studies (GWAS) are being 
conducted on European descendants.47 The results and information from these landmarks 
genetic studies are serving as the basis for developing the commercial direct-to-consumers 
genetic testing kits and informing the genetic based guidelines. This lack of inclusivity of 
other minority groups represents a major shortcoming for the generalizability and usability 
of these results and applicability of these genetic testing kits across the population at 
large.47,48 This lack of knowledge could widen the gap of health disparity across racial 
groups by creating disproportionate levels of knowledge about select populations. In 
addition, the lack of replications of major findings in mainstream–based GWAS 
underestimates the allelic architecture, genetic signatures and major linkage 
disequilibrium in these minority groups.48 
Clinical Genetic Research Challenges and Opportunities  
Although  genetic research continues to rapidly progresses, inclusion of specific 
racial, multiethnic and sub-ethnic groups in research remain a challenge.46 The lack of 
representation of special populations in genetic research has mobilized  efforts to raising 
awareness of the values and benefits of participating in both clinical and genetic-based 
research and creating the National Institute of Health Policy and Guidelines on the 
Inclusion of Women and Minorities in Clinical Research46 as well as tailoring the consent 
process to accommodate cultural and ethnic specifics to participate in genetic-based 
research.49  
There are some well-recognized challenges associated with conducting clinical 
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research in general, and specifically genetic-based research. These include ethical 
concerns, privacy issues, sharing genetic information with other investigators, handling 
incidental findings, processing of variants of unknown significance, and returning genetic 
data to participants.50,51 Addressing these challenges requires an adaptive mechanism to 
facilitate the research process while maintaining an adequate balance of risks and benefits 
to study participants. Another unique challenge complicating the conduct of genetic-based 
research is the study of vulnerable populations or minorities. These groups of individuals 
can present with language and cultural barriers, limited knowledge of genetics, and low 
literacy levels that may greatly hinder their participation in genetic research. These 
challenges can ultimately contribute to the development of health disparities of genetic 
knowledge preventing select communities from benefiting from these scientific endeavors. 
Consequently, recognizing important core merits of scientific, cultural, and social factors 
are important to designing ethically responsible approaches to informed consent in 
genetic-based studies involving ethnically, linguistically, socio-economically diverse 
population.  Table 1.1 provides a summary of core factors, which  ensure a successful a 
genetic-based research in special populations.49 
While the social and ethical issues associated with the process of informed consent 
for genomic research remain challenging for participants, community members, 
investigators, policy makers, and funding agencies have strived to overcome these 
challenges creating a research model that ameliorates these barriers. For example, the 
Community-Based Participatory Research (CBPR) paradigm has shown a great promise to 
mitigate these challenges.  The CBPR has been shown to work effectively in reducing 
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health disparities and targeting specific health problems identified by the community in a 
vulnerable population. This research model represents the community while collaborating 
with researchers to address health concerns identified by the community and recruiting 
participants from the community. This approach empowers the community and creates 
participatory environment for researchers and community to produce actionable data that 
can benefit the community.  Historically, community based participatory research is 
defined as a partnership approach that equitably involves all participants in all aspects of 
the research process where each person shares his/her expertise to enhance knowledge and 
to develop interventions that will benefit the whole community. However, to conduct a 
successful and effective CBPR, there are key principles that need to be agreed upon and 
followed by all individuals involved in the research process (Table 1.2). 52,53 
In addition, three key principles are also proposed to outline the framework for 
conducting genetic-based research studies within indigenous populations. These principles 
are 1) while respecting the culture of the community, do not violate basic principles of 
ethics, including the institutional review board rules and the use of bribery; 2) realize the 
existence of many local cultures within one seemingly homogeneous group and act 
accordingly; and 3) make a long-term commitment as one may need and want to return on 
multiple occasions. 
Implementing Community-Based Participatory Research Model in Minnesota 
Hmong  
Background: 
The lack of Hmong representation in genetic research, the rising prevalence of 
chronic diseases within the Hmong, and concerns about growing health disparities 
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between Hmong and Non-Hmong have alarmed Hmong-treating physicians and university 
investigators with interest in minorities genetics.  This combined interest between the 
community and academic researchers has led the Westside Healthcare System and the 
University of Minnesota, College of Pharmacy to build their partnership with the vision of 
creating a Hmong Genomic Board. The long-term goal of the board is to help address 
health disparities between the Hmong and non-Hmong. The short-term goal is to establish 
the framework by which the Hmong Genomic Board should function to conduct CBPR. 
The objectives of the Hmong Genomic Board were to help the community to identify and 
address some key health conditions that are greatly affecting a substantive number in the 
Hmong community while identifying means to increase the Hmong representation in 
genetic and non-genetic based research.   
By facilitating the process of conducting CBPR, the establishment of the Hmong 
Genomics Board became the first step towards creating health equity between Hmong and 
non-Hmong. Establishing a Hmong Genomics Board was not without its challenges. 
These challenges included (1) achieving genuine collaboration, establishing trust, 
addressing power differences, building equitable relationships to meet the goals of the 
board; (2) identifying key elements involved in effective collaborative efforts and 
evaluating the extent to which and how these elements contribute to partnership’s success.  
The following describes the approach used by our group in establishing this board to work 
toward our common goal.  
Approach: 
The evolution of the Hmong Genomic Board was led by two prominent leaders who 
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shared similar interest in addressing health disparities within minority populations in 
Minnesota. As an experienced primary care physician who works extensively with the 
Hmong (KCP) partnering with a University of Minnesota College of Pharmacy Professor 
(RJS) with expertise in pharmacogenomics led to the recognition of forming the Hmong 
Genomic Board, as the basis for future research endeavors within the Minnesota Hmong. 
With the vision of conducting prospective CBPR within the Minnesota Hmong, key 
Hmong community leaders and experts were identified and invited to participate in the 
newly formed board.  Once the identified members agreed to join the board, the purpose, 
scope and goals of the board were clearly established by all board members. Additionally, 
the board operating compact including roles, decision making, means of communication 
and rules of engagement were formed.  
Through on-going regular meetings and extensive and structured discussions, a 
newly formed partnership was offered to other stake holders and Hmong community 
members to plant the first Hmong Genomic Board in Minnesota. In details, the board 
included a wide array of people with different levels of influence on the community while 
engaging individuals with different expertise in their respective fields. For example, the 
Hmong Genomics Board included Hmong and non-Hmong physicians, Hmong nurses, 
Hmong pharmacists and graduate student, Non-Hmong students, Hmong community 
members and university of Minnesota researcher investigators. This board represented the 
incarnation of the key principles of CBPR and the core group that jointly and 
collaboratively identified key health concerns within the Hmong community while 
expanding on the approach and design to address these concerns. 
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Results and Discussion: 
After engaging in many interviews with key Hmong leaders and discussion amongst 
the board members, key lessons and guidelines were identified to be critical while 
working with the Hmong population. These lessons learned ranged from the basic 
understanding of the ethnographic nature of the Hmong to the more complex controversial 
issues associated with conducting a genetic-based research. For example, the Hmong 
language lacks terms that translate biomedical body physiology and anatomy. Therefore, 
explaining a disease state or organ malfunction would require the interpreter to use a 
lengthy paragraph to say what could be said with one word in the English language. This 
lack of sufficient terms in Hmong to correlate with the western medical terms can easily 
create major gaps in heath communication while widening the gaps of trusting western 
medicine. In addition, this language barrier may have other implications associated with 
the Hmong participation of clinical research in general and particularly genetic research. 
Therefore, creating consent forms and educational materials will require very special 
consideration given the limitations associated with the Hmong language. It was also 
decided that creating consent forms should be done using Hmong and English. The 
educational materials included more pictures to enhance communication rather than 
relying on words. For example, to explain heredity, layman language and cultural related 
examples (e.g. the man’s seed and woman’s egg) should be used to ensure full 
understanding of the topic presented to participants.  
Interactions with the community prior to the onset of the study will allow potential 
participants to become more familiar with the researchers and enable researchers to gauge 
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whether their approach to the community is effective. These interactions can be mediated 
via multiple mechanisms. One of which is building a relationship with the community 
leaders, heads of the clans, healthcare professionals from the Hmong population. Other 
mechanisms could include Hmong radio and TV stations to increase awareness of the 
community and build mutual trust.  
Study locations have been shown to play a major role in improving study 
participation and ensuring study participants returning to subsequent visits especially 
when the study involves multiple visits. Therefore, using clinical sites that are familiar to 
Hmong patients or using the same clinical sites from which they receive their regular 
medical care will substantially increase the likelihood of the participants to enroll into the 
study and complete the study if they needed to come back for multiple visits.  
The nature and amount of the biological samples are important to Hmong 
participants. For example, relying on non-invasive biological samples such as saliva or 
mouth swab is more acceptable than using more invasive sample like blood. However, if 
the study purpose is hematological disorders for example, minimizing the amount of blood 
drawn will improve the participant’s acceptance to be in the study. This is due to the belief 
system that some Hmong might have about having a finite blood volume, which makes 
them to believe that giving a large volume of blood can weaken their body and disrupt 
their reincarnation. 
Future Research Opportunities and Cultural Perspectives 
While the Hmong remain to be less represented in clinical or genetic-based research 
relative to other population groups, genetic-based investigations in the Hmong could not 
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only benefit the Hmong but may well enhance our understanding of the genetic basis of 
some common diseases in the public. Thus, our main objective is engaging the Hmong in 
clinical and genetic-based research to address some of their existing health disparities and 
advance precision medicine overall. Furthermore, the Hmong population may be ideal 
candidate for genetic exploration because the Hmong have a high cultural identify and a 
very low admixture rate outside their ethnic groups. These unique characteristics can it 
make easier to precisely address some of the key differences in prevalence of 
cardiovascular and non-cardiovascular diseases in the Hmong compared to non-Hmong 
independent of confounders in the pathogenesis of these diseases. This also leads us to 
postulate our central hypothesis that Hmong have a differential prevalence of disease-
gene pair risk alleles and drug-gene pair response alleles that distinguish them from non-
Hmong.  Therefore, the long-term goals of our research are to reduce the health 
disparities present in the Minnesota Hmong and advance precision medicine by engaging 
unique minority populations in genetic-based research.  
Concerning the most pressing health conditions affecting the Hmong, multiple 
disease states have been identified and reported to be substantially affecting a large 
percentage of the Hmong population. Some of these disease states included type 2 
diabetes, hypertension, kidney diseases and gout. While all the disease states listed above 
are important and highly associated with high morbidity and mortality, gout is believed to 
be a unique case since it is strongly associated with all the other diseases as the “common 
denominator” as well as an independent risk factor to hypertension, obesity and chronic 
kidney disease.18,23,54-57 In addition, anecdotal report on trends of Hmong’s dietary 
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lifestyle may well suggest the  increased risk of gout in the Hmong. Furthermore, 
exploration of the genetic basis of hyperuricemia and gout in the Hmong was recognized 
as step forward to address the needs of the Minnesota Hmong community. Such a 
recognition by the board members was the driver of ensuing work related to genetic 
investigations in the Hmong. Therefore, studies aimed towards greater understanding of 
the interactions between diet and genetics, which may lead to higher prevalence of gout in 
Hmong, is justified, supported by the community and medically warranted.  
Chapter Summary 
The Hmong is a unique racial group with high prevalence of gout and gout-related 
comorbidities. The Hmong population is underrepresented in clinical research especially 
that involves advancing genetic discoveries of disease risk.  This gap of inclusion 
represents a missed opportunity and health disparity of knowledge. The dietary lifestyles 
of the Hmong parallel the enhanced risk of developing hyperuricemia and gout. The 
Hmong community identified gout as a priority health condition to collaborate on with 
academic researches. Studies that address the genetic architecture of the uric acid 
disposition in the Hmong, the effect of Hmong dietary lifestyles on hyperuricemia and 
gout, and possible implications of genetic basis for the response to drugs that are 
commonly used to manage gout are justified as means to improve the quality of care 
provided to Hmong patients with gout. Recognition of the role of including minorities, 
women, and sub-populations in genetic research by the NIH, underscores the importance 
to pursue research within the Hmong community to address their unique health disparities 
while advancing the ultimate goal of personalized medicine for the population at large. 
 25 
 
 
 
 
 
Figure 1:1 Prevalence of gout by age categories and geographical locations 
This figure suggests that gout seems to increase in a linear fashion with age.10 
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Figure 1:2 Prevalence of gout by sex and countries 
Gout remains to be male dominated in countries with the highest prevalence of gout.10 
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Figure 1:3 Prevalence of self-report gout in Hmong males vs. US sex and age-matched 
populations17  
 
NHANES= National Health and Nutrition Examination Survey III (1988-1994) 
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Figure 1:4 Prevalence of self-report gout in Hmong females vs. US sex and age-matched 
populations17  
 
 
 
 
  
NHANES= National Health and Nutrition Examination Survey III (1988-1994) 
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Figure 1:5 Prevalence of physician-diagnosed gout in Hmong males vs. non-Hmong sex 
and age-matched populations17  
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Figure 1:6 Prevalence of physician-diagnosed gout in Hmong females vs. non-Hmong sex 
and age-matched populations17 
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Table 1:1 Scientific, cultural, and social factors to consider in tailoring informed 
consent for genomic research49 
1. Study design (disease versus non-disease studies; selected genes versus whole 
genome) 
2. Data and biological sample sharing requirements 
3. Reporting study findings to participants 
4. Cultural context of the study 
5. Participant language and literacy 
6. Participant knowledge of differences between research and clinical care 
7. Potential for stigmatization of the study population 
8. Inclusion of indigenous populations 
9. Strength of economic, scientific and health infra-structures at study sites 
10. Regulatory oversight 
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Table 1:2 Key Principles of Community-Based Participatory Research53 
1. Recognize community as a unit of identity 
2. Build on strength and resources within the community  
3. Facilitate collaborative, equitable partnership in all research phases and 
involve an empowering and power-sharing process that attend to social 
inequities  
4. Promote co-learning and capacity building  
5. Integrate and achieve balance between research and action of mutual benefit 
of all partners  
6. Emphasize public health problems of local relevance and ecological 
perspectives that recognize and attend the multiple determinants of health and 
disease 
7. Involve systems development through cyclical and iterative process  
8. Disseminate findings to all partners and involve all partners in the 
dissemination process 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 33 
Chapter 2 Chapter II 
Review Article 
Uric Acid, Hyperuricemia and Gout Contemporary Overview 
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Chapter Overview 
This chapter gives a comprehensive overview of the history, economic burden, 
pathophysiology, and pharmacotherapy of gout. Through this chapter, the reader should be 
able to appreciate that the optimal management of gout does not only reduce the risk of 
recurring gout flares, but can greatly reduce the burden of the comorbidities associated 
with gout.  
Gout: The Disease of Distinction  
Gout is an inflammatory arthritic condition caused by the deposition of monosodium 
urate crystals within the distal joints. The term gout is derived from the Latin word gutta- 
to drop. This term was coined by a Vielehardouin in the 13th century based on the humor 
theory that a fluid ran down the body into the legs.58,59 Gout is relatively one of the oldest 
known diseases in the history of medicine. The first gout-like cases have been recognized 
and documented by the Ancient Egyptians in 2640 BC.  In the 5th century BC, gout was 
recognized by Hippocrates and named as the “unwalkable disease” reflecting the reduced 
mobility and excruciating pain associated with gout. Hippocrates’ work to further 
understand the relationship between gout and other modifiable or non-modifiable risk 
factors has provided the foundation for key insights into risk factors for and management 
of gout. In fact, Hippocrates’s principles on the pathophysiology of gout some 2500 years 
ago, such as age and sex hormones, still carry clinical relevance today (Table 2.1).58,59 
Throughout history, acute gout occurring due to monosodium urate crystallization in 
the metatarsophalangeal joint (aka podagra) has been associated with meat rich food, 
excessive alcohol consumption, and certain lifestyles that could be afforded by a select 
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upper class of the society. Consequently, gout was referred to as “the disease of the 
kings”.58,59 Therefore, gout as a disease conferred a high social status and implied 
distinction. Moreover, having gout carried a special message because while it inflicted an 
excruciating pain, it rarely killed; thus, it was perceived as a death prophylactic disease. In 
addition, gout was historically known as “the old male disease” due to the notion that 
young men do not develop gout unless they indulge in sexual activities. On the contrary, 
the number of women affected by gout is far less than men but increases especially after 
menopause.  With a history spanning more than 2500 years ago, gout did not just afflict 
the quality of life of its sufferers, but has also played a major role in arts and politics.60 
While being influenced by Hippocrates’ views on gout, Michael Psellos (1016-1078 AD), 
a famous Byzantine monk, philosopher, writer and politician wrote a 15-lines poem titled 
“An Excellent Medical Work in the Iambic Manner” to describe the nature of acute and 
chronic gout. This poem could be considered as the first extensive documentation of the 
clinical signs and pathogenesis of not just the monoarticular form of gout (podagra) but 
also the polyarticular gouty arthritis.61  
On one hand, many politicians and key decision makers have suffered gout and 
experienced major gout attacks on days that resulted in their absence and precluded them 
from voting on major and historical decisions. On the other hand, some also believe that 
having gout has also unified a group of politicians on some key decisions that shaped our 
modern history. For example, it is believed that gout affliction has crystalized the 
relationship between Franklin, Jefferson, and Comte de Vergennes and has played a role 
in the origins and outcomes of the American Revolution as well as the Declaration of 
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Independence.59  
Epidemiology of Hyperuricemia and Gout 
The global prevalence of gout and its strongest predictor, hyperuricemia, have been 
on the rise in the past few decades. Consistently, data from major healthcare systems and 
the Health and Nutrition Survey(NHANES) in the U.S. have shown a rise in prevalence of 
hyperuricemia and gout(Table 2.2).11 For instance, descriptive data analysis of prevalence 
of gout and hyperuricemia over 10 years (1990-1999) in older adults in a managed care 
population demonstrated that ongoing increased prevalence of hyperuricemia and gout. 
While gender and age are important determinants in the development of gout, the overall 
prevalence of clinically significant hyperuricemia and/or gout, increased from 2.9 per 
1000 enrollees in 1990 to 5.2 per 1000 enrollees in 1999. In addition, the results showed 
that gout remains a disease of men (3:1, men to women) and the elderly noting that those 
>75years had the highest prevalence of gout per 1000 enrollees per year (Figure 2.1).62 
Furthermore, using data from 5,707 participants in NHANES conducted in 2007 and 2008, 
the mean serum urate levels was 6.14mg/dL among men and 4.87mg/dL among women. 
The overall prevalence of hyperuricemia was 21.4 % in the US.11,18 Specifically, the 
prevalence of hyperuricemia is 21.2% among men and 21.6% among women. This 
estimated prevalence considers the gender difference in the definition of hyperuricemia 
(>5.7 mg/dL vs. > 6.8 mg/dL) since women tend to have lower UA levels compared to 
men.  Although prevalence of hyperuricemia is nearly similar across genders, data from 
the NHANES 2007-2008 shows that the prevalence of gout varies between men (6%) and 
women (2%). This differential classification of hyperuricemia and prevalence of gout 
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between genders may have a variety of sources; one of which reflects the effect of 
circulating estrogen levels. Estrogen is known to have a uricosuric effect.63,64 However, 
the impact of gender on the prevalence of hyperuricemia or gout becomes less influential 
as women reach the postmenopausal age where circulating estrogen levels decline. The 
effect of age, however, might have a more significant impact on the development of 
hyperuricemia and gout.  It is expected that as age increases, the risks of developing 
hyperuricemia and gout also increase due to declining kidney function, risk of 
dehydration, increased use of drugs, and increased prevalence of other comorbidities. 
Thus, the combination of declining in estrogen levels and the complications of aging 
suggest women could be at higher risk for developing gout at later stages in life than men. 
It is also noted that prevalence of gout substantially differs across geographical regions of 
the world. While Greece presents with the highest prevalence of gout in Europe (4.75%), 
other countries like the Philippines, Jamaica, Iran, and African countries have reported 
prevalence of < 1% or it could be minimally reported in other parts of the world such as 
the South Korea (0.4%).10  While the effects of age and sex on the incidence of 
hyperuricemia and gout are well established, this geographical differential prevalence of 
gout further supports the role of environment and dietary habits as well as other lifestyles 
which could modulate the risk of developing gout.  
There are multiple limitations associated with the methods used to assess the 
prevalence or incidence of gout.  Some of the most encountered shortcomings are relying 
on participants’ self-report, which is confounded by recall bias, sampling limitations, 
misdiagnosis or case-definition of gout, and the timing of conducting the study. Owing to 
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these limitations and variation of methodologies used to estimate the prevalence and 
incidence of gout, the need for replication and longitudinal studies are warranted. This is 
to accurately quantify the prevalence and incidence of gout, which is a debilitating and 
costly disease to its sufferers and society at large.  
Economic Impact of Managing Patients with Gout 
Gout is associated with a substantial economic and humanistic burden to the 
healthcare system and its sufferers. The burden of gout on the society includes direct and 
indirect costs.  For example, missed days of work, loss of productivity, urgent care visits, 
and hospitalization all can add up a substantial economic stress on the induvial as well as 
the society. The estimated direct cost (2004 values) to manage a patient with gout is $6871 
per patient/year in contrast to $3705 to manage a patient without gout.65 Furthermore, 
using data from the 2005-2011 Medical Expenditure Panel Survey, it is estimated that 
mean per-person all-cause medical expenditures were more than 2.5-fold higher for adults 
with gout compared to the entire adult population without gout, mostly driven by 
hospitalization and inpatient stay. In addition, the total annual national medical 
expenditure attributable to gout was $7.7 billion, accounting for almost one of four dollars 
spent for medical care of the US adults with gout.66 A systematic review has also assessed 
the annual incremental direct cost of gout in those experiencing regular acute flares or 
have tophi present at 2004 and 2005 compared to 2008.67 The estimated cost ranged from 
$3165 to $5515 in 2004 to 2005, respectively. Using the 2008 data, however, the 
incremental direct cost of gout climbed to $10,222 and up to $21,467 in patients 
experiencing six or more gout flares per year.67  
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Although there is a lack of a universal instrument to assess the health-related quality of 
life in individuals with gout, the three mostly commonly used tools are the Health 
Assessment Questionnaire Index (HRQOL), Short Form 36 (SF-36), and its modified form 
known as the Short Form 6-dimensions (SF-6D). Using these instruments, the humanistic 
burden of gout can be quantified using a numerical scale a with maximum score of 1.  
These scores are positively correlated with the health-related quality of life and are 
negatively associated with acute gout flares. For instance, a systematic review has showed 
that patients who experienced >3 acute flares/year had SF-6D utility score 0.53 compared 
with 0.73 in gout patients who were asymptomatic or experienced mild symptoms.  
While the listed above quality of life assessment tools are inherently different in 
their scopes and discriminative powers to assess a subjective reporting of quality of life in 
patients with gout, the SF-6D scores derived from the SF-36 may have a higher 
discriminative power in a population health survey.68 However, the ability to determine 
which factors that predict changes in the health-related quality of life to identify those at 
risk to deteriorate and be targeted for treatment will constitute the most optimal method of 
assessment. 
Pathogenesis of Hyperuricemia and Gout 
Serum Uric Acid (SUA) is the end-product of purine metabolism. Sources of purines 
can include both endogenous such as the breakdown of nucleic acids, or exogenous from 
dietary sources.  Purines are generally converted to hypoxanthine, xanthine and ultimately 
uric acid via the xanthine oxidase (XO) enzyme (Figure 2.2). Based on an average purine 
content diet, approximately 5-6 mmol (~800-1000mg) of uric acid is produced daily.69 Of 
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this  amount, 3-4 mmol (~500-600mg) of urate is produced endogenously while the 
remaining 1-2 mmol (~200-300 mg) is produced from dietary sources of purines.69 Of the 
amount produced daily, approximately 70% of the uric acid is excreted by the kidney 
while the remainder is eliminated via the gastrointestinal tract, where it is degraded by 
bacterial uricase.70 
The role of uricase-producing bacteria in the intestine imposes the question of 
whether changes in gut microbiome may have an influence on the risk of developing gout. 
A study of gout patient cases (n=35) compared to healthy individuals (n=33) has identified 
that the intestinal microbiota profiles are distinct in both the organismal and functional 
structures. In fact, the intestinal microbiota of patients with gout are comparable to those 
of type-2 diabetes and metabolic syndrome. Furthermore, the reference microbial gene 
catalogue for gout cases revealed disorders associated with purine metabolism and butyric 
acid biosynthesis both of which to be the basis for developing gout. 71 
Elevated SUA is known as hyperuricemia and the strongest predictor of developing 
gout. As mentioned above, hyperuricemia is a function of dietary intake of purine sources, 
endogenous cell turnover and renal as well as extra renal eliminations of UA. In theory, 
changes in any of these factors affecting UA disposition, may account for hyperuricemia. 
In fact, defective renal elimination of UA accounts for approximately 80-90 % of gout 
cases knowns as UA underexcreters due to decreased urinary UA secretion. The remaining 
cases known as overproducers or because of renal UA overload or combined mechanisms 
(underexcretion of overproduction).70,72  Endogenously, sources of UA are cell turnover or 
de novo synthesis of purines. Therefore, hyperuricemia can be divided into two major 
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types: primary hyperuricemia and secondary hyperuricemia. The causes of primary 
hyperuricemia can be further divided into two main categories. The first category which 
results from UA overproduction which accounts for 10% of the population with gout.73 
While the over-production of UA can be an inherited genetic disorder as in the case of 
Lesch Nyhan Syndrome or a result of Tumor Lysis Syndrome, high intake of purine 
sources can also result in  high SUA levels and the development of hyperuricemia.69  
The second category of primary cause of hyperuricemia is attributed to the 
underexcretion of UA which accounts for 80-90% of patients with gout.70 Uric acid is 
extensively (90%)  reabsorbed from the kidney via the Four Component Theory (Figure 
2.6),74 which allows a small fraction of UA to be excreted. In fact, underexcretion of UA 
tends to be the dominating mechanism of developing hyperuricemia, which is supported 
by the observation that most of the patients with declining or poor kidney function tend to 
have higher SUA levels than those with normal kidney function. On the other hand, 
kidney function may not always explain the underexcretion associated with hyperuricemia 
as a substantial number of individuals with normal kidney function but still have higher 
baseline than the normal range for SUA levels. The etiology of such discordance between 
kidney function and SUA levels in some individuals has been attributed to genetic variants 
within select uric acid transporters genes mainly ABCG2, SLC17A1 and SLC22A12 in the 
kidney, which can increase SUA levels even in healthy individuals. The interaction of 
these genetic variants can render some to more efficient at reabsorbing uric acid while 
making others less efficient at secreting UA. 
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Genetics of Hyperuricemia and Gout 
Hyperuricemia and gout are highly heritable with estimates of up to 4575 and 65%76, 
respectively. The recent advances in genetic tools applied to large populations such as 
genome-wide association studies (GWAS), have helped to elucidate major genetic variants 
in UA disposition pathway, which may predict hyperuricemia or gout.  The genes which 
have been identified to be associated with hyperuricemia  mainly involve genes affecting 
uric acid excretion (ABCG2, SLC17A1), uric acid reabsorption (SLC22A12, SLC2A9, and 
SLC22A11) and a lipid metabolizing gene (GCKR).77 In addition, there are other genes 
responsible for supporting the pathway of UA disposition such as the scaffolding protein 
(PDZK1) which also play a role in affecting baseline SUA. The differential prevalence of 
hyperuricemia and gout coincides with race. For example, some racial groups such as 
African-Americans, Japanese12, and Hmong17 tend to have a higher prevalence of gout 
compared to Caucasian78 and European.76 This racial differential prevalence of 
hyperuricemia or gout also parallels the prevalence of genetic variants mainly single 
nucleotide polymorphisms (SNPs) consistent with the SNPs identified by GWAS.79-82 
These genetic findings may play a role in the explanation for why some the populations 
are known to have the highest  documented prevalence of gout such as the Maori and 
Aboriginal populations.9,10 
Although these genetic variants are found to be differentially prevalent across racial 
groups making certain populations to be at higher risk for the aforementioned diseases, at 
least one group studying several populations found that the magnitude and direction of 
impact these genetic variants were consistent across most of the studied populations.81 The 
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etiology of gout is a heterogeneous process involving genetic and non-genetic factors.  
While key genetic variants associated with baseline SUA or gout have been identified, 
recent candidate genes studies and GWAS have suggested some genetic variants to be 
associated with the gout subtypes: overproduction, underexcretion or combined in 
Japanese patients with gout.83  Specifically, genetic variants were found in SLC16A9 and 
SLC22A11, which may predict the overproduction and underexcretion of uric acid 
phenotype, respectively.84,85 This interplay between genetic polymorphisms within 
transporters and the therapeutic drugs that interact with these transporters highlight the 
potential value of genetic knowledge to guide drug therapy.  For example, these genetic 
polymorphisms, mainly SNPs, could also influence the response to urate lowering therapy, 
mainly allopurinol86 or possible side effects from co-administered drugs in patients with 
hyperuricemia or gout. A comprehensive depiction of the urate transportome as it relates 
to the different transporter genes associated with handling of uric acid in the kidney is 
presented in Figure 2.4.  
Risk Factors for Hyperuricemia 
There are modifiable and non-modifiable risk factors for developing hyperuricemia. 
The non-modifiable risk factors include age, sex, genetics, and race. As the person ages, 
kidney function typically declines and the ability to excrete UA declines. In addition, age 
is a key predictor of the development of chronic diseases for which the treatments often 
involve drug therapies which can interfere with UA disposition. With respect to gender, 
gout is more common amongst men compared to women.  However, the prevalence of 
hyperuricemia is similar between both genders. This is due to the differential definition 
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cut-off for hyperuricemia between genders which is higher for men than women (> 6.8 
mg/dL vs. > 5.7 mg/dL).  This differential definition is due to the uricosuric effect of 
estrogen, which in part explains why women have a lower incidence of gout. However, 
postmenopausal women tend to have a similar risk for developing gout compared to men. 
In men, however, androgens may increase systolic blood pressure by increasing the 
sodium and water retention through the activation of the renin-angiotensin aldosterone 
system (RAAS)87. Moreover, elevated SUA levels have been reported in patients receiving 
testosterone replacement therapy.88  Evidently, hormonal levels modulate SUA through 
different mechanisms across genders. Although hypothesis generating, one may theorize 
that the changes in androgen levels with aging can modulate the risk of developing gout. 
However, changes in renal function may overwhelm the impact of hormonal effects on the 
risk of gout with aging. 
Dietary and social lifestyles are also important factors in the development of gout 
and hyperuricemia. It is well documented that higher intake of purine sources, especially 
red meat and seafood, can worsen existing gout symptoms or unmask existing risk for 
developing gout. In addition, higher intake of high fructose corn syrup sources such as 
sweetened soft drinks can result in new onsets of acute gout attacks.32,89 Furthermore, 
sugar-sweetened soft drinks especially those with fructose can significantly increase the 
relative risk for gout with 1.85 [95%CI, 1.08 to 3.16].90  
Fructose consumption has dramatically increased over the past a few decades 
nationally and worldwide.15 This observation has been cited as a contributing factor 
responsible for some of the increase in the prevalence of hyperuricemia and gout in 
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countries where fructose is commercially used as a sweetener.15 The mechanism by which 
fructose increases SUA is not clearly understood; however, it has been proposed that 
fructose gets reabsorbed from the kidney via the GLUT-9 transporter91 (Figure 2.4) 
allowing high serum fructose levels, which are metabolized by fructose 1-phosphate via 
the rapid activity of fructokinase that takes place in the liver. This conversion results in a 
sharp depletion of ATP subsequently increasing uric acid levels (Figure 2.5). The 
depletion of ATP pool further stimulates the de novo synthesis of purine nucleotides 
pathway causing more UA production.89 In addition, a substantial amount of ingested 
fructose gets converted into lactate, which competes with uric acid excretion causing an 
increase in SUA. The effect of lactic acid on uric acid is supported by the observation that 
fructose-induced hyperuricemia is associated with decreased renal uric acid excretion in 
human.92-94 Collectively, these mechanisms are by which consumption of high fructose 
corn syrup can increase the risk of developing gout or the development of gout attacks.32 
Select forms of alcohol have also been implicated in the development of gout and/or 
exacerbation of gout attacks. This observation is mainly due to the varying levels of purine 
contents which are the precursors of UA. Furthermore, the effect of alcohol on UA 
production results from the conversion of ethanol into Acetyl-CoA, which leads to 
degradation of purine trinucleotides increasing levels of UA precursors. Like fructose, the 
formation of lactic acid from ethanol metabolism further decreases UA excretion leading 
to higher SUA. It is also important to note that some alcoholic drinks could have a higher 
effect on uric acid production owing to the high purine contents and percent of alcohol 
involved. For example, beer tends to have the greatest effect on uric acid, while wine 
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shows the lowest risk for worsening gout symptoms or new onsets of gout attacks.16 
Uric acid is a weak acid with a pKa of 5.8 and predominantly found in the ionized 
form, urate.  Since urine pH is critical for determining the amount of uric acid that is 
reabsorbed from the proximal convoluted tubule (PCT), we can postulate that chronic 
exposure to pH modifiers can have a substantive effect on the amount of ionized form of 
urate in the PCT. Thus, dietary or non-dietary sources that can acidify the urine may 
enhance the reabsorption of uric acid causing the buildup of uric acid in the kidney 
resulting in an acute uric acid nephropathy and possible uric acid kidney stones.38,39   
Secondary Hyperuricemia  
Drug-Induced Hyperuricemia 
Diuretics are some of the most commonly used drugs in the management of chronic 
diseases such as hypertension, fluid overload and heart failure. They are also associated 
with elevated SUA and significantly increase the risk of worsening gout symptoms and 
new onsets of gout flares.95 In order to assess the risk of developing gout with the use of 
diuretics, an analysis of large population-based cohort from the Atherosclerosis Risk in 
Communities study also known as the ARIC study, identified that the use of any diuretics: 
thiazide or loop was significantly associated with new incidence of gout compared to no 
use of diuretics (HR 1.48 [95%CI, 1.11 to 1.98]). Although not significantly different, the 
loop diuretics had a higher risk (HR 2.31 [95% CI, 1.36 to 3.91]) than thiazide diuretics 
(HR 1.44 [95% CI, 1.00 to 2.10]) with incident gout (Table 2.3).96 Diuretics are proposed 
to affect uric acid by direct and indirect mechanisms. The direct effect is marked by 
decreased uric acid excretion through the kidney by simply competing for excretion at the 
basolateral and apical sides. The indirect effect is mediated via the enhanced uric acid 
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reabsorption by the exchange of thiazide excretion at the Uric Acid Transporter 1 
(URAT1) and Organic Anion Transporter (OAT) [Figure 2.5].  Another key uric acid 
transporter is known as Multi Drug Resistance Protein 4 (MRP4), which is expressed on 
the apical side of the proximal tubule and is inhibited by certain thiazides and loop 
diuretics.97 Therefore, the inhibitory effect on MRP4 may explain the side effects of high 
uric acid associated with high doses of diuretics.97 
Although loop diuretics could modulate the risk for hyperuricemia or gout, they can 
also modulate the pharmacokinetics of urate-lowering drugs such as allopurinol. The co-
administration of loop diuretic such as furosemide with allopurinol is common in clinical 
practice especially in patients with gout and heart failure. Notably, furosemide does not 
only increase uric acid levels in individuals receiving allopurinol, but also the levels of 
oxipurinol. However, the increased levels of oxipurinol in patients receiving the 
combination was not associated with greater reduction of SUA.98,99 This interaction 
highlights the interplay of transporters associated with uric acid and oxipurinol disposition 
as well as the levels of XO expression in the presence of furosemide.100   
Aspirin is a cyclooxygenase-2 inhibitor and at the doses of 65-325mg/day, is widely 
used for primary prevention of stroke and cardiovascular diseases as well as secondary 
prevention of cardiovascular events in select patient groups. Aspirin has a biphasic effect 
on SUA levels. Specifically, at the lower dose (< 2.5gm/day), aspirin can increase SUA 
levels by competing with uric acid renal tubular excretion transporters mainly: OAT1, 
OAT3, and GLUT-9. At the higher doses, aspirin blocks the renal tubular excretion and 
renal tubular reabsorption mainly URAT1; however, the net effect of aspirin at the higher 
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doses is uricosuria.101 This phenomenon is explained by the fact  that the renal tubular 
excretion plays a lesser role compared to the renal tubular reabsorption, which further 
explains the net uricosuric effect of aspirin at the higher doses.102 To illustrate, a small 
randomized clinical trial tested the effect of 60mg (n=18) vs. 300mg (n=14) aspirin on the 
renal handling of uric acid and renal function over the course of two weeks. The study 
concluded that while either dose did not affect SUA or serum creatinine levels, both doses 
significantly reduced the fractional excretion of uric acid by the second week103. Although 
the study duration is relatively short to show a substantive effect on SUA, the significantly 
reduced FEUA% is consistent with the effect of aspirin on UA especially at the lower 
doses. 
Nicotinic Acid (Niacin or vitamin B3) is a supplement that is associated with 
increased SUA. Niacin is also used to manage patients with dyslipidemia to increase high-
density lipoprotein (HDL) and lower low-density lipoprotein (LDL) and triglycerides. 
Besides the well-documented side effects of flushing and GI disturbance, niacin can 
increase uric acid at the therapeutic doses (>1500mg/day) used to treat patients with 
dyslipidemia. The proposed mechanism of nicotinic acid associated hyperuricemia 
involves two key transporters.  These transporters are the URAT1 (SLC22A12) and 
OAT10 (SLC22A13), which facilitate nicotinic acid excretion at the expense of uric acid 
reabsorption.97,104 
Testosterone has been also associated with increased SUA. This, in part, explains 
why males tend to have a higher level of SUA compared to females. The mechanism by 
which testosterone increases uric acid was investigated in orchietomized mice model in 
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which testosterone was replaced exogenously. It was noted that testosterone replacement 
was associated with increased levels of mRNA and protein of the URAT1 and Sodium-
coupled Monocarboxylate Transporter (SMCT1). This further suggests a plausible 
mechanism for the high uric acid associated with testosterone replacement therapy via the 
enhanced uric acid reabsorption mechanism.105,106 In addition, it is believed that 
testosterone in part also increases muscle mass which itself a major source of purines 
explaining the rise in SUA with testosterone replacement therapy.88 
Cyclosporine and tacrolimus are widely used immunosuppressant drugs and 
commonly used in solid organ transplant patients. Hyperuricemia has been strongly 
associated with their use although the exact mechanism is not clearly understood.107 
However, it is presumed that both drugs may be interacting with OAT10 (SLC22A13) 
transporter causing SUA levels to rise. On one hand, amlodipine was prospectively shown 
in one study to have significantly reduced uric acid levels in cyclosporine-induced 
hyperuricemia patients who were  hypertensive renal transplant recipients.108  On the other 
hand, amlodipine has shown  to increase cyclosporine trough levels with up to 40% .108 
Although it is known that amlodipine may reduce the metabolism of cyclosporine levels 
by inhibiting CYP3A4, this study did not document any significant change in cyclosporine 
dose as a consequence of this interaction. Additionally, there was no change in serum 
creatinine, blood urea nitrogen, or mean arterial pressure values before and after 
amlodipine therapy.109 While the interplay between amlodipine and cyclosporine would 
suggest cytochrome P450 interaction, mainly CYP3A4, the interplay between 
cyclosporine, amlodipine, and uric acid would suggest a transporter-mediated interaction. 
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In addition, one might think that although amlodipine can increase cyclosporine levels, it 
is believed the changes in the eGFR because of amlodipine could counteract the effect of 
vasoconstriction-induced cyclosporine hence enhancing uric acid clearance.108   
While gout and hypertension have been linked, the effect of anti-hypertensive drugs 
have been also known to modulate the risk of gout. A nested case-control study design 
from the health improvement network database from the United Kingdom general practice 
conducted from 2000 and 2007, was used to assess the relative risk of incident gout 
associated with antihypertensive drugs.95 After adjusting for age, sex, body mass index, 
visits to the general practitioner, alcohol use, and pertinent drugs and co-morbidities, the 
relative risk of incident gout associated with the use of different antihypertensive drugs in 
patients with hypertension (n= 29,138) was different by drug class (Table 2.3). Notably, 
the multivariate analysis of relative risks of gout showed that there were both duration and 
dose associations with the effect those drugs have on the risk of gout. For example, the 
relative risk for calcium channel blockers was 1.09 for use less than one year, 0.89 for use 
of 1-1.9 years, and 0.77 for more than two years.  In total, 12,858 (51.9%) patients with 
gout had a recorded diagnosis of hypertension before the diagnosis of gout. After 
adjusting for age, sex, calendar year, and visits to a general practitioner, the relative risk of 
incident gout with hypertension was 1.99 compared to those without hypertension.95 This 
suggests that certain antihypertensive drugs can increase the risk of gout when used long-
term such as beta-blockers and diuretics while others can reduce SUA such as losartan and 
amlodipine [Table 2.3].  
Theophylline is a methylxanthine bronchodilator that is used in patients with chronic 
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obstructive pulmonary disorder. Although the metabolism of theophylline involves 
multiple cytochromes P450 enzymes, xanthine oxidase plays a major role in the formation 
of the active and inactive metabolites of theophylline.  While the use of theophylline 
remains limited due to its narrow therapeutic window, significantly elevated SUA levels 
were documented in asthmatic patients using theophylline compared to controls.110,111 
Although the exact mechanism by which theophylline can raise SUA levels remains 
inconclusive, it is presumed that theophylline raises uric acid production by enhancing 
purine catabolism by slightly inhibiting the activity of hypoxanthine/guanine 
phosphoribosyl transferase, which is a critical enzyme in the salvage pathway for purine 
synthesis.112,113 
Disease-Induced Hyperuricemia 
Acute exposure to higher levels of SUA has been clearly linked to the development 
of acute uric acid nephropathy, urolithiasis, formation of uric acid kidney stone and gout.  
For example, enhanced uric acid production due to rapid cell turnover, as in the case of 
tumor lysis syndrome or cell overgrowth as in the case of malignancies and leukemia, are 
strongly correlated with enhanced risk for acute kidney nephropathy. Chronic primary 
kidney disease, however, can be linked to chronic hyperuricemia and it has been proposed 
that the increasing prevalence of end-stage-kidney disease may be a result of the rising 
prevalence of gout.57 Other more complex diseases such as metabolic syndrome tend to be 
highly associated with hyperuricemia.20 Although it is controversial whether 
hyperuricemia is the cause of metabolic syndrome versus hyperuricemia is the culmination 
of metabolic syndrome,114 it is well documented that metabolic syndrome is more 
prevalent in patients with gout versus those without gout.  According to the NHANES III 
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(1988-1994), there is a significantly graded associated prevalence of metabolic syndrome 
defined by the NCEP/ATP with hyperuricemia with estimated prevalence of 18.9% for 
SUA <6mg/dL versus 70.7% for SUA > 10mg/dL.19 These observations of the association 
of hyperuricemia and metabolic syndrome, kidney disease and cardiovascular diseases, 
elevate the importance of managing hyperuricemia in the context of comprehensively 
addressing cardiovascular disease risks.  Summary of primary and secondary causes of 
hyperuricemia subtypes are listed in Table 2.4.   
Hyperuricemia Secondary to Renal Insufficiency  
The defective renal elimination accounts for approximately 80-90 % of 
hyperuricemia cases (underexcreters) while the remaining cases results from 
overproduction or combined mechanisms.69 Hyperuricemia and renal insufficiency are  
common clinical presentations that trigger a debate on the nature of the relationship 
between these two conditions. Although urate levels may not rise in patients with mild to 
moderate kidney function, urate levels tend to be markedly elevated in patients with 
creatinine clearance below 30mL/min. Conversely, FEUA% could rise exponentially 
when creatinine clearance falls below 30mL/min (see equation below) in patients with 
hyperuricemia secondary to renal insufficiency.69 This high FEUA% in this patient 
population may confound their hyperuricemia or gout assessment based on being 
underexcreters, overproducers, or both (Tables 2.5-6).  
𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹 = 𝐹𝐹𝑈𝑈𝑈𝑈𝑈𝑈 𝐹𝐹𝑈𝑈𝑈𝑈𝐴𝐴 𝑚𝑚𝑚𝑚/𝐴𝐴𝑑𝑑(𝑢𝑢𝑈𝑈𝑈𝑈𝑢𝑢𝑢𝑢) ∗ 𝐶𝐶𝑈𝑈𝑢𝑢𝐶𝐶𝐶𝐶𝑈𝑈𝑢𝑢𝑈𝑈𝑢𝑢𝑢𝑢 𝑚𝑚𝑚𝑚/𝐴𝐴𝑑𝑑(𝑆𝑆𝑢𝑢𝑈𝑈𝑢𝑢𝑚𝑚)
𝐹𝐹𝑈𝑈𝑈𝑈𝑈𝑈 𝐹𝐹𝑈𝑈𝑈𝑈𝐴𝐴  𝑚𝑚𝑚𝑚/𝐴𝐴𝑑𝑑(𝑆𝑆𝑢𝑢𝑈𝑈𝑢𝑢𝑚𝑚) ∗ 𝐶𝐶𝑈𝑈𝑢𝑢𝐶𝐶𝐶𝐶𝑈𝑈𝑢𝑢𝑈𝑈𝑢𝑢𝑢𝑢 𝑚𝑚𝑚𝑚/𝐴𝐴𝑑𝑑 (𝐹𝐹𝑈𝑈𝑈𝑈𝑢𝑢𝑢𝑢) × 100 
Uric Acid Reference Levels Confounders 
The reference range of serum urate is based on the levels at which there is an 
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increased risk of developing gout. As discussed earlier, levels of SUA can be affected by 
select drugs or changes in the kidney function. However, other variables can greatly 
modulate serum urate outside the normal reference levels [Table 2.7]. These variables 
include age, sex, race, genetics pregnancy and diet. Therefore, assessment of these 
variables should be incorporated in the patient’s initial evaluation for hyperuricemia or 
gout. 
Age and sex 
In males, the annual incidence rates for the first gout episode exponentially increase 
with SUA at or greater than 0.42mmol/L (~ 7.1mg/dL), which coincides with the 
saturation value of urate in plasma at 37°C.69  On average, women tend to have about 
0.06mmol/L (1mg/dL) urate levels lower compared to men, which is attributed to the 
uricosuric effect of estrogen. On the contrary, women tend to be affected by rheumatic 
diseases far greater than men. However, gouty arthritis seems to affect a relatively a small 
fraction of women (3-5%) compared to men (5-12%) with the overwhelming majority at 
the postmenopausal age.115  
Race and genetics 
The prevalence of asymptomatic hyperuricemia among Polynesian women (Maori, 
Cook Islanders, Samoans and Tongans) is doubled compared to Caucasians.9 This high 
prevalence of hyperuricemia is predominantly caused by the reduced FEUA% and is not 
associated with renal disease. The urate excretion rate is reported to be even lowers in 
Polynesian males.69 These findings further support the hypothesis that the indigenous 
pacific races share a similar genetic defect in renal handling of urate rather than a renal 
dysfunction causing hyperuricemia.  The exact mechanism that genetics can affect the risk 
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of hyperuricemia or gout is discussed in more depth in the next chapter.  
Pregnancy 
Urate levels initially fall by up to 25 % in the first trimester but rise to values of 20% 
higher than non-pregnant state. However, the urate levels are markedly elevated in pre-
eclampsia events.69,116  
Diet 
The recommended reference interval of 24-hours urine uric acid collection in 
patients on an average or normal purine content diet is 1.5-4.5 mmol/day (250-
750mg/day). In general, uric acid excretion can be either decreased or increased in 
response to a variety of pharmacologic agents. Nonetheless, the urinary uric acid excretion 
rate is elevated in a significant proportion of patients with uric acid stones and in those 
with states of uric acid overproduction such as in leukemia and polycythemia and after 
intake of food rich in nucleoproteins.69 
Risk Factors for Hypouricemia 
There are select and well documented lifestyles that can decrease SUA and reduce 
the risk of gout. While weight loss and regular physical activity can decrease SUA in the 
long-term, some dietary and food sources have been also associated with lowering 
SUA.117 For instance, adequate hydration is very important to promote uric acid filtration 
and subsequently excretion. This lifestyle is highly recommended in individuals who tend 
to have a higher risk for forming kidney stones. As mentioned previously, the acidification 
of urine can increase UA reabsorption; in contrast, the alkalization of urine can greatly 
enhance UA excretion. In fact, one of the treatment modalities of managing gout and uric 
acid kidney stones is the use of potassium citrate, which increases the pH of the urine 
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stimulating stone dissolution through increasing uric acid excretion. Dietary sources that 
could increase urine pH are low-fat dairy products e.g. skimmed milk.38   
While high-purine contents food can adversely affect gout, or trigger a gout attack, 
cherries have been shown and reported to ameliorate gout attacks and may reduce SUA. 
An internet-based observational case-crossover study has assessed the effect of cherry 
consumption in 633 patients with gout during 2-day hazard period (prior to gout attack) 
compared to 2-day control period.118 The study identified that consumption of any cherries 
was associated with a 35% lower risk of gout attack compared with no consumption. 
Additionally, the risk of gout attack was further lower with increased consumption of 
cherries with up to 3 servings over 2-days. Notably, the study identified that the exposure 
to the combination of allopurinol and cherries had 75% lower risk of gout attacks 
compared to without either exposure.  
Although the study by Zhang et al 118 did not assess the effect of cherry consumption 
on SUA levels, Jacob et al 119 investigated the effect of consuming two servings of 
cherries on plasma urate in 10 healthy women. The consumption of cherries was 
significantly (p<0.05) associated with reduced plasma urate at 5 hours post-dose (3.1 + 
0.25 mg/dL) compared to pre-dose (3.6 + 0.22 mg/dL). In addition, urinary urate/plasm 
creatinine excretion ratio significantly increased (p<0.05) 5 hours post-dose with peak 
excretion at 3 hour (p <0.01) compared to pre-dose. These results suggest that cherries 
may exert an acute uricosuric effect in addition to containing high levels of anthocyanin 
(anti-inflammatory) and ascorbic acid or vitamin C (antioxidant). Together, this may well 
explain the anti-inflammatory and uric acid-lowering effects associated with cherries 
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consumption during gout attacks.  
From an evolutionary perspective, it could be theorized that uric acid became the 
endogenous antioxidant as a compensatory mechanism when vertebrates lost their 
ascorbic acid synthesizing-gene. Moreover, the loss of uricase enzyme in humans, which 
converts uric acid to allantoin in other species, possibly made uric acid critical for 
survival. Therefore, the effect of vitamin C ingestion on uric acid metabolism has been 
explored in patients with hyperuricemia or gout. Indeed, it has been shown that ingestion 
of vitamin C especially at higher doses could enhance uric acid excretion.38 A study used 
vitamin C 500mg supplement for 2 months showed a significant reduction in uric acid. 
Furthermore, an epidemiological study conducted in Korean Multi-Rural Communities 
Cohort (n=9400) identified an overall significant trend for reduced risk of hyperuricemia 
associated with increased dietary and total vitamin C intake.  Stratified by gender, females 
had significant trends for reduced risk of hyperuricemia with either source of vitamin C; 
however, males only had a significant trend for reduced risk of hyperuricemia with dietary 
vitamin C.120 Although the urate-lowering effect mechanism of vitamin C remains unclear, 
it is hypothesized that vitamin C competes for uric acid reabsorption and possibly inhibits 
xanthine oxidase.  
Smoking has been an established risk factor for numerous diseases and 
comorbidities while being a leading cause of lung cancer. Smoking has also been shown to 
influence uric acid levels and modulate the risk for developing gout.121 While the exact 
mechanism by which smoking can affect uric acid levels remains unknown, recent studies 
have shown that smoking has been associated with lower SUA levels leading to reduced 
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risk for developing gout.122 Specifically, analysis of 54-year follow-up data from the 
Framingham Heart Study involving 2279 men and 2785 women who were gout free at 
their first assessment was used to assess the direction and magnitude of association of 
smoking and onset of gout. The study concluded that smoking was independently 
associated with overall reduced the risk of gout incidents of by 24% (HR 0.76, [95% 
CI,0.59 to 0.98]). When stratified by sex, the risk reduction of gout incidence was 
significant in men but not in women (HR 0.68, [95% CI, 0.59 to 0.98] vs. 0.92, [95% CI, 
0.6 to 1.41]), respectively.123 Also, the study noted that SUA was generally lower in the 
smokers than non-smokers; however, it did not reach statistical significance. The results of 
this study prompt the need for understanding the mechanism by which smoking can 
influence SUA or development of gout. To date, the main proposed mechanism for this 
observation may be the inactivation of XO by thiocyanate- the end product of 
detoxification of hydrogen cyanide present in cigarette smoke.124  However, the role of 
nicotine and its metabolites on SUA remains a hypothesis generating question.  
Hyperuricemia, Gout and Cardiovascular Diseases 
The association between gout and cardiovascular diseases has been observed since 
the late 19th century. This association became more evident in 1950s-1960s when several 
epidemiological studies have shown that not only hyperuricemia but the normal high SUA 
was also associated with incidence of cardiovascular related comorbidities.125  However, 
this association remains too controversial to mandate uric acid monitoring in order to 
follow an individual’s risk for cardiovascular disease. While there are reports that show 
uric acid can be an independent risk factor for developing cardiovascular disease as well 
 58 
as kidney diseases [Figures 2.6-7], uric acid may not be the direct cause of kidney disease 
but it may however lead to the development of hypertension which has a greater impact on 
the kidney than uric acid itself. Therefore, the causal relationship of uric acid and CVD 
requires a reappraisal and consideration of studies to show the direct effect of uric acid on 
CVD and kidney disease.23 
The effect of hyperuricemia on hypertension itself, has been a consistent observation 
from many studies involving animals and humans.56,126-130  In addition, the parallel of the 
magnitude of effect hyperuricemia has on blood pressure values has been consistent for 
adults with pre-hypertension and essential hypertension. In one study, an elevated SUA > 
5.5 mg/dL was observed in 90% of adolescents with essential hypertension whereas SUA 
levels were significantly lower in controls with white-coat or secondary hypertension. 
This finding further suggests that the development of hyperuricemia generally precedes 
the development of essential hypertension [Figure 2.7-8].131  
The mechanism by which hyperuricemia can cause hypertension may involve two 
primary mechanisms. Animal models of hyperuricemia suggest that high SUA can cause 
direct microvascular changes to the endothelial cells and vascular smooth muscles as well 
as systemic and glomerular hypertension. In addition, high SUA is also associated with 
increased renin level activity which in turns causes more vasoconstriction and decreased 
salt excretion (Figure 2.7-8).22  These proposed mechanisms may suggest that reversing 
hyperuricemia in individuals diagnosed with pre-hypertension or early onset of 
hypertension could achieve normal blood pressure upon treatment using urate-lowering 
therapy (ULT). To test whether lowering SUA could lower blood pressure, 30 adolescents 
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newly diagnosed with hypertension having SUA > 6mg enrolled into a randomized, 
double-blind, placebo-controlled crossover trial.132 The study showed using 200mg 
allopurinol twice daily for 4 weeks significantly lowered the casual and 24-hour 
ambulatory systolic and diastolic blood pressures. Specifically, the mean change in 24-
ambulaotry SBP for allopurinol was -6.3 mm Hg [95% CI, -3.8 to -8.9] vs 0.8 mm Hg 
[95% CI, 3.4 to -2.9] for placebo. Similarly, the mean change in the 24-ambulaotry DBP 
for allopurinol was -4.6 mm Hg [95% CI, -2.4 to -6.8] vs -0.3 mm Hg [95% CI, 2.3 to -
2.1]. However, these findings have not been replicated in large clinical trials to qualify the 
use of allopurinol in the manage of hypertension or treatment of asymptomatic 
hyperuricemia.  
Although gout as an independent risk factor for CVD could remain controversial, the 
question to be asked is whether the management of gout using ULT could reduce CVD 
associated mortality.  A large prospective case-matched cohort study was conducted over 
6.5 years to assess the risk of death from CVD and all-cause mortality in 40,623 
Taiwanese patients with gout aged >17 years.  In addition, the study assessed the effect of 
ULT on mortality risk in patients with gout. 133 The study concluded that patients with 
gout not treated with ULT had an increased risk as high as 143% and 45% for CVD 
mortality and all-cause mortality, respectively. On the other hand, patients with gout 
treated with ULT had 71% and 53% risk reduction for CVD mortality and all-cause 
mortality, respectively. Furthermore, the duration of ULT was also important in predicting 
CVD mortality risk reduction, especially in patients using ULT >2 years. While the effect 
of ULT on CVD mortality did not differ across drug classes, most participants in the study 
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were taking benzbromarone (73%) followed by allopurinol (53%).133  
This study highlights two critical aspects for managing patients with gout. First, the 
benefits of managing gout extend beyond the immediate gout therapy outcomes of 
reducing flares or preventing the formation of urate crystals. Second, the treatment 
modality for managing gout may have a little impact on CVD outcomes rather than the 
patients is being treated and controlled 
Uric acid and Neurodegenerative Diseases 
While high uric acid levels and gout are strongly associated with increased 
cardiovascular and endocrine comorbidities, the antioxidant effect of uric acid may have a 
neuroprotective effect which could explain the mutual exclusivity of gout and multiple 
sclerosis.134 From an evolutionary perspective, the loss of uricase activity led to higher 
SUA levels, which may have had survival benefit as an antioxidant in humans and higher 
primates and sustaining blood pressure during evolutionary bottlenecks. This theory could 
provide a rationale for mammals having a very low SUA levels relative to humans. 
Furthermore, epidemiological studies have shown that individuals with that low SUA 
levels have a higher risk and faster progression of Parkinson’s disease (PD).135 
Levels of SUA have been shown to be influenced by genetic variabilities, primarily 
SNPs, within key uric acid transporters.80,81 83Given the normal physiological role of uric 
acid as a natural antioxidant, the Mendelian Randomization approach would suggest that 
more patients with neurodegenerative diseases would be carriers of risk alleles associated 
with lower SUA than controls. To address and test this hypothesis, a case-control study 
design was used to estimate the genetic risk score of previously reported eight loci in 
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patients with PD (n= 1061) and without PD (n=754). The study concluded that male 
patients with PD had a lower SUA than controls (5.61 vs. 6.27, p=0.04). In addition, the 
study identified that patients with > 9  genetic risk score (range 0-16) associated with low 
SUA, had OR of 1.55 (95% CI, 1.10-2.18) compared to controls with 2-7 risk alleles to 
have PD.136 In contrast, SUA levels did not show a significant effect on the development 
of dementia in patients with PD.137 
Additionally, a study by Lu et al 138 evaluated the potential role of gout and the risk 
of developing Alzheimer Disease (AD) in the general population using matched cohort 
design for age, sex, entry-time, and body mass index from an electronic database 
representative of the UK general population. The study identified that gout was 
significantly and inversely associated with new cases of AD. After a median follow-up of 
5 years, HRs for developing AD among patients with gout were 0.71(95% CI, 0.62- 0.80), 
and 0.76 (95% CI, 0.66- 0.87) in both univariate and multivariate analyses, respectively.  
With evidence suggesting that uric acid is a neuroprotective, one may postulate that using 
uric acid therapeutically in neurological disease or cerebral injuries may contribute 
positively to the overall therapeutic outcomes. Although some research is ongoing to 
investigate the use of uric acid in established neurodegenerative diseases, the combined 
use of uric acid with the thrombolytic agent- alteplase in acute ischemic stroke has been 
conducted.  Specifically, a study in patients with ischemic stroke assessed the proportions 
of patients with excellent outcomes at 90 days after receiving uric acid versus placebo in 
addition to alteplase. Although the primary outcomes occurred more in the uric acid group 
versus placebo (39% vs. 33%, p=0.099), other subgroup analyses showed marginal 
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significant effect favoring the co-administration of uric acid with alteplase therapy.139 
Pathophysiology of Gout  
Gout is not a stagnant disease but rather progressive and, if not controlled, can result 
in greater damage to the tissues and joints. However, gout is divided into multiple stages 
depending on the disease presentation. Generally, gout is preceded by asymptomatic 
hyperuricemia, which is followed by the first onset of acute gout attack. Further, the acute 
gout attack can be recurrent attacks interspersed by intercritical asymptomatic 
hyperuricemia. Ultimately, if not controlled, gout can progress to a symptomatic 
tophaceous gouty arthritis and enhanced risk of forming uric acid kidney stones.   
Gout is the most common arthritic inflammatory disease caused by the deposition of 
Monosodium Urate (MSU) crystals in the joints as well as soft tissues. While the 
concentration of SUA is a critical determinant of MSU crystals formation, the tissue 
environment also plays a key role in their precipitation. For instance, tissues and joints 
that are not highly perfused may result in a local environment whereby a reduction in 
temperature at that joint may enhance MSU formation.140 Moreover, the existence of an 
ongoing trauma or injury at those joints or tissues around them can augment the risk of 
crystal formation. These observations are  supported by the observed association between 
osteoarthritis and gout.141 Therefore, the preemptive management of gout flares in patients 
with a history of joint disease can incur clinical benefit by deterring new onset of joint-
related or musculoskeletal diseases. Furthermore, the optimal management of uric acid 
levels of patients with existing joint disease can further reduce and prevent tissue 
inflammation and ward off further joint damage or the development of gout later in life 
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[Figure 2.3].  
The deposition of the MSU is dependent on the solubility and saturation levels of the 
ionic product of sodium and SUA. Generally, SUA concentrations that exceed 6.8mg/dL 
are considered critical for MSU crystals formation and deposition within and between 
joints.140 Monosodium urate crystals tend to primarily affect the distal joints. For example, 
the metatarsal phalanges tend to be the most targeted joints for crystals deposition causing 
tophi.140 While the distal joints are the primary sites for MSU deposition, the extra-
articular manifestations and the soft tissues including kidney, synovial membrane and the 
vasculature system share the burden of elevated levels of SUA causing interstitial 
nephritis and synovitis, respectively. MSU crystals tend to reside in the site of origin and 
within the synovial fluids. However, the dissolution or shedding of the MSU crystals is a 
major trigger for the immunological response characterizing the swelling, erythema, and 
pain associated with acute gout attacks [Figure 2.3]. This response is mediated by the 
monocytes’ phagocytic activity towards the MSU crystals consequently activating NALP3 
also called cryopyrin. The release of NALP3 inflammasome complex triggers the release 
of IL-1 and other cytokines subsequently the infiltration of neutrophils. 142  
Pharmacotherapy of Gout and Hyperuricemia  
In clinical practice, asymptomatic hyperuricemia is not usually treated and no FDA 
approved drugs have been indicated for its management. Nonetheless, since elevated SUA 
is a precursor to gout, the pharmacotherapy associated with managing patients with gout 
naturally targets SUA levels as the key therapeutic outcome. The treatment goals for 
managing a patient with gout include achieving SUA <6mg/dL, reduce the risk for new 
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onset or recurrence of acute gout attacks, and optimal management of other diseases or 
comorbidities.  Additional goals include ensuing dietary and lifestyle changes, improve 
quality of life, and ultimately prevent further joint damage due to chronic gouty 
arthritis.143  Acute gout attacks are extremely painful and often debilitating for the patient 
and associated with a high indirect societal cost (lost days of work, physical immobility, 
reduced quality of life). While the frequency of gout attacks is a marker for how gout is 
controlled, the immediate resolution of acute gout symptoms is of a paramount goal to 
patients with gout and the society at large.144 A pictorial summary of the drugs used to 
manage acute gout attacks and longer-term management of gout is shown in Figure 2.9.  
Management of Acute Gout Attacks 
In general, there are several approaches to managing acute gout attacks. Preference 
is given to those therapies thought to be the most effective, tolerated and with the least 
side effect profile. Therefore, the general approach involves an individualized assessment 
of the benefits and risks of each of the following drug therapies.   
The first line of drug pharmacotherapies used to manage acute gout attacks are the 
non-steroidal anti-inflammatory drugs (NSAIDs), followed by colchicine followed or 
corticosteroids.  Although these drugs are equally efficacious, the selection amongst drug 
classes is patient-specific and possibly cost driven.  For instance, consideration of the 
patient’s current medication list and existing comorbidities as well as drug cost are critical 
determinants for choosing the right drug for the right patient to optimize response and 
resolve existing symptoms.145,146 Further discussion on the therapeutic options within each 
class and some key considerations while using these drugs for managing patients with 
acute gout attacks is summarized in the following sections.  
 65 
NSAIDs have been used extensively in managing a wide range of symptoms of pain 
and inflammatory disease states; acute gout attack is a classic indication for the use of 
NSAIDs to control pain and reduce inflammation.  The mechanism of action of NSAIDs is 
to inhibit the Cyclooxygenase (COX) enzyme, which is responsible for the conversion of 
arachidonic acid to prostaglandins, which play major role in the pain signaling cascade 
during acute gout attack. Consequently, targeting the prostaglandins formation cascade 
presents as a reasonable mechanism to reduce the pain associated with gout attack. 
Although NSAIDs are effective and less costly drugs to control pain, they are associated 
with some adverse events in a select patient population. Therefore, assessment of the 
patient’s risk for CVD, gastrointestinal (GI) bleeding, chronic kidney disease, existing 
peptic ulcer, or the use of concomitant drugs that would potentiate the risk for bleeding are 
important to consider when selecting an NSAID. Furthermore, though most NSAIDs are 
equally effective, some NSAIDs tend to have an additive benefit to use amongst patients 
with gout. For instance, indomethacin has been shown to possess some uricosuric effects 
relative to piroxicam.147  
Moreover, most the NSAIDs (ibuprofen, naproxen, diclofenac, celecoxib) are 
substrates for hepatic metabolism via the CYP2C9. Therefore, knowledge of CYP2C9 
genetic status of reduced function may further guide the selection between different 
NSAIDs while minimizing the risk for GI bleeding.148 However, it must be borne in mind 
that the prescribing habits of clinicians change over the course of time and by region, 
which could explain the declining trend of NSAID prescriptions whereas colchicine is 
trending up, in part due to the cardiovascular risks associated with NSAID use. 
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Furthermore, celecoxib is the only NSAID on the market that selectively inhibits COX-2 
enzyme, which may be associated with decreased risk of GI bleeding for patients who are 
not candidates for colchicine or long-term use of corticosteroids. Additionally, the co-
prescribing of proton pump inhibitors with long-term use of NSAID can further reduce the 
risk of GI bleeding.  
Colchicine is an alkaloid derived from extracts of meadow saffron, which was 
discovered in the early 1700 AD to provide some relief during gout attacks. The exact 
mechanism of colchicine to alleviate pain is by disrupting the polymerization and 
mobilization of the microtubules subsequently interfering with the neutrophil functions, 
lysosomal degranulation, and leukocyte chemotaxis.  Furthermore, colchicine suppresses 
the MSU crystals-induced NALP3 inflammasome driven capsase-1 activation and 
interleukin (IL)-1 β processing. These effects collectively suppress the inflammation 
response and the infiltration of the immunological cells at the site where MSU crystals 
triggering attacks. 149 
The dosing regimen of colchicine has undergone major changes as a result of the 
findings from the randomized, double-blind, placebo-controlled, parallel-group, dose-
comparison colchicine study, which assessed the safety and efficacy of a low dose 
colchicine versus the high dose colchicine.150 The study identified that the low dose of 
colchicine defined as 1.2mg at the onset of the gout attack followed by 0.6mg an hour 
later was as equally effective as the high dose defined as 1.2mg at onset of gout attack 
followed by 0.6mg hourly for a total of 6 hours. Furthermore, the lower dose of colchicine 
had lower incidences of adverse events than those associated with the high dose.  
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Colchicine is a p-glycoprotein substrate, metabolized in the liver by CYP3A4, and 
cleared by the kidney; therefore, assessment of liver function and kidney function as well 
as the presence of strong CYP3A4 inhibitors (clarithromycin, cyclosporine, verapamil, 
ketoconazole) are important for dosing adjustment. On one hand, colchicine is known to 
have a narrow therapeutic index, significantly associated with gastrointestinal toxicities 
(nausea, vomiting, diarrhea) and potentially myotoxic (muscle weakness, myalgia, 
rhabdomyolysis). These unique characteristics of colchicine warrant careful assessment of 
potential adverse events to minimize the risk of colchicine toxicity when co-administered 
with drugs that are known to be CYP3A4 inhibitors and/or p-glycoprotein 
substrates.146,149,151 On the other hand, the long-term use of colchicine has been 
significantly associated with reduced risk of myocardial infarction in patients treated for 
the duration of 3 years with relative risk of 0.20 [95% CI, 0.07 to 0.57] though it was not 
significantly associated with reduced all-cause mortality.152 
Corticosteroids (CS) are effective option in the management of acute gout attacks, 
especially if the patient cannot tolerate oral NSAIDs or colchicine.  The routes of 
administration of CS (oral, parenteral, intra-articular) further allow their use in various 
clinical settings as well as disease states. The main mechanism of action of CS is the 
inhibition of the phospholipase A2, thereby blocking the eicosanoids production, 
leukotriene synthesis, and various leukocyte inflammatory functions. While large 
randomized control trials are lacking, small studies have consistently shown comparable 
efficacy of using either oral NSAIDs or corticosteroids in resolving acute gout attacks. 
Intra-articular triamcinolone and methylprednisolone, however, represent unique options 
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for patients with up to 2 joints experiencing inflammation. Obviously, intra-articular 
administration carries a higher risk of unmasking latent infection and one must rule out 
septic arthritis is needed before injection. 149  
Canakinumab is an approved Interleukin-I (IL-1) inhibitor representing a unique 
option for patients with Systemic Juvenile Idiopathic Arthritis (SJIA). Although it is not 
FDA approved for use in gout attacks, it presents a possible alternative for patients 
experiencing frequent gout attacks and intolerant or refractory to other therapeutic options, 
or not candidates for colchicine, CS, or NSAIDs.153 Given the shared inflammation 
pathway associated with both SJIA and MSU-induced inflammation, it is believed that 
canakinumab could be as effective if not superior to other agents used to manage acute 
gout attack.149 In fact, two published phase III studies154 compared canakinumab (n=230) 
and triamcinolone (TA)(n=236) in patients with acute Gout flare. Compared to TA 40mg 
intramuscularly (IM), canakinumab 150mg subcutaneously was found not to be only 
significantly associated with reduced pain score, but also delayed the time to first new 
flare and reduced the risk of new flares by 62% versus TA 40mg IM (HR: 0.38; 95% CI 
0.26 to 0.57). However, adverse events reported more frequently with canakinumab 
included infections, low neutrophil count and low platelet count. Summary of 
pharmacological options for the management of acute gout attack are listed in Tables 2.8-
9.  
 Long-term Management of Gout 
Lowering serum urate could be achieved via two different mechanisms. The first 
mechanism is to decrease SUA production and/ or enhance UA excretion. The second 
mechanism is to prevent UA reabsorption. In either case, a goal of SUA < 5-6mg/dL , 
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depending the severity of gout, may not be achieved using only one approach which 
prompts the need for a combined approach. Therefore, understanding the mechanism of 
actions of these therapeutic modalities can enhance the selection of effective drug 
regimens to reach SUA goal.143  Dosing and considerations of selecting ULT are 
summarized in Table 2.10. 
Allopurinol is a purine analog xanthine oxidase (XO) inhibitor and has been 
extensively used since 1950s to manage patients with gout and remains the most 
prescribed drug amongst 96% of patients with gout. 155 Allopurinol is rapidly absorbed 
from the GI track resulting in a bioavailability of 80% with a range of 67-90%. 
Allopurinol has a short half-life (1-2 hours), however, the main urate-lowering activity is 
attributed to the active metabolite oxipurinol, which has a much longer half-life (12-23 
hours) than allopurinol.156 Oxipurinol is mainly eliminated by the kidney and therefore 
changes in kidney function or polymorphisms in the transporters responsible for 
oxipurinol disposition may greatly explain the wide range seen in the oxipurinol half-life.  
Based on the oral bioavailability and the molecular weights of allopurinol and oxipurinol, 
it is estimated that a 100mg of allopurinol results in 90mg of oxipurinol.156  The maximal 
decrease of urate following a single dose of allopurinol is reached between 6-24 hrs post-
allopurinol dose. With XO being the rate limiting step in forming uric acid, it is the major 
metabolizing enzyme for forming oxipurinol from allopurinol. Furthermore, both 
allopurinol and oxipurinol are inhibitors of XO. On the other hand, a growing evidence 
supports that allopurinol is also a substrate for the aldehyde dehydrogenase enzyme while 
being also a substrate for the XO enzyme. This may be explained by the lack of XO 
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enzyme saturation with chronic dosing of allopurinol and the high variability of the urate-
lowering response to allopurinol.156  
Although it is the most commonly prescribed urate-lowering therapy drug with clinically 
established efficacy, allopurinol is significantly associated with a Severe Cutaneous 
Adverse Reactions (SCARs), which include hypersensitivity syndrome, Stevens-Johnson 
Syndrome, and toxic epidermal necrolysis. These serious and sometimes fatal adverse 
events have been linked to a genetic variant within the Human Leukocyte Antigen (HLA) 
B noted as HLA-B*58:01.157,158  
The HLA-B is considered part of the Major Histocompatibility Complex-I (MHC-I), 
which plays a key role in the immune system response to present endogenous and 
exogenous bound peptide antigens to T cells.  HLA-B is considered the most polymorphic 
gene in the human genome with more than 1500 alleles to date to present wide variety of 
“self” and “non-self” peptides. Carriers of this genetic variant, HLA-B*58:01, are at a 
much higher risk for allopurinol induced SCARs compared to non-carrier. Therefore, the 
use of allopurinol in these patients is contraindicated. The prevalence of this genetic 
variant is markedly higher in Asian subpopulations mainly the Korean, Han Chines, and 
Thai descents. Although allopurinol induced-SCARs are rare with estimated risk of 0.1 to 
0.4%, it is one of the most serious adverse events with mortality rate of up to 25%.  While 
there are therapeutic alternatives for allopurinol, the use of a prospective screening for 
HLA-B*58:01 carrier status can efficiently strategize the utilization of available urate 
lowering therapy while preventing major adverse effects that can be fatal in some 
patients.159 
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Moreover, the risk for these serious cutaneous adverse events has also been 
associated with non-genetic factors. These factors include the dose initiated, titration 
period, and kidney function. Though the presence of the risk allele should be sufficient for 
the decision of not prescribing allopurinol, the knowledge of the patient’s genotype is not 
commonly available at initiation of allopurinol therapy. Alternatively, it was suggested 
that starting the patient on the lowest dose possible of allopurinol (100mg) daily while 
monitoring for adverse events and titrating slowly (every 2-4 weeks) to SUA goal can 
dramatically reduce the risk of developing SCAR.153 Fortunately, patients who are carrier 
of the risk allele of HLA-B*5801 can be alternatively treated with febuxostat.  
Febuxostat is a non-purine analog XO inhibitor and effectively lowers SUA 
production. Unlike allopurinol, febuxostat is not associated with the risk for developing 
SCAR and non-selectively inhibits both isoforms of the xanthine oxidoreductase. In fact, 
in a study of 756 patients with gout and SUA> 8mg/dL, 53% of  patients(n=255) treated 
with 80mg febuxostat and 62% of patients (n=250) treated with 120mg febuxostat have 
achieved SUA<6 mg/dL compared to  21% of patients (n=251) treated with 300mg 
allopurinol (p<0.001).160 However, the febuxostat arm had a higher incidence of 
cardiovascular related mortality. Another key difference between febuxostat relative to 
allopurinol is the route of elimination. Febuxostat is mainly metabolized in the liver via 
UGT1A2, whereas oxipurinol is mainly cleared through the kidney unchanged. This key 
difference in elimination presents as a reasonable therapeutic alternative in patients with 
impaired or declining kidney functions.161 On the other hand, febuxostat has been also 
associated with elevated liver enzymes; therefore, regular monitoring of liver function is 
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recommended. Also, it must be born in mind that febuxostat is far more expensive than 
allopurinol which is a limiting factor for its clinical use.161   
Although the available XO inhibitors can effectively reduce SUA, many patients 
receiving these drugs fail to achieve their SUA target goal. This phenomenon could be 
explained by three possible mechanisms. One of the major reasons is compliance to urate-
lowering therapy, which is a major area for improvement.162,163 The second reason could 
be attributed to the fact that most patients with hyperuricemia are UA underexcreters 
rather than overproducers, which is not accounted for in the diagnosis of gout or treatment 
guidelines.164 The third reason could be due to the genetic variabilities within the 
transporters or metabolizing enzymes influencing the disposition of urate-lowering 
drugs.86,165,166 Therefore, assessment of the etiology and classification of hyperuricemia 
could further enhance the diagnosis and selection of the appropriate therapeutic option. 
Evidently, the use of XO inhibitors is extremely effective in managing patients with 
UA overproducer status. However, allopurinol is a unique ULT option due to oxipurinol, 
which can work by inhibiting XO as well as competing with UA reabsorption through the 
same transporter making allopurinol the first line drug of choice due to its established 
efficacy, low cost, and patient safety.153  
Probenecid was the first prototype uricosuric drug to come to market over 60 years 
ago, to manage patients with chronic gouty arthritis. The exact mechanism of probenecid 
is mediated by blocking uric acid reabsorption via the OATs and URAT1 transporters on 
the apical side of the proximal convoluted tubule. Unlike other uricosuric agents, 
probenecid could increase uric acid clearance by 4-6-fold at 1-2gm per day. This dramatic 
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increase in uric acid clearance can enhance the risk of uric acid nephropathy, uric acid 
nephrolithiasis and uric acid urolithiasis.167 Consequently, probenecid is not recommended 
in patients with CrCl < 30mL/min or have a history of kidney stones. However, using 
daily divided probenecid doses, increase liquid consumption and adequate urine flow 
while alkalinizing the urine can greatly decrease the risk of uricosuria associated 
complications.  
The efficacy of probenecid as a monotherapy in patients with primary gout has been 
clinically debated. Specifically, patients with reduced kidney function or chronic kidney 
disease are at a higher risk for developing more probenecid-related side effects compared 
to those with normal kidney function treated with probenecid. To investigate this debate 
further, a retrospective observational study assessed the efficacy and tolerability of 
probenecid as monotherapy (n=30) or in combination with allopurinol (n=27) for the 
treatment of gout. The study found that the proportion of patients achieving target SUA (< 
6mg/dL) in the monotherapy group (33%) and in the combination therapy (37%) were not 
different (p=0.75). Further, the adverse events attributed to probenecid did not 
significantly differ between the patients with eGFR > 50 ml/min/1.73 m2 19% 
(8/42) versus eGFR < 50 ml/min/1.73 m2 13% (2/15).168 
The interaction of co-administering probenecid with allopurinol and the overall 
impact on SUA reduction in healthy volunteers and patients with gout was also evaluated. 
Consistently, those studies concluded that although probenecid increased the renal 
clearance of oxipurinol, the net effect of SUA reduction in the combination therapy was 
significantly higher than probenecid alone.169,170  In summary, probenecid is moderately 
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effective in lowering SUA in patients with declining kidney function and may be used as  
monotherapy in patients who are intolerant to allopurinol. Furthermore, probenecid is an 
effective add-on treatment for patients with gout not achieving their SUA goal by using 
allopurinol alone.  
Lesinurad is a uricosuric drug that was approved by the FDA in 2015.  It inhibits 
uric acid reabsorption by blocking the URAT1 and OAT4 transporters thus enhancing uric 
acid renal clearance. Lesinurad is indicated in combination with XO inhibitor for the 
treatment of hyperuricemia associated with gout in patients who have not achieved target 
SUA levels with XO inhibitor.171 At 200 and 400 mg doses added to allopurinol, lesinurad 
significantly increased proportions of patients achieving SUA target versus allopurinol-
alone therapy by month 6 (55.4%, 66.5% and 23.3%, respectively, p<0.0001).172 On the 
other hand, renal-related adverse events occurred in 5.9% of lesinurad 200 mg + 
allopurinol group, 15.0% of lesinurad 400 mg + allopurinol group and 4.9% of 
allopurinol-alone group, with serum creatinine elevation of >1.5x baseline in 5.9%, 15.0% 
and 3.4%, respectively.172 
Consequently, the maximum FDA approved dosage is 200mg daily and to be given with 
allopurinol or febuxostat. The dose should be taken in the morning with food and water. 
Also, patient should be instructed to remain hydrated to avoid risks of acute renal failure 
or nephrolithiasis. Lesinurad can be cautiously used in patient with eCrCL < 60mL/min 
but not to be used in patients with eCrCl <45mL/min. Lesinurad is a CYP2C9 substrate 
therefore genetic polymorphisms in CYP2C9 or co-administration with CYP2C9 substrate 
drugs can result in drug-drug interactions.  Specifically, one might expect elevated levels 
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of lesinurad in individual with genotype of CYP2C9*2 and *3. Furthermore, lesinurad 
should not be used with allopurinol at doses below 300mg/day or 200mg/day if eCrCl is < 
60mL/min. Moreover, if the xanthine oxidase inhibitor therapy was interrupted, lesinurad 
should be also interrupted.  
Fenofibrate is an approved lipid lowering drug and has been associated with SUA 
reduction of 15% and up to 46% in patients with gout with hyperlipidemia.173 The 
presence of hyperlipidemia in patients with gout is highly prevalent which makes 
fenofibrate an optimal choice for patients with hyperlipidemia suffering from gout. 174 
Although the use of fenofibrate as uricosuric agent is not FDA approved, current 
guidelines for the management of gout recommend its use in patients who may benefit 
from further reduction of SUA, especially with dyslipidemia.143,153 The urate-lowering 
effect of fenofibrate is believed to be mediated through URAT1 transporter inhibition by 
fenofibric acid.175 Moreover, some statins such as pravastatin and atorvastatin have shown 
some additive benefits of lowering uric acid, improving renal function while being used to 
lower cholesterol.176 These urate-lowering benefits associated with these drugs can 
enhance the co-prescribing habits when patients need a further urate-lowering reduction.  
Losartan is an approved antihypertensive agent and has shown to reduce SUA by 
6% and up to 23% in patients with a select URAT1 genotype through enhancing UA 
excretion.173,177,178 Thus, the use of losartan can complement the effect of other ULT while 
controlling for high blood pressure which is a common comorbidity amongst patients with 
gout.174 The exact mechanism by which losartan enhances UA excretion is not clearly 
understood; however, it is presumed that losartan blocks the URAT1 transporter while 
 76 
alkalinizing the urine which further enhances UA excretion. It is worth noting that the 
specific selection of an antihypertensive to manage a gouty person with hypertension can 
both be complementary to treating both conditions or counterproductive, at least to the 
management of hyperuricemia or gout. This represents an opportunity to clinicians for 
comprehensive reviews of their patients being managed for these two conditions. Other 
antihypertensive class such as the calcium channel blocker, amlodipine has shown an 
additive benefits by lowering uric acid while being used to lower high blood pressure in a 
select patient population.108 Study synopses that investigated the effects of losartan and 
fenofibrate on uric acid levels are summarized in Table 2.10.  
Pegloticase is the human recombinant form of the uricase enzyme, which has been 
developed and approved in the management of advanced cases of tophaceous gouty 
arthritis. Pegloticase is an intravenous uricolytic enzyme that converts UA to the water-
soluble form, allantoin. Although it rapidly and effectively reduces SUA, pegloticase has 
been associated with some serious adverse events. For instance, pegloticase antibodies 
have been developed, infusion reaction has occurred, and anaphylaxis events have been 
reported. Moreover, the administration of pegloticase in patients with the glucose-6-
phosphate dehydrogenase (G6PD) deficiency is contraindicated due to the increased risk 
of hemolysis and methemoglobinemia. Therefore, knowledge of G6PD status is warranted 
especially in patients with African and Mediterranean ancestry.  
Canagliflozin is a sodium glucose cotransporter 2 (SLGT2) inhibitor and an 
approved antidiabetic drug, which has been associated with SUA reduction with up to 
13%.179 Furthermore, a study has shown the SLGT2 inhibitor, luseogliflozin, to be also 
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associated with SUA reduction by up to 25%. Although the mechanism by which 
canagliflozin reduces SUA is unknown, luseogliflozin has been shown to significantly 
increase urinary excretion of uric acid in healthy subjects and by modulating Xenopus 
oocytes expressing GLUT9-2 transporter.180 Summary of all pharmacologic treatments 
used for the long-term treatment of gout attack is listed in Table 2.11. Additionally, 
dietary recommendations for long-term management of patients with gout are summarized 
in Table 2.12.  
Hyperuricemia and Gout Perspectives 
Relative to non-primates, humans have much higher levels of uric acid due to the 
lack of the enzyme uricase which is responsible for converting uric acid to allantoin. This 
physiological increase in concentration of uric acid has led to the belief that uric acid 
played major physiological and protective roles in humans to enhance survival and protect 
against diseases that could be human specific. One of the key roles of uric acid is its 
antioxidant effect which helps the body to detoxify from oxygen free radicals and 
peroxynitires that are formed because of the XO enzyme activity. These radicals if not 
intercepted, they could cause major damage to tissues and trigger major inflammatory 
response. Now that uric acid is an antioxidant which allows us to propose the question of 
why and how high uric acid levels would be strongly associated with a more of a pro-
inflammatory effect by causing joint damage, endothelial dysfunction, and kidney 
damage? One of the proposed theories is that uric acid remains an important extra-cellular 
antioxidant, but high concentration of uric acid above solubility levels results in the two 
major events. First, the formation of MSU which is recognized by the body as a foreign 
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object triggering a strong inflammatory response known as acute gout attack. Second, the 
infiltration of uric into soft tissues because of exceeding the saturation levels would result 
in a direct damage to those tissues while presenting itself as an invader to the intracellular 
defense mechanism causing major damage to both tissues and organs. 
The optimal management of gout although attainable in a primary care setting, many 
patients with gout go untreated or fail to reach their goal of SUA < 6mg/dL.76,181 
Furthermore, patients with gout experiencing recurrent acute attacks may require a more 
aggressive goal of SUA < 5mg/dL. Moreover, patients with gout although maybe 
prescribed ULT, adherence rate to gout medications is known to be lower compared to 
other medications. This is partly caused by the inter-critical periods of asymptomatic 
hyperuricemia, which in turns do not result in gout attacks. Therefore, raising awareness 
about gout and an extensive as well as a thorough patient education are key steps to 
optimize patient’s adherence. On the other hand, educating physicians and clinicians on 
the optimal dosing of ULT can help patients reaching their target goal of SUA as well as 
prevent or minimize the risk of acute gout attacks. Other strategies have been proposed to 
monitor adherence to ULT to rule out patients who are refractory to one therapy or the 
other; however, these strategies heavily rely on measuring drug levels as an assessment of 
adherence and mainly allopurinol. The response to allopurinol is known to possess a 
markedly high intersubjective variability with little research being done on understanding 
the root cause of this variability. Further research is needed to prospectively determine the 
different covariates associated with allopurinol response while better our understanding of 
the differential prevalence of risks factors associated with hyperuricemia across different 
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racial groups.   
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Figure 2:1 The Prevalence of gout across different age groups and gender between 1990-
1999 using managed care data62 
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Figure 2:2 Schematic diagram of the physiological formation and elimination of uric acid 
in human and the sites of action for urate lowering therapies 
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Figure 2:3 Schematic diagram of the processes involved in Monosodium Urate Crystal 
formation and consequent events associated with both management approaches 
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Figure 2:4 Schematic diagram the renal handing of uric acid and urate transportome182  
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Figure 2:5 Schematic pathway for purines metabolism. 
This figure also highlighted mechanism by which high consumption fructose can lead to 
high production of uric acid which leads to a higher depletion of the ATP leading to more 
IMP and inosine to form uric acid. The depletion of the ATP also stimulates the de-novo 
synthesis of ATP which is also a major source for purine metabolism.    
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Figure 2:6 Schematic diagram of the uric acid 4-Components Theory. 
This theory explains the high efficacy of the kidney in reabsorbing uric acid via multiple 
processes which explains the small fractional urinary excretion of uric acid.74  
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Figure 2:7 Proposed model for cardiovascular risks associated with hyperuricemia. 
The figure depicts the three possible mechanisms by which hyperuricemia could be 
contributing to the development of cardiovascular diseases as well as the role of 
cardiovascular disease or the management of these condition could be also contributing to 
the development of hyperuricemia. 
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Figure 2:8 Model for hyperuricemia associated comorbidities. 
This figure a more mechanism based for the interplay between the hyperuricemia and 
kidney diseases and kidney associated diseases 
 
 
NO: Nitric Oxide  
RAAS: Renin Angiotensin Aldosterone System 
CKD: Chronic Kidney Disease 
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Figure 2:9 Schematic diagram of the treatment modalities in managing gout. This figure 
depicts the 2-fold approach of managing gout- control of gout symptoms and targeted 
urate lowering therapy by gout classification.  
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Table 2:1 Hippocrates’ Five Aphorisms on Gout59 
Aphorism Detail 
VI-28 Eunuchs do not take the gout, not become bald 
VI-29 A woman does not take the gout, unless her menses be stopped  
VI-30  A youth does not get gout before sexual intercourse 
VI-40 In gouty affections, inflammation subsides within 40 days 
VI-55 Gouty affections become active in spring and autumn  
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SUA: Serum Uric Acid 
* Values are the percent (95% confidence interval). The data were adjusted for clusters 
and strata of the complex sample design of the National Health and Nutrition Examination 
Survey (NHANES) 2007-2008, with incorporation of sample weights. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2:2 Unadjusted and age-adjusted comparison of the prevalence of gout and 
hyperuricemia among US adults between NHANES-III (1988-1994) and NHANES 
2007-2008*11 
 NHANES-III        
1988-1994 
NHANES      
2007-2008 
Difference 
Prevalence of gout (%) 
     Unadjusted 
     Age-adjusted 
 
2.7 (2.3, 3.0) 
2.9 (2.5, 3.3) 
 
3.9 (3.3, 4.4) 
3.9 (3.4, 4.5) 
 
1.2 (0.6, 1.9) 
1.0 (0.4, 1.7) 
Prevalence of 
hyperuricemia (%) 
     Unadjusted 
     Age-adjusted 
 
18.2 (17.2, 19.3) 
19.1 (18.1, 20.0) 
 
21.4 (19.7, 23.2) 
21.5 (20.1, 23.0) 
 
3.2 (1.2, 5.2) 
2.4 (0.7, 4.2) 
Mean SUA, mg/dL 
     Unadjusted 
     Age-adjusted 
 
5.33 (5.29, 5.37) 
5.36 (5.32, 5.40) 
 
5.48 (5.41, 5.55) 
5.49 (5.44, 5.53) 
 
0.15 (0.07, 0.24) 
0.13 (0.07, 0.18) 
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Table 2:3 Relative risk of incident gout among antihypertensive drug classes95 
Drug Class Relative Risk 95% Confidence Interval  
Calcium channel blockers  0.87  0.82 to 0.93 
Losartan  0.81 0.70 to 0.94 
Diuretics  2.36 2.21 to 2.52 
Beta blockers  1.48 1.17 to 1.32 
Angiotensin  
converting enzyme  
1.24 1.17 to 1.32 
Non-Losartan angiotensin II 
receptor blockers  
1.29 1.16 to 1.43 
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Table 2:4 Causes, risk factors, and classification of hyperuricemia69,70 
Urate overproduction Urate underexcretion Combined 
Primary  Primary  Primary 
Idiopathic 
HGPRT deficiency (Lesch-
Nyhan) 
Keely-Seegmiller syndrome 
PRPP synthetase over-activity 
Idiopathic 
Familial Juvenile Gouty 
Nephropathy (FJGN) 
 
 
 
 
 
 
Secondary  Secondary Secondary 
Purine-rich diet 
Increased cell turnover 
Tumor lysis 
Glycogenoses types III, V, VII 
Drugs 
Renal insufficiency 
Medullary cystic disease 
Hypertension 
Dyslipidemia 
Acidosis (lactic and keto) 
Lead poisoning 
Hypothyroidism 
Hyperparathyroidism 
Sarcoidosis 
Down Syndrome 
Alcohol 
Exercise 
Shock 
Glycogenosis type I 
Aldolase-B 
deficiency 
HGPRT: Hypoxanthine-guanine phosphoribosyltransferase 
PRPP: Phosphoribosyl pyrophosphate 
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Table 2:5 Interpretation of 24-hour urine uric acid before and after a low purine diet69 
 Pre-low purine 
diet (mmol/d) 
(mg/d) 
Post-low purine 
diet (mmol/d) 
(mg/d) 
 
Management 
High purine 
intake  
> 6.0 (1000) < 4.0 (650) Diet 
Overproducers  > 6.0 (1000) > 4.5 (750) Family studies 
Enzyme studies 
Consider risk of uric acid 
nephropathy and stones 
Underexcreters < 6.0 (1000) < 2.0 (350) Check FEUA 
FEUA: Fractional Excretion of Uric Acid 
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ROL: Renal overload  
RUE: Renal underexcretion  
 
 
 
 
 
 
 
 
 
 
 
Table 2:6 Uric Acid Handling Classifications183 
 Urinary Uric Acid Excretion Rate (UUE) (mg/hr/1.73m2) 
UUE > 25mg/hr/1.73m2 UUE < 25mg/hr/1.73m2 
%
 F
ra
ct
io
na
l E
xc
re
tio
n 
of
 U
ri
c 
A
ci
d 
(F
EU
A
%
) FE
U
A
 >
 5
.5
%
 
Uric acid overproduction 
(ROL) Normal uric acid handling 
FE
U
A
 <
 5
.5
%
 
Uric acid overproduction 
and uric acid under 
excretion (Combined) 
Uric acid under excretion (RUE) 
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Table 2:7 Uric acid normal reference intervals per age group and gender69 
Adult Males 0.20- 0.42 mmol/L (3.4 -7.1 mg/dL) 
Adult Females 0.14-0.36 mmol/L (2.4-6.1mg/dL) 
Children 0.10-0.30 mmol/L (1.7-5.1 mg/dL)  
 To convert uric acid mg/dL to mmol/L, multiply by 0.05948 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 96 
 
Table 2:8 Guidelines for the management of acute gout attacks149 
 
 
2016 European League  
Against Rheumatism 
Recommendations8 
2012 American College of Rheumatology 
Guidelines for Management of Gout9 
First-line agents Oral colchicine and/or 
NSAIDs (+PPI if 
appropriate), CS 
Oral colchicine, NSAIDs, or CS 
Choice of drug NSAIDs and colchicine 
should not be used in patients 
with severe renal impairment 
Colchicine should be started 
within 12 h of flare onset 
Choice of drug depends on patient, physician 
preference, comorbidities, and        
contraindications 
Initiation within 12-14 h after attack onset  
Treatment may need to continue for 7-10 d 
Oral colchicine Loading dose of 1 mg 
followed 1 h later by 0.5mg 
Should not be given to 
patients receiving strong 
CYP3A4 inhibitors 
1.2 mg administered as soon as possible,   
followed by 0.6 mg 1 h later; followed by   
0.6 mg once or twice daily until attack   
resolves 
Initiation not recommended ≥ 36 h after  
attack onset 
Not recommended when attack in a patient  
taking colchicine prophylaxis 
Intra-articular 
aspiration and 
long-acting CS 
injections 
Effective and safe after  
septic arthritis ruled out 
Effective and safe after sufficient precautions 
have been taken 
Intra-articular CS favored in attacks involving 
1-2 joints 
ULT started 
during an attack 
No recommendations   ULT could be started during an attack,  
if inflammation is controlled 
Differs from common practice of starting  
ULT 2-4 wk from resolution of an attack  
before starting ULT 
IL-1 inhibitors  Canakinumab, approved by the EMEA for  
treatment of adult patients with frequent gout 
attacks not included in recommendations 
Combination 
treatment 
Combination of colchicine 
and NSAIDs in severe attacks 
Combination of colchicine and NSAIDs in 
severe attacks 
Abbreviations: CS, corticosteroids; EMEA, European Medicines Agency; IL-1, 
interleukin-1; NSAIDs, nonsteroidal anti-inflammatory drugs; ULT, urate-lowering 
therapy 
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Table 2:9 Pharmacologic agents for acute gout attacks145 
Drug Class  Drugs Dosing Adverse effects* Considerations 
NSAIDS 
(first-line) 
Indomethacin 
Naproxen 
Sulindac 
Use FDA-approved 
anti-inflammatory or 
analgesic doses 
GI pain, 
dyspepsia, 
heartburn, nausea 
Caution required for patients 
with PUD, active bleeding, 
anticoagulation or antiplatelet 
therapy, renal dysfunction, 
CKD, HTN, fluid retention, 
CHF, or hepatic disease 
Anti-gout 
agent 
(first-line) 
Colchicine 1.2 mg loading dose 
and 0.6 mg 1 hr 
later, then 0.6 mg 
after 
12 hrs, as needed, 
1-2 times/d until 
symptoms resolve 
GI (cramping, 
abdominal pain, 
nausea, vomiting, 
diarrhea) 
Initiate within 12 hrs after 
symptom onset. If patient has 
received colchicine therapy 
within 14 days, use an NSAID 
or corticosteroid instead. 
Caution required for patients 
with renal dysfunction, CKD, 
or hepatic disease 
Contraindicated with 
concurrent use of P-
glycoprotein or CYP3A4 
inhibitors 
Systemic 
CS 
(first-line) 
Prednisone 
 
 
 
 
 
 
0.5 mg/kg/d for 
5-10 days 
OR 
2-5 days at full dose, 
then taper for 7-10 
days 
GI (abdominal 
distension, 
ulcers), 
hypertension, 
headache, 
insomnia 
Caution required for patients 
with DM, fluid retention, 
ongoing infection or increased  
infection risk, or PUD 
IA, IV or IM administration 
possible for patients who are 
NPO 
Methyl-
prednisolone 
Methylprednisolone 
dose pack: Taper per 
package instructions 
Hormone 
(stimulates 
CS 
production) 
ACTH 25-40 IU SC Musculoskeletal, 
endocrine, 
metabolic, GI, 
cardiovascular, 
nervous system, 
dermatological 
effects, 
hypersensitivity 
reactions 
Options for patients who are 
NPO. Less effective in patients 
on long-term oral CS therapy. 
Short duration of action 
ACTH, adrenocorticotropic hormone; CHF, congestive heart failure; CKD, chronic kidney disease; DM, 
diabetes mellitus; FDA, US food and drug administration, GI, gastrointestinal; HTN, hypertension; IA, intra-
articular; IM, intramuscular; IU, international unit; IV, intravenous; NPO, nothing by mouth; NSAID, 
nonsteroidal anti-inflammatory drug; PUD, peptic ulcer disease; SC, subcutaneous, CS, Corticosteroids * 
Partial listing 
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Table 2:10 Summaries of urate-lowering effects of losartan and fenofibrate studies 
Study Drug  Study design  SUA Change Study Comments  Reference  
Losartan 50mg QD 
(n=16) Vs. Candesartan 
8mg QD (n=16) for 1 
month  
Comparative 
prospective 
randomized trial in 
patients with HTN 
10% (S) reduction 
with losartan and no 
change with 
candesartan   
Japanese cohort PMID: 186
70416 
Losartan 50mg QD Vs. 
enalapril 
in transplant patients 
treated with CsA (n=13) 
for 3 weeks 
Prospective, open, 
randomized, two-way 
cross-over study 
Losartan (NS) 
reduced SUA 7.8 to 
7.3mg/dl, enalapril 
(NS) increased SUA 
7.8 to 8.2mg/dl 
 PMID: 113
28912  
Losartan 100mg QD x 
2wks in PTs with HTN 
(n=101) 
URAT1 
polymorphisms and 
SUA reduction with 
losartan  
11% (S) reduction 
with losartan w/up to 
23% in rs1529909 
(TT) 
Chinese cohort  
rs3825016 is ↑ in 
hypertensive PTs 
w/HU 
PMID: 260
86348 
Losartan 50mg QD then 
BID vs. Irbesartan 
150mg QD then BID x 
4wks (n=13)  
Randomized double-
blind controlled cross-
over in PTs with HU, 
Gout, and HTN 
Losartan QD (S)↓ 
SUA from 9 to 
8.3mg/dL. Irbesartan 
had no effect on 
SUA 
European cohort  
Poor compliance 
with BID dosing  
PMID: 115
93107  
Losartan 50mg QD + 
BZB 50 QD (n=13) or 
ALL 200 BID (n=12) 
Prospective, add-on 
therapy in JPT patients 
treated for gout and to 
treat HTN  
8% (S)↓ in SUA 
after 2 months when 
added to BZB 
(n=13) or ALL 
(n=12) 
losartan (S)↑ the 24-
hr UUE rate and 
CLUA 
PMID: 127
59298 
Fenofibrate 300mg QD 
+ BZB(n=13) or 
ALL(n=12) 
Prospective, add-on 
therapy in JPT patients 
treated for gout and to 
treat hyperlipidemia   
15% (S) ↓ in SUA 
after 2 months when 
added to BZB 
(n=13) and ALL 
(n=14) 
Fenofibrate (S) ↑ 
the 24-hr UUE rate 
and CLUA 
Fenofibrate 160 mg 
daily for 2 months 
(n=14)  
Prospective open label 
pilot study in Korean 
gouty patients 
23% (S)↓ in SUA 
after 2 months (6.93-
5.22 mg/dL), SCr 
(S) ↑(1.12-
1.27mg/dL) 
100% males 
43% had 
dyslipidemia  
PMID: 169
13436 
Fenofibrate 200mg QD 
(n=10) x 3 weeks  
Open label cross-over 
study with fixed dose 
of ALL 
19% (S) ↓ in SUA 
after 3 weeks  
100% UK male 
36% (S)↑ CLUA 
PMID: 125
95630  
Single dose Fenofibrate 
300mg (n=9)  
Single dose 
administration in 9 
healthy JPT males  
26% significant 
reduction in SUA 
over 12 hr  
Fenofibrate is a 
URAT1 inhibitor in 
 
PMID: 200
75570  
QD, daily; BID, twice daily; (S), statistically significant; (NS), non-statistically significant; UUE, Urinary 
uric acid excretion; HU, hyperuricemia; SUA, serum uric acid; ClUA, uric acid clearance; ALL, allopurinol, 
BZB, benzbromarone, CsA, cyclosporine 
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Table 2:11 Considerations of using urate-lowering therapy145 
Class Drug Dosing Considerations 
Xanthine  
oxidase 
inhibitor 
(first-line)  
Allopurinol Initiate at 100 mg/d;  
titrate upward by 100 mg 
every 2-5 weeks to reach 
target serum urate acid level; 
maximum dose: 800 mg/d 
Requires renal dosing: Initiate at 50 
mg/day for patients with CKD (stage 4 
or worse) 
Potentially fatal hypersensitivity 
syndrome (testing recommended for 
high risk groups†) 
Febuxostat Initiate at 40 mg/d; titrate to  
maximum dose (80 mg/d) 
after 2 weeks if serum uric 
acid level is not achieved 
May cause liver enzyme elevation, 
arthralgia, or rash 
Liver tests needed in patients  
who develop fatigue, anorexia, right 
upper abdominal discomfort, dark 
urine, or jaundice 
Uricosuric  
Agent 
(Second-line) 
Probenecid 250 mg twice daily for 1 
week, then 500 mg twice 
daily; titrate in 500 mg 
increments every 4 weeks 
until target serum uric acid 
level is reached; maximum 
dose: 2 g/day 
Avoid in patients with history of 
urolithiasis  
Caution in eCrCL <50 mL/min 
Lesinurad  200mg daily in combination 
with XOI  
Avoid use in patients with eCrCl 
<45ml/min 
May cause acute renal failure if used as 
a monotherapy 
Losartan** 
(ARB) 
No FDA-approved dosing Useful for patients with hypertension 
 
Fenofibrate** No FDA-approved dosing Useful for patients with dyslipidemia 
Uricolytic  Pegloticase 8 mg IV every 2 weeks IV infusion over ≥120 min 
Severe infusion and allergic  
reactions possible 
May exacerbate HF 
Contraindicated in patients with G6PD 
deficiently  
High cost 
ARB, angiotensin receptor blocker; HF, heart failure; CKD, chronic kidney disease; FDA, US Food and 
Drug Administration; HTN, hypertension; IV, intravenous; G6PD, Glucose-6-Phosphate Dehydrogenase, 
XOI, Xanthine Oxidase Inhibitor. * Patients receiving urate-lowering therapy should be started on anti-
inflammatory agent, as well. † Koreans with CKD (stage 3 or worse) and all Han-Chinese and Thai patients 
**Not FDA Approved for the management of gout or hyperuricemia 
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Table 2:12 Dietary recommendations for patients with gout145 
Avoid Limit Encourage 
Organ meat high in purine 
content (sweetbreads, liver, 
kidney) 
Serving sizes of purine-rich 
meats (beef, lamb, pork) and 
seafood (sardines, shellfish) 
Low-fat or 
nonfat dairy 
products 
High fructose corn syrup-
sweetened sodas and other 
beverages and foods 
Serving sizes of fruit juice, table 
sugar, sweetened beverages and 
desserts, and table salt, including 
salt in sauces and gravies 
Vegetables 
 
Alcohol overuse (>2 drinks/day 
for men and >1 drink/day for 
women). Refrain from all 
alcohol during periods of 
frequent gout attacks or 
advanced, poorly controlled gout 
Alcohol (particularly beer, but 
also wine and spirits) 
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Chapter 3  
Assessment of Genetic Polymorphisms Associated with Hyperuricemia or Gout in 
the Hmong 
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Introduction:  
The global prevalence of hyperuricemia has grown dramatically over the past two 
decades.15 In the United States, the prevalence of hyperuricemia significantly increased 
from 18.2% in 1988-1994 to 21.4% in 2007-200811,15,18. Hyperuricemia is typically 
classified by serum uric acid (SUA) > 6.0mg/dL and is the strongest predictor of gout, the 
most common inflammatory arthropathy disease 134,143,184. When serum uric acid levels 
exceeds its solubility threshold (> 6.8mg/dL), the risk of monosodium urate crystal 
formation is high and often leads to a variety of acute and chronic complications.  
Although fundamentally a metabolic disorder, hyperuricemia has also been strongly 
associated with increased risk for cardiovascular diseases, chronic kidney disease, renal 
stones, and new onset of type 2 diabetes mellitus, which all have a significant impact on 
morbidity and mortality56,185,186. 
Hyperuricemia results from an imbalance between the production and excretion of 
SUA. Overproduction of uric acid (UA) may be attributed to diets rich in purine 
content 141 or pathological conditions leading to accelerated breakdown or production of 
endogenous nucleic acids. While breakdown of endogenous purines represents the main 
sources of SUA, underexcretion of UA is typically the most common cause of 
hyperuricemia21.  Uric acid is primarily excreted renally with only 30% being eliminated 
non-renally.  Specifically, UA excretion takes place in the proximal convoluted tubule 
(PCT) yet, the majority (~ 90%) of filtered UA is reabsorbed in the descending renal 
tubule21. Uric acid excretion is confounded by declining kidney function, concomitant use 
of select drugs (e.g. niacin, low dose aspirin, thiazides, and loop diuretics) and urine pH.  
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Several non-modifiable factors such as age, gender, and race can also influence SUA 
levels. 
Considerable variability in the prevalence of hyperuricemia and gout across 
various races and ethnicities has been described.78 For example, African-Americans,82 
Maori,9 Japanese,12 and Hmong,17 have each been shown to have a higher prevalence of 
hyperuricemia or gout relative to Caucasians, raising the suspicion that there is a genetic 
basis for this observation.9 These observations are supported by studies which have 
identified a differential prevalence of single nucleotide polymorphisms (SNPs) within 
genes affecting the urate transportome,80-82 which is in part responsible for elevated SUA 
levels.187-191 Genome wide association studies (GWAS) have identified transporters 
including SLC22A12, SLC2A9, ABCG2, and SLC17A1 as well as the scaffolding protein 
PDZK1, to have the highest degree of impact on SUA.192 Although other genes are 
involved, their mechanisms of contribution to elevated SUA remain unclear.193,194 
Minnesota Hmong represent an important, underserved minority group numbering 
over 64,000.195 Hmong patients suffer from a 2-fold higher prevalence of gout 26 and 5-
fold higher incidence of UA ureteral and kidney stones,17,24 compared to non-Hmong 
Minnesotan patients.  To ascertain if genetic polymorphisms may contribute to the 
Hmong’s predisposition to hyperuricemia and gout, the frequencies of validated risk 
alleles within five candidate genes (SLC22A22, SLC2A9, ABCG2, SLC17A1, and PDZK1) 
were quantified in a Hmong cohort, and compared with published data from a racially 
concordant population of Han-Chinese in Beijing (CHB) and a racially discordant 
population of Utah residents with ancestry from northern and western Europe (CEU). In 
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addition, the association between baseline SUA concentration and risk alleles was 
explored within a subset of the Hmong cohort. 
Methods: 
Study Participants  
Using the principles of community-based participatory research,196 we created and 
partnered with the Hmong Genomics Board, which co-designed the study, recruited the 
participants, and collected the data.  From March 2009 through May 2009, self-reported 
Hmong adults > 18 years of age were recruited in various settings including; medical 
clinics, three college campuses, a Minnesota Hmong college student conference and a 
Hmong national conference held in Wisconsin. As part of the consent process, people 
received written and verbal information in Hmong or English about what genes are, how 
they vary in populations, and why they might affect health and medication use.  Once 
informed consent was obtained, saliva samples were collected using ORAgene® OGR-500 
kits (Ottawa, ON, Canada) per manufacturer’s protocol.  In addition, demographic 
information (age, gender, years in US, formal education), medical history (past medical 
history, medicines, and family history) and anthropometric measurements (heights, 
weights, waist circumference and blood pressure) were collected.  Additionally, although 
not the primary purpose of this study, we offered to perform blood tests (specifically 
SUA) on participants > 30 years of age and based on their willingness to provide blood 
samples. This project was approved by the University of Minnesota Human Research 
Protection Program (UMN IRB # 0711M21884). 
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SNP Selection Criteria 
Three primary GWAS papers investigating the association of SNPs with SUA 
were used to guide our approach to selecting the primary genes and relevant SNPs.  The 
first was a GWAS by Vitari et al 197 which included 986 Croatian’s isolate and identified 
SLC2A9 to be associated with SUA levels, fractional excretion of uric acid (FEUA) and 
gout. The second was a meta-analysis by Kolz et al 80which included 28,141 subjects of 
European descent and identified 9 genes and 9 loci to be associated with SUA levels.  The 
third study was another meta-analysis by Kottgen et al,81 consisting of over 140,000 
subjects from a European ancestry.  Kottgen et al 81 identified 18 new loci in association 
with SUA using Gene Relationships Across Implicated Loci approach.  The latter meta-
analysis is significant for two reasons.  First, it provided validation of previously identified 
SNPs associated with elevated SUA and augmented that data with another phenotype –
namely FEUA.  Further, it specifically evaluated whether the observed SNP associations 
were generalizable to individuals of non-European ancestry.  By replicating their findings 
within large cohorts of African-Americans, Indians and Japanese populations, it concluded 
that the SNP effects on SUA concentrations were comparable in magnitude and identical 
in direction for the majority of SNPs studied 81. Therefore, key SNPs identified by any of 
these studies were considered important to pursue in addition to other SNPs identified by 
candidate gene approaches using phenotypes such as FEUA, fructose load test and simply 
the presence of gout 198,199. 
The final SNP list for the present study was further filtered by considering only 
those SNPs in genes directly associated with UA homeostasis  with a reported minor allele 
frequencies in excess of 5% based on data from CEU200 and not otherwise in linkage 
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disequilibrium (r2 < 0.8) with other SNPs. Our final list included 8 SNPs in 5 genes 
directly associated with SUA homeostasis.  
Genotyping 
DNA was purified and extracted from 235 saliva samples. Briefly, 4 mL of saliva 
was incubated in a water bath at 50°C overnight. Following incubation, the appropriate 
amount of purifier was added followed by 10 minutes of ice incubation. The samples were 
centrifuged for 20 minutes at maximum speed (4000rpm) at room temperature. In order to 
precipitate the DNA, the yielded supernatant after centrifugation was transferred to new 
centrifuge tubes followed by adding an equivalent amount of ethanol and then kept in the 
refrigerator overnight. Samples were then centrifuged for 20 minutes at maximum speed 
(4000 rpm) at room temperature. The yielded supernatant was then discarded and the 
DNA pellet was dried for 30 minutes followed by adding 1 mL of Tris-EDTA (TE) buffer 
placed on a rotator (34rpm) overnight. Finally, samples were prepared, labeled, and 
analyzed for quality and quantity using an eight-multichannel Nano-drop (ND8000 V.2.). 
Eight candidate SNPs in five key genes were genotyped at the Biomedical Genomic 
Center (BMCG) at the University of Minnesota (Minneapolis, MN, USA). Six SNPs were 
genotyped by Sequenome iPLEX Gold method using Bruker Autoflex II MALDI/TOF 
mass spectrometer (rs505802, rs2231142, rs12129861, rs11942223, rs1014290, 
rs1183201). The other two SNPs (rs3733591, rs734553) were genotyped by 
TaqMan® applied biosystems™.  
Sequenom Genotyping 
Genotyping was performed using iPLEX Gold method. iPLEX reagents and 
protocols for multiplex PCR, single base primer extension (SBE) and generation of mass 
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spectra, as per the manufacturer’s instructions. Multiplexed PCR was performed in 5-µl 
reactions on 96-well plates containing 10 ng of genomic DNA. Reactions contain 0.5 U 
HotStar Taq polymerase (QIAGEN), 100 nM primers, 1.25X HotStar Taq buffer, 1.625 
mM MgCl2, and 500 µM dNTPs. Following enzyme activation at 94 °C for 15 min, DNA 
was amplified with 45 cycles of 94 °C x 20 secs, 56 °C x 30 secs, 72 °C x 1 min, followed 
by a 3-min extension at 72 °C. Unincorporated dNTPs were removed using shrimp 
alkaline phosphatase (0.3 U, Sequenom). Single-base extension was carried out by 
addition of SBE primers at concentrations from 0.625 µM (low MW primers) to 1.25 µM 
(high MW primers) using iPLEX enzyme and buffers (Sequenom, San Diego, CA, USA) 
in 9-µl reactions. Reactions were desalted and SBE products measured using the 
MassARRAY system, and mass spectra analyzed using TYPER software (Sequenom, San 
Diego, CA, USA), in order to generate genotype calls and allele frequencies.  
Statistical Analysis 
Data from the HapMap200 served as our source for the frequencies of the variant 
alleles in CEU and CHB populations. The allele frequencies were then compared to 
Hmong allele frequencies using Pearson’s Chi-Square or Fisher’s exact test when 
appropriate based on cell count. A Bonferroni adjustment was used to account for multiple 
comparisons between risk alleles using a critical value p<0.0063 for significance. In our 
analysis, the “risk allele” was defined as the allele that was associated with higher SUA or 
could adversely increase SUA levels.  Using the American College of Rheumatology 
Guidelines of [SUA] < 6mg/dL in patients treated for gout, we defined the risk of 
hyperuricemia in our Hmong cohort as [SUA] > 6mg/dL. Ascertaining the association of 
the risk of hyperuricemia using the SUA cutoff with genotype was calculated using 
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Pearson’s Chi-Square test or Fisher’s exact test. Means of SUA were compared across 
genotypes using One-Way ANOVA.  
Results: 
Two hundred and thirty-five Hmong adults participated in the study (Figure 3.1). 
Demographics and anthropometric measures are summarized in Table 3.1.  Briefly, the 
mean (+SD) age of all study participants was 30.3 (±15.7) years with a slight majority of 
females (55%). More than 60% of the participants had body mass index > 25 kg/m2.  
Prevalence of self-reported gout was 5.1%.  In addition, 57 participants agreed to have 
their SUA levels measured, with a mean (+SD) SUA level of 6.3 (± 1.7) mg/dL. Of the 57 
participants, 27 (47%) had SUA levels > 6mg/dL. 
All the selected SNPs were in Hardy Weinberg equilibrium with call rates >99.0%.  
Seven of the 8 targeted SNPs were significantly different when comparing the prevalence 
between Hmong and CEU (Table 3.2-3). Among the 7 SNPs showing a difference, 6 of 
the risk alleles [rs505802 (C>T), rs2231142 (G>T), rs12129861 (G>A), rs11942223 
(T>C), rs734553 (G>T), and rs1183201 (T>A)] were significantly more prevalent in the 
Hmong compared to the CEU population. However, the prevalence of the risk allele 
rs3733591 (A>G) was found to be significantly lower in the Hmong compared to CEU. 
For the comparisons between Hmong and CHB populations, 3/8 SNPs showed statistically 
significant differences.  Two of the risk alleles were significantly more prevalent in the 
Hmong compared to CHB [rs3733591 (A>G) and rs1014290 (C>T)], and 1 risk allele 
rs12129861 (G>A) had lower prevalence. For the 57 adults with measured SUA levels, no 
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significant associations between risk alleles and SUA levels or risk of hyperuricemia 
(SUA > 6mg/dL) were found.  Association data analyses are not shown.  
Discussion:  
This study identifies a statistically higher prevalence of validated risk alleles in our 
Hmong cohort compared to published data in European (CEU) and Han Chinese (CHB) 
populations.  Specifically, 6/8 risk alleles were more prevalent in the Hmong than CEU, 
and 2/3 risk alleles were more prevalent in the Hmong than the CHB. This observation 
represents the first report of its kind, which may support a genetic basis for the notably 
higher prevalence of hyperuricemia and gout observed in the Hmong, relative to non-
Hmong residing in Minnesota.  Our findings of differences between Hmong and CHB 
population further support the importance of utilizing the more precise genomic-based 
guidance for risk associations rather than race or ethnic classifications. The roles that 
select genetic variations within genes (SLC22A12, SLC2A9, ABCG2, SLC17A1 and 
PDZK1) affecting UA disposition play in the manifestation of hyperuricemia, 
development of gout and modulating drug responsiveness are worthy of discussion.  
SLC22A12 encodes for the URAT1 transporter found on the apical side of the PCT 
in kidney. Loss-of-function mutations of URAT1 cause idiopathic renal hypouricemia due 
to high urinary urate excretion177 and presumably a gain of function mutation could lead to 
hyperuricemia201. Considered a major carrier facilitating UA reabsorption, this transporter 
was deemed a logical target for urate lowering therapies. The inter-genic SNP rs505802 
(C>T) with an estimated prevalence of the (T) allele at 73% was identified by Kolz et al 80 
to be associated with a lower SUA.  In contrast, the prevalence of the (T) allele in our 
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Hmong cohort was only 35% (p <0.001) suggesting a higher risk for hyperuricemia in the 
Hmong, relative to Europeans. Incidentally, the estimated prevalence of the (T) allele in 
the CHB population was 26% which, although not significantly (p=0.0068) lower 
compared to our Hmong cohort, suggests that the Hmong and CHB populations (both 
considered to be Asian) appear to display substantive differences in allele frequencies. 
Two other SNPs [rs893006 (A>G), and rs11231825 (C>T)] within SLC22A12 were found 
to be significantly associated with elevated levels of SUA in a Japanese cohort, 188 or 
reduced fractional excretion of uric acid (FEUA) in a German population.187 Notably, both 
of these SNPs are in complete linkage disequilibrium (LD, r2=1) with the previously 
mentioned rs505802.  
Consequently, not only does rs505802 influence renal UA disposition, but it may 
also influence response to urate lowering therapies. The basis for this argument resides in 
our understanding of the mechanism of action of two common urate-lowering therapies: 
probenecid and allopurinol.  Both probenecid and more precisely, the active metabolite of 
allopurinol, known as oxipurinol, inhibit URAT1 by competing for reabsorption with 
UA.169,170 Thus, our finding of a higher prevalence of the risk allele associated with 
hyperuricemia (rs505802C>T) may not only partially explain the higher prevalence of 
gout in the Hmong, but also provide a basis for anecdotal reports questioning the 
effectiveness of allopurinol when used in the Hmong 26.  Genotype based differences on 
renal handling of UA and the effectiveness of urate lowering therapies complicate the 
interpretation of risk for hyperuricemia and response to select medications.  Studies that 
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de-couple these competing factors should elucidate our understanding of the potential 
basis for genotype-guided selection of drug therapy.  
SLC2A9 encodes for GLUT9 transporter which is a high capacity transporter for 
fructose, glucose, and UA. GLUT9 is not only expressed in the kidney, liver, but it is also 
expressed in the chondrocyte of human articular cartilage.202 The latter maybe an 
important contributing factor for the deposition of monosodium urate crystals within and 
around joints affected with gout. The intronic SNP rs734553 (G>T), was shown to be 
significantly associated with increased SUA in the CEU population with an estimated 
prevalence of the (T) allele at 74%.80  In our Hmong cohort, the estimated prevalence of 
the (T) allele was 99%; which was significantly higher than CEU (P<0.0001). In this case, 
the prevalence of the (T) allele was not different between the Hmong and CHB, both at 
~99% (p=0.269).  Once again, the Hmong’s genetic predisposition to hyperuricemia is 
enhanced relative to CEU.  Notably, the SNP rs734553 (G>T), is in moderate LD (r2= 0.8) 
with the intronic SNP rs11942223 (T>C) for which the (C) allele has been shown to be 
protective against hyperuricemia.198 The prevalence of the protective (C) allele in our 
Hmong cohort (1.3%), was again lower prevalence compared to CEU (25%) (p<0.001).  
Also within SLC2A9, the non-synonymous SNP rs3733591 (Arg265His) has been 
consistently associated with gout. For instance, Tu et al 199 identified that a copy of the 
risk allele (C) had a higher risk for tophi with an OR of 2.05 (1.11-3.77, p=0.0176) in the 
Han-Chinese population while  Urano et al203 demonstrated an increased risk for gout in 
Japanese with an OR of 1.52 (1.19-1.95, p=7.3x10-4). In our Hmong cohort, the risk allele 
rs3733591 (A>G) is lower (41%) compared to CEU (80%) (p<0.001), but higher than 
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CHB (30.7%) (p=0.005) further suggesting that the Hmong is a unique ethnic group in 
spite of being commonly classified as CHB.  
Reduced FEUA is common in patients with gout and is a risk factor for developing 
hyperuricemia. The intronic SNP rs1014290 (C>T) within SLC2A9 identified by Vitart et 
al 197 was found to be significantly associated with decreased FEUA and development of 
gout in multiple populations of European descent. The presence of the T allele was 
significantly associated with OR (1.57 and 1.40) for reduced FEUA and gout, 
respectively. In our present study, the prevalence of T allele in our Hmong population 
(69.5%) was lower than CEU (74.3%, p=0.19), but higher than in CHB (59.6%, p=0.006). 
This further suggests that decreased FEUA may be a contributing   mechanism for 
developing gout in the Hmong which, again, differs from the CHB.   
SLC17A1 encodes the voltage gated human sodium-dependent phosphate co-
transporter type 1 protein (NPT1) on the apical membrane of the renal proximal tubule. 
Chiba et al 204have recently identified the putative mechanism and role by which NPT1 
affects uric acid suggesting that NPT1 functions as a renal urate excreter. In a Japanese 
case-control study these same investigators also identified the missense SNP rs1165196 
(I269T) of SLC17A1 gene to be a gain of function change which could protect against 
renal urate underexcretion.  Kolz et al 80identified the intronic SNP rs1183201 (T>A) of 
the SLC17A1 gene to be significantly associated with decreased serum uric acid with the 
effect allele (A) being the protective allele in CEU. In addition, this SNP was also found 
within a larger region on chromosome 6 suggesting its high LD with other SNPs. This 
finding could explain the moderate LD (r2 =0.868) between these two SNPs (rs1165196 
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and rs1183201) in CEU and strong LD (0.967) within CHB. Zhou et al 205have 
successfully replicated similar findings in CHB males case-control study by showing that 
SNP rs1183201 was significantly associated with gout and SUA and in consistency with 
Kolz et al  findings.80 
In our Hmong cohort, the frequency of the effect allele (A) for rs1183201 was 3-fold 
lower than that observed in Caucasians (16.4% vs. 50%, p<0.001). However, the 
frequency of the effect allele did not differ between Hmong and CHB (16.4% vs. 13.3%, 
p=0.54). The extensive validation of this SNP (rs1183201) across different ethnic groups 
and its direct role on renal uric acid excretion highlights a plausible mechanism for the 
Hmong to be at higher risk for developing gout, relative to other populations. These 
consistent findings in part, provide possible genetic basis for the differential prevalence of 
gout in Hmong relative to non-Hmong living in Minnesota17.  
ABCG2 encodes for the superfamily of ATP-binding cassette (ABC) protein which 
is a xenobiotic efflux transporter and major carrier for endogenous substances. Genetic 
polymorphisms in ABCG2 have been associated with SUA and gout in select 
populations.206-208 The missense SNP (rs2231142) Gln141Lys (G>T) has been shown to 
be associated with elevated SUA in CEU men 80 and indeed, the prevalence of the risk 
allele (T) in our Hmong cohort (36%) was higher than that in the CEU population (11%) 
(p<0.001). Significantly, this SNP (rs2231142) has also been strongly associated with 
response to allopurinol in White non-Hispanic and Hispanic populations.86 This 
observation further strengthens the argument that genetic variability of transporters is 
associated with disposition of UA and could also modulate drug response.  
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The scaffolding structural protein PDZK1’s role on UA disposition was evident 
from the meta-analysis conducted by Kolz et al 80 who showed that the inter-genic SNP 
rs12129861 (G>A) was significantly associated with lower SUA levels.  This protein is 
essential for UA transporter activity including URAT1, OAT4, and NPT1.182 The 
prevalence of the (A) allele for rs12129861 (G>A), associated with decreased SUA, in our 
Hmong cohort (33%) was lower than CEU (46%) (p <0.001), but was higher than CHB 
(20%, p=0.002).  This finding is consistent with the elevated risk of gout in the Hmong 
relative to CEU while being supportive of our premise that there are differences between 
Hmong and CHB.  
Finally, while different allele frequencies in Hmong could owe to their unique 
population history rather than a genuine causal effect on hyperuricemia or gout, we 
believe that the extensive validation of these selected SNPs across different population 
groups and ethnicities provide the basis to theorize that the different allele frequencies in 
the Hmong may be contributing to their enhanced risk of gout compared to CEU.  
In general, advancing age increases the risk of developing gout due to several 
factors including declining kidney function, increased dehydration, increased use of drugs 
and increased prevalence of other comorbidities. The estimated prevalence of gout in our 
Hmong cohort was 5.1% which is close to the 6.2% reported by Portis et al17 and notably 
higher than the overall US prevalence of  3.9%.11 Our findings may provide evidence to 
support a genetic component to the clinical observations of a higher prevalence of gout, 
hyperuricemia, and UA kidney stones17,24 and reported suboptimal use of allopurinol26 in 
Minnesota Hmong compared to non-Hmong.  The consistency of urate transportome risk 
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alleles within our Hmong cohort compared to other populations is at the very least 
suggestive of a genetic component to their elevated risk. However, several limitations of 
our study require further discussion.  
Limitations:  
The key limitations of our study include those common to investigations of 
complex questions within minority populations. In our example, the Hmong are a minority 
refugee population in which to conduct research, especially involving the collection of 
DNA or blood is challenging. However, working with the Hmong Genomics Board and 
translators as partners in research, ensured that participants were appropriately informed as 
to the nature and purpose of the study.  Another limitation of our study relates to sample 
size. Although the total sample size (n=235) represents a reasonable basis to estimate the 
prevalence of the 8 targeted SNPs, the modest sample size of individuals with measured 
SUA (n=57) and gout (n=12), limits the power of our analysis to determine an association 
between the genotypes tested, and risk of hyperuricemia or gout. Similarly, our sample 
size precluded meaningful analyses of these associations based on a sex-specific definition 
of hyperuricemia that otherwise may be more appropriate than our clinically oriented cut 
off for hyperuricemia of SUA > 6mg/dL. We cannot exclude the possibility of a selection 
bias in that those who volunteered to have their SUA measured may differ from those who 
did not volunteer.  A larger and appropriately powered study will be needed to ascertain 
the effect of these select SNPs on SUA levels and the presence of gout.   
Although some investigators have found an association with SUA and gout with 
other genes (GCKR and LRRC16A),80,205,209 these genes were not evaluated in our 
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population. Further investigations of direct associations with these genes and key other 
SNPs are worthy of direct study in this unique population. Finally, we did not have 
comprehensive information for concomitant use of drugs or dietary habits, both of which 
may have influenced SUA levels. Indeed, diet is an important determinant of SUA levels 
and is cited as a key common risk factor in those populations exhibiting elevated 
prevalence of gout and hyperuricemia.31 Any additional study will need to explore dietary 
variations and its association with gout 
Conclusions:  
Hyperuricemia risk alleles are more prevalent in the Hmong than CEU and CHB 
and are directionally consistent with the increased risk of hyperuricemia and gout when 
compared with either CEU or CHB populations. Although the mean age in our Hmong 
cohort was significantly lower relative to previous reports and we had a preponderance of 
female subjects, the Hmong in this study remain to exhibit a higher prevalence of self-
reported gout compared to the US population. Given the extensive work by others in 
replicating the role of key SNPs discovered in Europeans to be comparable in magnitude 
and identical in direction in Indians, African-Americans and Japanese, we believe that our 
findings have advanced our knowledge of the risk for hyperuricemia and gout in the 
Hmong.   
Future perspectives:  
If replicated, the translational implications of our findings may lead to genomic-
based differentiation of prevention and treatment strategies for individuals with specific 
genetic profiles.  The consideration of genetic factors in the selection of therapies may 
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also lead to improved patient outcomes and lower health care costs.  Comparative efficacy 
studies utilizing genetic information have the potential to improve pharmacotherapeutic 
outcomes by avoiding un-necessary trials of less efficacious drug therapies.  Ultimately, 
this genetic information may advance our capacity to apply principles of precision 
medicine to achieve improved outcomes. In addition, individual’s genotype may 
ultimately replace the imprecise descriptors such as race when considering individual’s 
risk for gout and/or response to gout therapy.  
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Figure 3:1Risk of Hyperuricemia* and Self-reported Gout in 235 Participants 
 
Distribution of individuals among those with unknown or measured serum uric acid 
(SUA) by self-reported history of gout. *Risk for hyperuricemia in our study was defined 
as SUA > 6mg/dL   
 
 
 
 
 119 
 
 
 
 
 
 
Table 3:1 Clinical characteristics and demographics of study participants (n=235) 
Participant Characteristics   No. (%)or Mean +SD Min Max 
Age (years) 30.3 ± 15.7 18 87 
Sex  
Females  
Males  
 
130 (55.3) 
105 (44.7) 
  
Smoking Status 
Never smoked 
Former smoker 
Current smoker  
Missing data 
 
191 (81.3) 
20 (8.5) 
20 (7.2) 
7 (3.0) 
  
Medical History  
Type 2 Diabetes  
Hypertension  
Hyperlipidemia 
Gout 
Kidney Stone  
 
31 (13.2) 
15 (6.4) 
14 (6.0) 
12 (5.1) 
6 (2.6) 
  
BMI (kg/m2) 27.8 + 6.2 16.7 52.1 
Serum uric acid (SUA) (mg/dL) (n=57) 
Females SUA (mg/dL) (n=39) 
Males SUA (mg/dL) (n=18) 
6.3 ± 1.7 
5.9 ± 1.6 
7.1 ± 1.6 
3.5 
3.5 
4.8 
11.4 
9.9 
11.4 
Waist Circumference inches/(cm) 
Females 
Males 
 
33.3 ± 5.7/ (84.5 ± 14.4) 
35.6 ± 5.4 / (90.4 ± 13.6) 
 
24.5/ (62) 
26.0/ (66) 
 
50.0/ (127) 
51.5/ (131) 
Systolic Blood Pressure (mmHg) 117 + 16 80 178 
Diastolic Blood Pressure (mmHg) 72 + 10 40 101 
Self-reported years in USA (years) 15.6 + 8.7 3 31 
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Table 3:2 Allele Frequencies within Hmong, European (CEU), and Han-Chinese (CHB) 
Gene (SNP)/Allele* Hmong 
No. (%) 
CEU 
No. (%) 
P. Value 
Hmong 
Vs. CEU 
CHB 
No. (%) 
P. Value 
Hmong Vs. 
CHB 
SLC22A12 (rs505802)      
C 297 (64.8) 62 (27.4) <0.001 204 (74.5) 0.0068 T 161 (35.2) 164 (72.6) 70 (25.5) 
Total 458 226  274  
SLC2A9 (rs3733591)      
A 265 (58.6) 43 (19.7) <0.001 190 (69.3) 0.005 G 187 (41.4) 175 (80.3) 84 (30.7) 
Total 452 218  274  
SLC2A9 (rs11942223)      
T 452 (98.7) 180 (75.0) <0.001 178 (98.9) 1 C 6 (1.3) 60 (25.0) 2 (1.1) 
Total 458 240  180  
SLC2A9 (rs734553)      
T 459 (98.5) 167 (73.9) <0.001 173 (99.6) 0.269 G 7 (15.0) 59 (26.1) 1 (0.4) 
Total 466 226  174  
SLC2A9 (rs1014290)      
T 317 (69.5) 168 (74.3) 0.191 161 (59.6) 0.006 C 139 (30.5) 58 (25.7) 109 (40.4) 
Total 456 226  270  
ABCG2 (rs2231142)      
G 293 (63.7) 201 (88.9) <0.001 194 (70.8) 0.059 
T 167 (36.3) 25 (11.1)  80 (29.2)  
Total 460 226  274  
SLC17A1(rs1183201)      
A 75 (16.4) 63 (50) <0.001 12 (13.3) 0.559 
T 381 (83.6) 63 (50)  78 (86.7)  
Total 456 126  90  
PDZK1 (rs12129861)      
G 307 (67.3) 122 (53.9) <0.001 220 (80.3) 0.002 
A 149 (32.7) 104 (46.1)  54 (19.7)  
Total 456 226  274  
*Bolded allele indicates the risk allele, which is defined as the allele that is associated 
with higher SUA or could adversely increase SUA levels) 
P<0.0063 indicates statistical significance 
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Table 3:3 Genotype Frequencies Comparisons between Hmong, European (CEU) and Han-
Chinese (CHB) 
Gene (SNP) / 
Genotype 
Hmong 
No. (%) 
CEU 
No. (%) 
P. Value 
Hmong Vs. 
CEU 
CHB 
No. (%) 
P. Value 
Hmong 
Vs. CHB 
SLC22A12 (rs505802)      
CC 101 (44) 10(9) 
<0.001 
76(55.5) 
<0.001 CT 95 (41.5) 42(37) 52(38) 
TT 33(14.5) 61(54) 9(6.6) 
Total 229 112  137  
SLC2A9 (rs1014290)      
TT 105(46.0) 6 (5.3) 
<0.001 
23 (17.0) 
<0.001 TC 107(46.9) 46 (40.7) 63 (46.7) 
CC 16 (7.0) 61 (54.0) 49 (36.3) 
Total 228 113  135  
SLC2A9 (rs11942223)      
TT 223 (97.4) 33 (50.8) 
<0.001 
44 (97.8) 
0.999 TC 6 (2.6) 31 (47.7) 1 (2.2) 
CC 0 (0.0) 1 (1.5) 0 (0) 
Total 229 65  45  
SLC2A9 (rs734553)      
TT 226 (97.0) 60 (53.1) 
<0.001 
136 (99.3) 
0.266 GT 7 (3.0) 47 (41.6) 1 (0.7) 
GG 0 6 (5.3) 0 
Total 233 113  137  
SLC2A9 (rs3733591)      
GG 38 (17) 71(65) <0.001 9(7) 0.0077 
GA 111(49) 33(30)  66(48)  
AA 77(34) 5(5)  62(45)  
Total 226 109  137  
ABCG2 (rs2231142)      
GG 96 (41.7) 89 (78.8) <0.001 69 (50.4) 0.211 
GT 101 (43.9) 23 (20.4)  56 (40.9)  
TT 33 (14.3) 1 (0.9)  12 (8.8)  
Total 230 113  137  
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Table 3.3 Cont.  
SLC17A1(rs1183201)      
AA 7 (3.1) 17 (27) <0.001 0 0.489 
AT 61 (26.8) 29 (46)  12 (26.7)  
TT 160 (70.2) 17 (27)  33 (73.3)  
Total 228 63  45  
PDZK1 (rs12129861)      
GG 105 (46.1) 35 (31.0) 0.0039 88 (64.2) <0.001 
AG 97 (42.5) 52 (46.0)  44 (32.1)  
AA 26 (11.4) 26 (23.0)  5 (3.6)  
Total 228 113  137  
P<0.0063 indicates statistical significance 
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Addendum Overview 
The following is a summary of select preliminary investigations of allele frequencies 
for SNPs of very important pharmacogenes, which are relevant to select drug therapies. In 
addition, we expand our analyses that were previously published in chapter III. The 
purpose is to summarize likely areas of further investigations when exploring unique 
genetic differences in disease risk and drug response that may be relevant to the Hmong.   
Assessment of Select Pharmacogenes in the Hmong: 
The solute carrier organic anion 1B1 gene (SLCO1B1) is located on chromosome 12 
(p12.1) and encodes the organic anion transporter 1B1 (OAT1B1), which is primarily 
expressed on the basolateral side of the hepatocyte.210 The primary function of OAT1B1 
transporter is the uptake of endogenous compounds such as bilirubin or xenobiotics such 
as simvastatin and simvastatin acid from the portal vein into the liver for metabolism. The 
single nucleotide polymorphism (SNP) rs4149056 T>C (Val174Ala) within the SLCO1B1 
has been identified from a genome-wide association scan (GWAS) to be linked with 
statin-induced myopathy (SIM).211 Multiple retrospective studies have validated the 
association between SIM and the rs4149056 T>C within SLCO1B1.212,213  In fact, patients 
who are carriers of the risk allele (C) are at a significantly higher risk of developing SIM 
with more than 4-folds higher than the T allele, which warrants dose reduction or using an 
alternative to simvastatin.214 Based on our preliminary analyses of 235 Hmong 
participants, the prevalence of the risk allele (C) in the Hmong is significantly lower than 
Europeans (2.6 vs 12.1%, p<0.001) (Table 4.1). This may suggest that the Hmong are less 
likely to develop SIM based on the genetic polymorphism in SLCO1B1 compared to 
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European counterparts at least via this mechanism.  
The phase (I) metabolism enzyme encoding gene, CYP2C19 is located on 
chromosome 10 (q23.33).210 CYP1C19 is an important metabolizing enzyme for 
commonly and chronically used drugs such as losartan, phenytoin, citalopram, 
escitalopram, omeprazole, esomeprazole, and clopidogrel.215 Specifically, the antiplatelet 
drug clopidogrel, which is an adenosine diphosphate receptor antagonist, is commonly 
used in post-myocardial infarction, stroke, peripheral arterial disease patients as well as in 
patients undergoing percutaneous coronary intervention. Clopidogrel is a prodrug that can 
be converted into the inactive metabolite (85%) via the carboxylesterase pathway or the 
active metabolite (15%) via CYP2C19 activity. The response to clopidogrel is highly 
variable and is considered to be infective in up to 30% of patients taking it.216 Genetic 
variations in CYP2C19 have been strongly associated with the response to clopidogrel 
leading to the development of genetic-based guidelines for using clopidogrel based on the 
patient’s genotype.217,218  
For example, the Clinical Pharmacogenetics Implementation Consortium (CPIC) 
guidelines recommend patients with a copy of the reduced or loss of function in CYP2C19 
e.g. CYP2C19*2 or*3 allele are not candidate for taking clopidogrel, and alternative 
therapies should be commenced.219 Although the reduced or loss of function in the 
CYP2C19 is common, a gain of function allele (*17) has been also reported.220 However, 
there is no recommendation based on the gain of function in CYP2C19 to date. In the 
Hmong, the frequency of CYP2C19*2 was found to be higher than Europeans (37.0 vs. 
14.5%, p<0.001), but the frequency for CYP2C19*17 was found to be lower than 
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Europeans (0.2 vs. 22.4%, p<0.001). The frequency of CYP2C19*3, however, was 
indifferent between the Hmong and Europeans (0.2 vs. 0%, p=1.0) (Table 4.1). From the 
sample population studied, these results translate into 58.4% of Hmong are either 
homozygote or heterozygote for CYP2C19*2.  This high percentage of individuals who 
would not be candidates for clopidogrel represents important information, once validated, 
to be clinically available for clinicians when deciding on antiplatelet therapy for patients 
self-reported as Hmong.  
Warfarin is a vitamin K epoxide reductase (VKORC1) antagonist and is widely used 
as an anticoagulant for the treatment of deep venous thrombosis and stroke prevention in 
patients with atrial fibrillation.221 Response to warfarin is highly variable with a 
substantial intra-and inter-patients’ variability requiring frequent testing and monitoring to 
achieve the target INR. Warfarin is a racemic mixture with the S-enantiomer being the 
active drug that is metabolized by mostly CYP2C9.222 Changes in the activity of CYP2C9 
can greatly influence the response to warfarin and warrant dose adjustment.223 Moreover, 
changes in the sensitivity of VKORC1 (drug target) can also influence the dose required to 
achieve the target INR. In addition to CYP2C9 and VKORC1, residual variability in 
response to warfarin remained unexplained in select patient populations.224 Specifically, 
the response to warfarin in African-American populations have been shown to be 
significantly affected by CYP4F2 in addition to CYP2C9 and VKORC1.225 This is to 
illustrate the fact that there are population-specific genetic variations and the value of 
multiethnic GWAS to advance precision medicine.     
Genetic polymorphisms (SNPs) in CYP2C9, VKORC1 and CYP4F2 have been 
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associated with the cumulative/weekly doses of warfarin to achieve the target INR. For 
example, rs1799853 C>T (Cys144Arg) or CYP2C9*2 is associated with reduced Vmax of 
the metabolic activity by 50% relative to the CYP2C9*1 (normal function) resulting in a 
reduced clearance of the active drug, S-warfarin, with an average of 20% reduction in 
warfarin metabolism.226,227 Consequently, carriers of the CYP2C9*2 will require lower 
doses of warfarin compared to CYP2C9*1 carriers.227 Another missense SNP rs1057910 
A>C (Ile359Leu) within the CYP2C9 noted as CYP2C9*3, which is associated with 
reduced metabolic clearance of S-warfarin relative to CYP29*2 with an average reduction 
of 40% relative to the CYP2C9*1.226 Furthermore, the rs9923231 C>T within the 
VKORC1 promotor region has been associated with decreased expression with the T allele 
versus the C allele.226 Therefore, carriers of the T allele will require a lower dose of 
warfarin compared to the C allele. Finally, the CYP4F2 is a primary liver vitamin K1 
oxidase that catalyzes the metabolism of vitamin K1 to hydroxyvitamin K1 and removes 
vitamin K from the vitamin K cycle. It acts as an important counterpart to VKORC1 in 
limiting excessive accumulation of vitamin K.228 The rs2108622 C>T (Val433Met) within 
CYP4F2 has been also linked with a higher weekly warfarin dosing with the T allele vs. C 
allele. For instance, a study of Italian patients concluded that the rs2108622 (TT) patients 
require 5.49 mg/day of warfarin versus 2.93 mg/day for (CC) patients. Analysis of 
variance of the study indicated that about 7% of mean weekly warfarin dose variance is 
explained by CYP4F2 genotype.229    
In our 235 Hmong participants, the warfarin response complex alleles identified to 
be important for other populations were significantly different in terms of prevalence, 
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relative to Europeans (Table 4.1). Specifically, the Hmong have a nearly 3-fold higher 
prevalence of CYP2C9*3 compared to Europeans. (21.2% vs. 7.3%, p<0.001) However, 
CYP2C9*2 was not detected in our Hmong cohort. This results in 61.7% as 
CYP2C9*1/*1, 37.2% as CYP2C9*1/*3 and 4.1% CYP2C9*3/*3. Moreover, the risk allele 
(T) of rs9923231 within the VKORC1 was significantly higher in Hmong than Europeans 
(88.4% vs. 38.8%, p<0.001). In contrast, the prevalence of the risk allele (T) of rs2108622 
within CYP4F2 was significantly lower in Hmong compared to Europeans (8.9% vs. 29%, 
p<0.005); however, it was similar to that found in an African  cohort (8.9% vs. 8.2%, 
p=1.00).45 Given the significant and differential prevalence of the risk alleles in the 
warfarin response complex in CYP2C9, VKORC1 and CYP4F2 between the Hmong and 
European counterparts, we would predict that  on average, Hmong receiving warfarin 
would likely require a lower  maintenance dose of warfarin compared to European-descent 
patients with the same clinical characteristics.  
Assessment of Select Disease Risk Genes in the Hmong   
The Hmong have a distinct prevalence of several comorbidities that led the Hmong 
Advisory Board to bring them to the attention of the research team as potential 
pharmacogenomics/genetics research.  In addition to gout, the Hmong have a 2-fold 
higher incidence of type 2 diabetes mellitus (T2DM) and higher incidence of head/neck, 
nasopharyngeal cancers as well as hepatocellular carcinoma.2,5-7,230 From an exploratory 
perspective, we estimated the frequencies of two genetic variations within 2 genes, cyclin-
dependent kinase inhibitor 2A/B (CDKN2A/B) that has strongly linked with the risk of 
diabetes and nicotinamide adenine dinucleotide phosphate oxidoreductase (NQO1)which 
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has been strongly linked with the risk of cancer. 
The CDKN2A/B gene is located on chromosome 9(9p21), and provides instructions 
for making several proteins, acts as a tumor suppressor gene and has been linked to cancer 
and type 2 diabetes (T2DM).231-234 The genetic variation rs10811661 C>T adjacent to the 
CDKN2A/B has been linked to impaired fasting blood glucose and the risk of T2DM.231-233 
A meta-analyses of 17 studies with 29,990 cases and 40,977 controls using four genetic 
models consistently showed an increased risk for T2DM with the T allele relative to the C 
allele. The allele contrast model had OR = 1.21, 95% CI (1.18-1.24), an additive genetic 
model had OR = 1.51, 95% CI (1.40-1.63), dominant genetic model had OR = 1.37, 95% 
CI (1.28-1.47), and the recessive genetic model had OR = 1.25, 95% CI 1.21-1.29).233 In 
our Hmong cohort, the prevalence of the risk allele (T) was significantly lower than 
Europeans (56.1% vs. 83.2%, p<0.001) (Table 4.1), which is not in parallel with the high 
prevalence of T2DM in the Hmong compared to non-Hmong.  However, because of the 
low predictive value of this genetic variant for risk for T2DM, it precludes us to make 
definitive interpretations from this information. 
The NQO1 gene is located on chromosome 16 (16q22), and encodes NQO1 protein 
for inactivating and detoxifying carcinogenic compounds6 and ameliorating some of the 
drug-induced nephrotoxic side effects of select drugs such as cisplatin.235 The rs1800566 
G>A (Pro187Ser) within NQO1 causes the NQO1 protein to be rapidly degraded via the 
ubiquitin dependent pathway shortening the half-life of the enzyme to 1.2 hours, 
compared to 18 hours for a normal NQO1 protein.236 The prevalence of the risk allele (A) 
within the NQO1 is nearly 3-fold higher in the Hmong than in European, which parallels 
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the higher incidence of select cancer types in the Hmong population and Han-Chinese in 
general (Table 4.1).6,237  
Although we limited our genetic assessment to 2 key SNPs associated with two 
complex disease states, T2DM and cancer, we acknowledge that the development of 
diseases like cancer or diabetes are complex and multigenic in nature. However, the 
different and distinct allele frequencies within genes known to influence the development 
of the disease cannot be ignored in the overall assessment of the individual’s risk 
stratification for these complex health conditions.  
Assessment of Pharmacogenetics of Purine Analogs in the Hmong 
Xanthine oxidoreductase (XOR), aldehyde oxidase1 (AOX1) and molybdenum 
cofactor sulfurase (MOCOS) are the major enzymes involved in purine metabolism, which 
is the precursor of uric acid (UA) production.238 Thus, change in the levels of activities in 
those enzymes may affect baseline UA and possibly the disposition of drugs that are 
metabolized by those enzymes as well as certain disease states that are modulated by UA 
production.166,238   
The XOR is a molybdenum iron-sulfur flavin hydroxylase synthesized as xanthine 
dehydrogenase (XDH) and predominantly expressed in the liver and gastrointestinal tract. 
Higher than normal levels of expression of XOR have been also associated with hypoxic 
conditions, endothelial dysfunction, ischemic injuries and pro-inflammatory cytokines.239-
241 There are two major isoforms of XOR:  xanthine oxidase (XO) and xanthine 
dehydrogenase (XDH). The primary role of XDH is to convert hypoxanthine to xanthine 
and ultimately to UA. Therefore, a decrease in activity or a loss of function primarily in 
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XDH can result in a condition known as xanthinuria, which is an excess urinary excretion 
of the purine base xanthine.242 Nonetheless, this condition is considered uncommon. 
Notably, hypoxanthine does not accumulate to an appreciable degree because it is recycled 
through a salvage pathway by the enzyme hypoxanthine guanine phosphoribosyl 
transferase (HGPRT). Two inherited forms of xanthinuria principally result from a 
deficiency of the enzyme XDH. Specifically, type I xanthinuria, which is the result of an 
isolated deficiency of XDH242 and type II xanthinuria, which is characterized by a 
deficiency of XDH and other related enzymes e.g. AXO1 or MOCOS.243 
Plasma accumulation and excess urinary excretion of the highly insoluble xanthine 
due to the deficiency of XDH may lead to arthropathy, myopathy, crystal nephropathy, 
urolithiasis, or renal failure.242,243 Inhibiting the activity of XOR is the most common 
approach to reduce UA production. The most widely used XOR inhibitors are allopurinol 
and febuxostat. While febuxostat inhibits both isoforms of the enzyme (XO and XDH), 
allopurinol preferentially inhibit the reduced form of the enzyme (XDH).156,244 Therefore, 
knowledge of genetic polymorphisms associated with metabolism of febuxostat and 
allopurinol can help predict optimal dosing to achieve target SUA. Specifically, 
allopurinol’s activity is mediated by the formation of the long-acting active metabolite, 
oxipurinol. Thus, being a substrate and an inhibitor of XDH, allopurinol could be 
considered as a prime example for the effects of genetic polymorphisms within purine 
genes on the response to drugs.   
AOX1 is also a molybdenum iron-sulfur flavin hydroxylase. The exact physiological 
role of AOX1 remains unclear; however, it is presumed to contribute to the overall purine 
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metabolism. In addition, AOX1 has been also involved in the metabolism of purine-like 
drugs such as allopurinol and 6-mercapto purine (6-MP). Molybdenum hydroxylases such 
as AOX1 and XOR require a final step of maturation to gain enzymatic activity, namely 
the addition of a terminal sulphido ligand to the molybdenum center.245 This step is mainly 
catalyzed by MOCOS, a two-domain protein acting as a homodimer. 245 
Although the effect of genetic polymorphisms in XOR, AOX1 and MOCOS on 
baseline UA are limited, drugs that are known to be metabolized by the same enzymes can 
be greatly influenced by these genetic polymorphisms. For example, a study assessed the 
association between xanthine oxidase inhibitors (XOI) and genetic polymorphisms within 
6 genes associated with the metabolism and clearance of XOIs in 100 patients with gout 
and stable XOI dose as the primary outcome. 166 While being a retrospective in design and 
lacking corrections for making multiple comparisons, the study identified several SNPs to 
have significant associations with different tiers of allopurinol or allopurinol-equivalent 
stable doses (< 300mg/d, 300mg/d and > 300mg/d). Specifically, the intronic rs75995567 
T>C within AOX1 was found to be significantly (p=0.031) associated with using higher 
stable doses of allopurinol (> 300mg/d).166 Generally, allopurinol is uncommonly 
prescribed in doses greater than 300mg/day. 
Additionally, Kurzawski et al246 enrolled 156 renal transplant recipients with at least 
12 months of graft survival and receiving triple immunosuppressive therapy (azathioprine 
(AZA), cyclosporine and prednisone) to investigate the effects of SNPs in XDH, AOX1 
and MOCOS genes in relation to clinical parameters and drug adverse events.246 The study 
identified that individuals carrying the missense rs55754655 A>G (Asn1135Ser) within 
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AOX1 required a significantly higher dose of AZA compared with non-carriers suggesting 
decrease formation of the active metabolites of 6-MP. However, the missense rs594445 
C>A (His703Asn) within MOCOS resulted in a lower activity requiring a significantly 
lower dose of AZA dose compared with non-carriers.246  
Given the interplay of MOCOS and AOX1 activities in terms of their roles in AZA 
dosing needs and the shared metabolic pathway between AZA and allopurinol, it is 
plausible that decreased function in MOCOS can reduce XOR activity affecting baseline 
UA and allopurinol metabolism.166 Therefore, it could be theorized that the production of 
oxipurinol and UA will be decreased in participants with the risk alleles in either MOCOS, 
AOX1 or XDH.   
To assess whether the risk alleles in key purine metabolizing genes: XDH, AOX1, or 
MOCOS may be contributing to the higher baseline SUA or higher incidence of gout in 
Hmong than non-Hmong, the prevalence of 3 previously identified SNPs246 (rs4407290, 
rs3731722, rs594445) were compared to CEU. Notably, two SNPs (rs4407290 G>A 
within XDH and rs594445 C>A within MOCOS) out of the 3 SNPs were identified by 
Kurzawski et al.246 However, the third SNP, rs3731722 A>G (His1297Arg) within AOX1, 
was of a particular interest as it’s been shown to be significantly associated with 
allopurinol dose in a different study.166 Using Chi-Square test or fisher’s exact test when 
appropriate, only the frequency of the rs594445 within MOCOS was found to be 
significantly different in our Hmong cohort than CEU (Table 4.2). Within our Hmong 
cohort of 235 adults, the estimated prevalence of risk allele (A) was higher in CEU than 
Hmong (27.3% vs. 10.1%, p<0.001). Notably, the A allele for rs594445 C>A is associated 
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with a lower enzymatic activity of MOCOS relative to the C allele. This finding suggests 
that the Hmong have a higher frequency of the normal activity of MOCOS, which is an 
important cofactor for the normal activity of AOX1 and XOR relative to CEU. This 
observation may also in part, explain the higher baseline SUA in the Hmong men and 
women (7.14 and 5.97mg/dL)79 relative to the average US men and women (6.14 and 
4.87mg/dL),11 respectively. Whether this missense rs594445 C>A is associated with 
developing gout is yet to be determined. However, higher baseline SUA is the hallmark 
for developing gout. 
Assessment of Uric Acid Genetics in the Hmong 
We previously reported on the prevalence of select 8 SNPs within 5 genes known to 
influence the elimination and reabsorption of uric acid in the Hmong in relation to other 
populations.79 In this addendum, we expand our analysis to include additional SNPs 
within genes using the same approach highlighted in our previous work and the approach 
summarized for the selection of SNPs in pathway pharmacogenetics.247 Specifically, the 
prevalence of rs2242206 G>T within SLC16A9, rs17300741 within SLC22A11 G>A, 
rs780094 C>T within GCKR and rs742132 G>A within LRRC16A were estimated in the 
Hmong then compared to CEU and CHB (Tables 4.2-3).  
SLC16A9 is located on chromosome 10 and encodes the monocarboxylic acid 
transporter 9 (MCT9).  Although the exact role of MCT9 in UA disposition is not well 
understood, it is believed to act as a UA and carnitine efflux transporter.80,248 The meta-
analysis by Kolz et al80 identified an association between the intronic rs12356193 G>A 
within SLC16A9 with increased SUA. Metabolomics studies have also shown that 
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rs12356193 within SLC16A9 is associated with DL-carnitine and propionyl L-carnitine. 
Moreover, the DL-carnitine and propionyl-L-carnitine are strongly associated with UA.80 
In our Hmong cohort, we genotyped for the rs2242206 G>T within SLC16A9 due to 
being a missense SNP (K285T) and more prevalent in a concordant population group to 
the Hmong such as CHB. Furthermore, both SNPs (rs2242206 and rs12356193) are in 
high linkage disequilibrium. Again, the prevalence of the risk allele (T), which is 
associated with the dysfunctional transporter, was significantly higher in the Hmong than 
CEU (51.5 vs 22.7%, p<0.001). Given the effect of this transporter on UA, reduced 
function of the MCT9 transporter may possibly lead to a substantial accumulation of UA 
due to decreased excretion. Indirect support of this rationale may come from a study by 
Nakayama et al84 which demonstrated that the presence of this T for rs2242206 G>T 
within SLC16A9 in Japanese patients with gout has been significantly associated with UA 
overproduction, a gout sub-type sometimes referred to as renal overload, but not 
specifically leading to gout susceptibility.   
SLC22A11is located on chromosome 11 and encodes the organic anion transporter 4 
(OAT4), which is primarily expressed on the apical side of the proximal convoluted 
tubule. Relative to the URAT1 transporter, the OAT4 transporter plays a modest role in 
UA reabsorption back into systemic circulation and is inhibited by select uricosuric 
drugs.249 The effect of genetic polymorphism rs17300741G>A within OAT4 has been 
associated with a significantly increased baseline SUA level within CEU.80 It has also 
demonstrated a  borderline significant level of association with subjects of the renal 
underexcretion gout sub-type but not gout susceptibility in Japanese.85 In the Hmong, the 
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prevalence of the risk (A) was found to be nearly 2-fold higher compared to CEU (93.7 vs 
46.5%, p<0.001). This observation further suggests that the prevalence of risk alleles in 
the Minnesota Hmong appear to parallel the observed higher prevalence of gout and 
increased risk of hyperuricemia.  Given the putative physiological role of this transporter, 
it is plausible to that individuals with the (A) allele for rs17300741G>A could have the 
normal to increased function of the transporter relative to the individuals with the (G) 
allele.  If confirmed, it may explain an increased ability for UA reabsorption thereby 
enhancing the risk for developing hyperuricemia and gout.  
Additional genes in this addendum have been previously identified by Kolz et al80, 
validated by others and assessed in our present Hmong cohort. These genes are not 
transporter genes rather structural and enzymatic genes indirectly related to baseline SUA. 
For instance, the LRRC16A is a protein coding gene for CARMIL1 (Capping Protein 
Regulator and Myosin 1 Linker 1) located on chromosome 6. Diseases associated with 
decreased function of CARMIL1 include elevated SUA and gout.80,209  Furthermore, 
variation in the GCKR (glucokinase regulatory protein) activity has been shown to be 
associated with increased SUA and gout,205,209 while being also associated with lipid and 
glucose metabolism.   
The intronic SNP rs742132 G>A within LRRC16A has been linked to increased 
SUA in CEU80 and increased risk for gout in Japanese.209 The frequency of the risk allele 
(A) in the Hmong was 86.3% compared to CEU 69.7% (p<0.001). Again, the Hmong 
appear to have a genetic basis for being at higher risk for both increased SUA and gout 
compared to CEU. The intronic SNP rs780094 C>T within GCKR has been also linked to 
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increased SUA in CEU80 and increased risk for gout in Han Chinese males.205 The 
frequency of the risk allele (T) for rs780094 in the Hmong was 28.6% compared with 
40.9% (p=0.003) seen in CEU. Although the frequency of this risk allele observed the 
Hmong was not directionally consistent with their increased risk of hyperuricemia or gout, 
we believe this gene is directly associated with glucose and lipid metabolism.  
In comparison to CHB, the Hmong were found to have a higher prevalence of the 
risk allele (C) of rs594445 C>A within MOCOS (89.9% vs. 72.3%, p<0.001) and the risk 
allele (A) of rs742132 G>A within LRRC16A (86.3% vs. 75.7%, p=0.001). In contrast, the 
Hmong were found to have a lower prevalence of the risk allele (T) of rs780094 C>T 
within GCKR compared to CHB (28.6% vs. 59.2%, p<0.001) (Table 4).  
In summary, apart from rs780094C>T within the GCKR, the prevalence of the risk 
alleles listed in Table 4.2 are consistent with the increased risk of hyperuricemia and gout 
in the Hmong compared to CEU.  Despite the Hmong typically being classified as a subset 
of CHB, they manifest a higher prevalence of the risk alleles associated with 
hyperuricemia and gout compared to reference cohorts of CHB. Collectively, our findings 
listed in Tables 4.2-3 are consistent with our earlier report on the prevalence of 8 risk 
alleles in the Hmong compared with CEU and CHB.  
Assessment of hyperuricemia or gout risk alleles by Sex in Hmong 
The global prevalence of hyperuricemia and gout is more common in men than 
women. Specifically, Hmong men have a much higher prevalence of gout compared to 
CEU (11.5 vs 4.1%).17 The prevalence of gout among Hmong women, however, is similar 
to that reported in CEU (1.9 vs. 1.9%).17 Consequently, assessing the frequencies of the 
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risk alleles between Hmong men and women is warranted may lead to a genetic signature 
for this observation. From our assessment of allele frequencies in our Hmong cohort,79 we 
identified that the rs1183201A>T within the SLC17A1 was significantly different between 
Hmong women and men (Table 4.4-5). SLC17A1 encodes the sodium-dependent 
phosphate cotransporter type 1 (NPT1), which is a UA efflux transporter.204 Stratified by 
sex, we found the frequency of risk allele (T) in Hmong males was modestly higher than 
in Hmong women (88.5 vs 80.4, p=0.026) (Tables 4.2-3). Since rs1183201 A>T within the 
SLC17A1 is associated with the risk of gout,205 SUA levels,80 this finding suggests that 
genetic polymorphisms in the efflux NPT1transporter  may play a role in Hmong males’ 
susceptibility for gout compared to women. Indeed, the prevalence of the risk (T) for the 
rs1183201 A>T is 50% in CEU versus 83.6% (<0.001) in the Hmong.  
A meta-analysis of sex specific results using a CEU population of 12,328 males and 
15,813 females did not show any additional genome-wide significant locus to have sex-
specific effects on SUA levels.80  However, it identified that the gender specific effect for 
the minor allele (G) of rs734553 T>G within the  SLC2A9, resulting in a 2-fold larger 
effect size on SUA concentrations in women compared to men. For ABCG2, however, the 
effect of the minor allele (T) of rs2231142 G>T demonstrated a larger effect on UA 
concentrations in men compared to women. For the other loci, effect sizes did not 
significantly differ by gender.80 
In summary, along with the non-genetic factors (diet and lifestyles) and sex-
hormonal differences between males and females, genetic variations such as SNPs in uric 
acid transporter encoding genes can differentially influence the risk of developing gout 
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between sexes.  
Genetic Assessment of Hyperuricemia in the Hmong 
In our earlier work,79 our SNP by SNP analysis did not show any association 
between the 8 SNPs in the 5 targeted genes and the risk of hyperuricemia. However, a 
limitation of our previously conducted analysis was the use of a very conservative 
definition of hyperuricemia (SUA > 6mg/dL). In this analysis, we use serum uric acid 
saturation threshold for defining hyperuricemia (SUA> 6.8mg/dL) and Fisher exact test 
with p<0.05 for significance. This analysis resulted in one SNP rs1183201 within 
SLC17A1 to be significantly associated with clinical definition of hyperuricemia as shown 
in Table 4.6. Though this is consistent with previously published data on the association of 
rs1183201 A>T within the SLC17A1 and increased SUA, we note that rs1183201 A>T 
was not in HWE in the participants with SUA > 6.8mg/dL. In the allele contrast model 
analysis, however, the rs1183201 A>T was not significantly associated with 
hyperuricemia.  As previously described, the rs1183201 A>T is a missense SNP with the 
risk allele T being associated with a dysfunctional UA efflux transporter NPT1 and has 
been associated with elevated baseline SUA and increased risk for gout while being more 
prevalent in Hmong males than Hmong women.  
Assessment of Baseline SUA Predictors in the Hmong 
Using multiple linear regression with serum uric acid as the dependent variable and 
14 SNPs within 12 genes, eCrCl measured by Cockcroft-Gault and sex as the independent 
variables, the model explained 52% (P=0.02) of SUA variability. While eCrCl was a 
significant predictor for SUA (p<0.001), the rs3733591 within SLC2A9 achieved 
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statistical significance (P=0.046) and rs505802 within SLC22A12 was borderline 
significant (P=0.058) (Table 4.7). 
Using a hierarchical multiple linear regression approach to identify predictors of 
baseline SUA variability, we analyzed 50 out of the 57 participants with known baseline 
SUA, sex, eCrCl, and complete genotypes information for 14 SNPs within 12 genes. With 
baseline SUA as the dependent variable and controlling for eCrCl, the independent 
variables i.e. sex and genotypes were tested in a stepwise regression fashion using 
probability criteria of F-to-enter <0.05 and probability criteria-of F-to-remove >0.10.  
In addition to eCrCl, gender was the only significant predictor of baseline SUA. In 
combination, gender and eCrCl explained 34% (P=0.002) of the variability around 
baseline SUA. Although physiologically consistent with the impact of sex and kidney 
function on the risk of developing hyperuricemia or gout the effect size of these genetic 
factors on baseline SUA are relatively small.  Consequently, our limited sample size 
precludes us from identifying any association of SNPs with baseline SUA in our Hmong 
cohort after adjusting for confounding variables such as kidney function and sex.  
Association of Uric Acid Levels with Cardiovascular Diseases in the Hmong 
Out of the 57 participants with measured SUA, available anthropometrics data 
(waist circumference, systolic and diastolic blood pressure), levels of HDL, and known 
status of taking antidiabetic medications, we identified that 26.3% (15/57) of the study 
participants have metabolic syndrome (MS) based on  NCEP/ATPIII guidelines.250 The 
mean (±SD) of SUA for participants with MS was 7.1 (±1.8) mg/dL . Participants (10/57) 
without risk factors for MS, however, did not have statistically different mean SUA of 6.1 
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(±2.2) than those with MS. Although our results remain consistent with the estimated 
prevalence of MS to be 18% in subjects with SUA < 6mg/dL,20 it remains lower than the 
prevalence of MS in individuals with mean SUA of 7.1 mg/dL.19 Evidently, the 
percentage of participants with metabolic syndrome could have increased should we have 
a full metabolic and lipid panel on those participants. Notably, the same 57 study 
participants had measured non-fasting glucose levels thus we did not use the measured 
glucose levels for assessing the risk for MS.  
Consistent with the increased risk for developing MS, SUA levels have been also 
associated with the different components that make up the MS. In addition, levels of SUA 
were negatively associated with eCrCl and it is believed that higher SUA level is a major 
risk factor for increased incidence of chronic kidney diseases.11 Analysis of our data on 57 
Hmong with known SUA, depict a trend for associations between SUA with other 
cardiovascular risk factors consistent with the literature and other epidemiological studies. 
Specifically, SUA levels were positively associated with SBP (P=0.055), and total 
cholesterol (p=0.055) (Figure 4.1-2); however, they were negatively associated with HDL 
(P=0.071) and eCrCl (P<0.001) (Figure 4.3-4).  
In summary, we document the trend of association between SUA levels and the risk 
of MS as well as cardiovascular disease risk factors. Although our sample size was small 
to show a significant association, we note the consistent trends of increased SUA levels 
with the risk factors known to increase the incidence of cardiovascular diseases.   
Conclusions 
The Minnesota Hmong have a distinct allele frequencies of clinically validated 
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pharmacogenes associated with key cardiovascular drugs compared to European descents. 
In addition, we note a distinct prevalence of two key risk allele genes associated with 
T2DM and decreased detoxification of carcinogen compounds in the Hmong relative to 
European descents. Consistent with the high prevalence of hyperuricemia and gout in the 
Hmong, select allele frequencies of genes involved in purine metabolism and uric acid 
disposition are higher in the Hmong compared with CEU and CHB and directionally 
consistent with increased risk of hyperuricemia and gout. With hyperuricemia and gout 
being more prevalent in Hmong than non-Hmong, we also identified that Hmong men 
tend to have a significantly higher prevalence of the risk allele (T) of rs1183201 A>T 
within SLC17A1 than Hmong women while remaining substantially higher than CEU 
overall.  
Finally, SUA levels have been long known to be strongly associated with 
hypertension, chronic kidney disease, diabetes, dyslipidemia and metabolic syndrome in 
large epidemiological studies. In our sample of 57 participants with known SUA levels, 
we observed similar patterns of association in our Hmong cohort. For instance, 
participants with metabolic syndrome had a higher level of SUA than those without; 
however, the difference was not significant. Additionally, we observed borderline 
significant associations between SUA levels and systolic blood pressure, eCrCl, HDL and 
total cholesterol.  
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Figure 4:1 Association between SUA levels and SBP 
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Figure 4:2 Association between SUA and total cholesterol 
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Figure 4:3 Association between SUA and HDL 
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Figure 4:4 Association between SUA and eCrCl 
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Table 4:1 Frequencies of Select VIP and Disease Risk Genes in Hmong and Europeans 
 Hmong (N=235) Europeans (1000 Genome Project) 45 
Gene (SNP) Allele Allele N 
(%) 
Genotype N (%) Allele N 
(%) 
Genotype N (%) 
SLCO1B1  
(rs4149056) 
T>Cǂ† 
T 
C 
446 (97.4) 
12 (2.6) 
TT 
CT 
CC 
217 (94.8) 
12 (5.2) 
0 (0) 
844 (83.9) 
162 (16.1) 
TT 
CT 
CC 
351 (69.8) 
142 (28.2) 
10 (2.0) 
CYP2C19*2 
(rs4244285) 
G>Aǂ† 
G 
A 
276 (63.0) 
162 (37.0) 
 
GG 
AG 
AA 
90 (41.6) 
91 (42.9) 
34 (15.5) 
860 (85.5) 
146 (14.5) 
GG 
GA 
AA 
363 (72.2) 
134 (26.6) 
6 (1.2) 
CYP2C19*3 
(rs4986893) 
G>A 
G 
A 
457 (99.8) 
1 (0.2) 
GG 
AG 
AA 
228 (99.6) 
1 (0.4) 
0 (0) 
1006 
(100) 
0 
GG 
AG 
AA 
503 (100) 
0 
0 
CYP2C19*17 
(rs12248560) 
C>Tǂ† 
C 
T 
461 (99.8) 
1 (0.2) 
CC 
CT 
TT 
230 (99.6) 
1 (0.4) 
0 (0) 
781 (77.6) 
225 (22.4) 
CC 
CT 
TT 
300 (59.6) 
181 (36.0) 
22 (4.4) 
VKORC1 
(rs9923231) 
C>Tǂ† 
C 
T 
 
54 (11.6) 
410 (88.4) 
 
CC 
CT 
TT 
5 (2.2) 
44 (19.0) 
183 (78.9) 
616 (61.2) 
390 (38.8) 
CC 
CT 
TT 
192 (38.2) 
232 (46.1) 
79 (15.7) 
CYP2C9*2 
(rs1799853) 
C>Tǂ† 
C 
T 
458 (100) 
0 (0) 
CC 
TT 
229 (100) 
0 (0) 
881 (87.6) 
125 (12.4) 
CC 
CT 
TT 
389 (77.3) 
103 (20.5) 
11 (2.2) 
CYP2C9*3 
(rs1057910) 
A>Cǂ† 
A 
C 
350 (78.8) 
94 (21.2) 
AA 
CA 
CC 
137 (61.7) 
76 (34.2) 
9 (4.1) 
933 (92.7) 
73 (7.3) 
AA 
CA 
CC 
431 (85.7) 
71 (14.7) 
1 (0.2) 
CYP4F2 
(rs2108622) 
C>Tǂ† 
C 
T 
419 (91.1) 
41 (8.9) 
CC 
CT 
TT 
194 (84.3) 
31 (13.5) 
5 (2.2) 
714 (71.0) 
292 (29.0) 
CC 
CT 
TT 
261 (51.9) 
192 (35.2) 
50 (9.9) 
NQO1 
(rs1800566)  
G>Aǂ† 
G 
A 
176 (38.9) 
276 (61.1) 
GG 
GA 
AA 
29 (12.8) 
118 (52.2) 
79 (35) 
794 (78.9) 
212 (21.2) 
 
GG 
GA 
AA 
315 (62.6) 
164 (32.6) 
24 (4.8) 
CDKN2A/B 
(rs10811661) 
C>Tǂ† 
C 
T 
202 (43.9) 
258 (56.1) 
CC 
CT 
TT 
46 (20.0) 
110 (47.8) 
74 (32.2) 
169 (16.8) 
837 (83.2) 
CC 
CT 
TT 
16 (3.2) 
137 (27.2) 
350 (69.6) 
ǂ† indicates (allele and genotype) statically significant difference between Hmong and 
European (P<0.005 for significance) 
Note: many of those SNPs deviated from HWE due to monomorphism or low frequency 
Bolded allele indicates the risk allele 
VIP: Very Important Pharmacogenes 
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Table 4:2 Frequencies of Purine and Uric Acid Modulator Genes in CEU and Hmong 
Gene (SNP) Genotype CEU N (%) 45 Hmong N (%) P-value 
XDH 
(rs4407290) G>A 
Chromosome 2 
GA 
GG 
Total 
5 
94 
5.1 
94.9 
9 
218 
227** 
4.0 
96.0 
 
0.75 
AOX1* 
(rs3731722) A>G 
Chromosome 2 
AG 
AA 
Total 
9 
90 
9.1 
90.9 
21 
208 
229** 
9.2 
90.8 
 
1.00 
MOCOS* 
(rs594445) C>A 
Chromosome 18 
AA 
CA 
CC 
Total 
7 
40 
52 
7.1 
40.4 
52.5 
5 
36 
187 
228 
2.2 
15.8 
82.0 
 
 
<0.001 
SLC16A9* 
(rs2242206) G>T 
Chromosome 10 
GG 
GT 
TT 
Total 
61 
31 
7 
61.6 
31.3 
7.1 
55 
114 
62 
231 
23.8 
49.4 
26.8 
 
<0.001 
SLC22A11 (rs17300741) G>A 
Chromosome 11 
AA 
AG 
GG 
Total 
23 
46 
30 
23.2 
46.5 
30.3 
202 
27 
1 
230 
87.8 
11.7 
0.4 
 
<0.001 
LRRC16A 
(rs742132) G>A 
Chromosome 6 
AA 
GA 
GG 
Total 
46 
46 
7 
46.5 
46.5 
7.1 
171 
55 
4 
230 
74.3 
23.9 
1.7 
 
 
<0.001 
GCKR 
(rs780094) C>T 
Chromosome 2 
CC 
TC 
TT 
Total 
34 
49 
16 
 
34.3 
49.5 
16.2 
117 
96 
18 
231 
50.6 
41.6 
7.8 
 
0.007 
Bolded allele indicates the risk allele 
* Missense SNP  
** Not in a Hardy-Weinberg Equilibrium 
P<0.006 for significance  
Note: many of those SNPs deviated from HWE due to monomorphism or low frequency 
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Table 4:3 Frequencies of Purine and Uric Acid Modulator Genes in CHB and Hmong 
Gene (SNP) Genotype CHB N (%)45 Hmong N (%) P-value 
XDH 
(rs4407290) G>A 
Chromosome 2 
GA 
GG 
Total 
10 
93 
9.7 
90.3 
9 
218 
227** 
4.0 
96.0 
 
0.044 
AOX1* 
(rs3731722) A>G 
Chromosome 2 
GG 
AG 
AA 
Total 
2 
12 
89 
1.9 
11.7 
86.4 
 
0 
21 
208 
229** 
0 
9.2 
90.8 
 
0.083 
MOCOS* 
(rs594445) C>A 
Chromosome 18 
AA 
CA 
CC 
Total 
8 
41 
54 
7.8 
39.8 
52.4 
5 
36 
187 
228 
2.2 
15.8 
82.0 
 
<0.001 
SLC16A9* 
(rs2242206) G>T 
Chromosome 10 
GG 
GT 
TT 
Total 
16 
55 
32 
15.5 
53.4 
31.1 
55 
114 
62 
231 
23.8 
49.4 
26.8 
 
0.227 
SLC22A11 
(rs17300741) G>A 
Chromosome 11 
AA 
AG 
GG 
Total 
89 
13 
1 
86.4 
12.6 
1.0 
202 
27 
1 
230 
87.8 
11.7 
0.4 
 
0.742 
LRRC16A 
(rs742132) G>A 
Chromosome 6 
AA 
GA 
GG 
Total 
57 
42 
4 
55.3 
40.8 
3.9 
171 
55 
4 
230 
74.3 
23.9 
1.7 
 
0.002 
GCKR 
(rs780094) C>T 
Chromosome 2 
CC 
TC 
TT 
Total 
16 
52 
35 
15.5 
50.5 
34.0 
117 
96 
18 
231 
50.6 
41.6 
7.8 
 
<0.001 
Bolded allele indicates the risk allele 
* Missense SNP  
** Not in a Hardy-Weinberg Equilibrium (N=235) 
P<0.006 for significance  
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Table 4:4 Allele Frequencies Stratified by Sex in Hmong 
Gene (SNP) Allele*  Male (N=105) Female (N=130) P-value 
N % N % 
SLC17A1 
(rs1183201) 
T 184 88.5 201 80.4 0.026 
A 24 11.5 49 19.6 
PDZK1 
(rs12129861) 
A 72 34.6 79 31.6 0.492 
G 136 65.4 171 68.4 
SLC22A11 
(rs17300741) 
A 198 95.2 233 92.5 0.230 
G 10 4.8 19 7.5 
ABCG2 
(rs2231137) 
A 109 52.4 138 55.2 0.548 
G 99 47.6 112 44.8 
ABCG2 
(rs2231142) 
A 75 35.7 90 35.7 1.00 
C 135 64.3 162 64.3 
SLC16A9 
(rs2242206) 
T 103 49.5 135 53.1 0.438 
G 105 50.5 119 46.9 
ABCG2 
(rs2725220) 
G 186 89.4 223 87.8 0.584 
C 22 10.6 31 12.2 
AOX1 
(rs3731722) 
A 199 95.7 238 95.2 0.806 
G 9 4.3 12 4.8 
SLC2A9 
(rs11942223) 
T 208 99.5 243 98.0 0.226 
C 1 0.5 5 2.0 
SLC2A9 
(rs3733591) 
A 118 56.7 148 60.2 0.458 
G 90 43.3 98 39.8 
SLC2A9 
(rs1014290) 
T 142 69.3 173 68.7 0.708 
C 60 29.7 79 31.3 
XDH  
(rs4407290) 
A 4 1.9 5 2.0 1.00 
G 204 98.1 241 98.0 
SLC22A12 
(rs505802) 
T 66 32.4 95 38.0 0.210 
C 138 67.6 155 62.0 
MOCOS 
(rs594445) 
A 15 7.3 31 12.4 0.071 
C 191 92.7 219 87.6 
LRRC16A 
(rs742132) 
A 181 87.0 216 85.7 0.689 
G 27 13.0 36 14.3 
GCKR 
(rs780094) 
T 59 28.1 73 29.0 0.841 
C 151 71.9 179 71.0 
HLA-B 
(rs9263726) 
G 206 98.1 246 98.4 1.00 
A 4 1.9 4 1.6 
*Bolded allele indicates the risk allele 
Risk allele is defined as the allele that is not associated with reduced SUA based on the 
GWAS by Kolz et al 80 
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Table 4:5 Genotype Frequencies by Sex in Hmong 
Gene (SNP) Genotype Male (N=105) Female (N=130) P-value N % N % 
SLC17A1 
(rs1183201) 
TT 83 79.8 79 63.2 
0.0104 AT 18 17.3 43 34.4 
AA 3 2.9 3 2.4 
PDZK1 
(rs12129861) 
AA 12 11.5 15 12.0 
0.554 AG 48 46.2 49 39.2 
GG 44 42.3 61 48.8 
SLC22A11 
(rs17300741) 
AA 95 91.3 107 84.9 
0.081 AG 8 7.7 19 15.1 
GG 1 1.0 0 0.0 
ABCG2 
(rs2231137) 
AA 28 26.9 36 28.8 
0.778 AG 53 51.0 66 52.8 
GG 23 22.1 23 18.4 
ABCG2 
(rs2231142) 
AA 14 13.3 18 14.3 
0.951 CA 47 44.8 54 42.9 
CC 44 41.9 54 42.9 
SLC16A9 
(rs2242206) 
TT 24 23.1 38 29.9 
0.477 GT 55 52.9 59 46.5 
GG 25 24.0 30 23.6 
ABCG2 
(rs2725220) 
GG 82 78.8 99 78.0 
0.394 CG 22 21.2 25 19.7 
CC 0 0.0 3 2.4 
AOX1 
(rs3731722) 
TT 95 91.3 113 90.4 
0.823 TC 9 8.7 12 9.6 
CC 0 0.0 0 0.0 
SLC2A9 
(rs3733591) 
AA 34 32.7 43 35.0 
0.651 GA 50 48.1 62 50.4 
GG 20 19.2 18 14.6 
SLC2A9 
(rs1014290) 
TT 7 6.9 9 7.1 
0.934 CT 46 45.5 61  48.4 
CC 48 47.5 56  44.4 
XDH 
(rs4407290) 
AA 0 0.0 0 0.0 
1.00 GA 4 3.8 5 4.1 
GG 100 96.2 118 95.9 
SLC22A12 
(rs505802) 
TT 11 10.8 23 18.4 
0.278 CT 44 43.1 49 39.2 
CC 47 46.1 53 42.4 
MOCOS 
(rs594445) 
AA 1 1.0 4 3.2 
0.262 CA 13 12.6 23 18.4 
CC 89 86.4 98 78.4 
P<0.05 indicates statistically significant 
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Table 4:6 Risk of Hyperuricemia by Genotype 
SLC2A9 (rs734553) * TT GT GG P-value 
SUA <6.8 mg/dL (n) 34 0 0 
NS SUA >6.8 mg/dL (n) 19 1 0 
SLC2A9(rs1014290) TT TC CC  
SUA <6.8 mg/dL (n) 14 17 1 
NS SUA > 6.8mg/dL (n) 7 10 2 
SLC2A9 (rs11942223) * TT TC CC  
SUA <6.8 mg/dL (n) 33 0 0 
NS SUA > 6.8mg/dL (n) 17 1 0 
PDZK1(rs12129861) * AA AG GG  
SUA <6.8 mg/dL (n) 3 12 18 
NS SUA > 6.8 mg/dL (n) 2 8 8 
ABCG2 (rs2231142) * AA CA CC  
SUA <6.8 mg/dL (n) 2 12 19 
NS SUA > 6.8 mg/dL (n) 3 6 11 
SLC22A12 (rs505802) * TT TC CC  
SUA <6.8 mg/dL (n) 6 15 11 
NS SUA > 6.8 mg/dL (n) 2 9 9 
SLC2A9 (rs3733591) * GG GA AA  
SUA 6.8 mg/dL(n) 4 17 11 
NS SUA > 6.8mg/dL (n) 3 10 5 
SLC17A1 (rs1183201) TT AT AA  
SUA <6.8 mg/dL (n) 20 12 1 
0.02 
SUA > 6.8mg/dL (n)* 17 1 1 
 
Hyperuricemia was defined as SUA > 6.8 mg/dL 
* Indicates the SNP was not in a Hardy-Weinberg Equilibrium (N=57) 
P<0.05 indicates statistical significance using Chi-Square or Fisher’s exact test 
NS: Not Significant 
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Table 4:7 Baseline SUA Multiple Linear Regression Summary Statistics* 
 Coefficients SE P-value R2 Adj. R2 SE Sig. F 
Intercept 9.431 2.713 0.001 
0.54 0.32 1.3 0.02 
eCrCl 
(mL/min) 
-0.039 0.011 0.001 
Gender -0.772 0.449 0.095 
SLC17A1_ 
rs1183201 
0.187 0.466 0.690 
PDZK1_ 
rs12129861 
-0.404 0.332 0.232 
SLC22A11_ 
rs17300741 
0.657 0.594 0.277 
ABCG2_ 
rs2231137 
0.165 0.487 0.737 
ABCG2_ 
rs2231142 
0.016 0.639 0.980 
SLC16A9_ 
rs2242206 
-0.221 0.349 0.532 
XDH_ 
rs2364916 
0.034 0.313 0.915 
ABCG2_ 
rs2725220 
-0.008 0.726 0.991 
SLC2A9_ 
rs3733591 
-0.721 0.348 0.046 
SLC2A9_ 
rs1014290 
-0.375 0.375 0.324 
SLC22A12_ 
rs505802 
0.607 0.309 0.058 
MOCOS_ 
rs594445 
-0.473 0.557 0.402 
LRRC16A_ 
rs742132 
0.596 0.406 0.152 
GCKR_ 
rs780094 
0.020 0.362 0.956 
*Dependent variable was baseline serum uric acid (N=50) 
Using an additive model when coding the SNPs 
P<0.05 indicates statistical significance 
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Chapter 5  
The Pharmacodynamics, Pharmacokinetics, and Pharmacogenomics of Allopurinol in 
Hmong Adults with Gout or Hyperuricemia:  The Genetics Of HyperUricemia and Gout 
Therapy in Hmong (GOUT-H) Study 
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Introduction 
Gout, the most common inflammatory arthritic condition, is caused by deposition 
of monosodium urate crystals in distal joints.140 Hyperuricemia, the hallmark for 
developing gout, is strongly associated with cardiovascular diseases251 including 
hypertension56, metabolic syndrome54 and type 2 diabetes mellitus.186 The prevalence of 
gout and hyperuricemia are rising globally and within the US, in part due to changes in 
lifestyles, increasing longevity and obesity. In addition, race, ethnicity and genetics may 
contribute to developing hyperuricemia and gout.80,81,208 For example, the prevalence of 
risk alleles associated with hyperuricemia and gout vary by ancestry in a manner 
consistent with the prevalence of gout.81,205 For the most part, genetic polymorphisms 
linked to the development of hyperuricemia and gout are found within genes encoding uric 
acid (UA) transporters including ABCG2, SLC2A9, SLC16A9, SLC17A1, SCL22A11, and 
SLC22A12. Other genes that may also play a role include PDZK1, LRRC16A and 
GCKR.80,81 While the overall prevalence of gout in the US is 3.9%,11 select ethnic and 
racial groups may be up 10.4% 10,11 A prime example is the Hmong.17   
The Hmong are a unique Asian sub-population numbering over 250,000 in the US 
with over 64,000 living in Minnesota.252 In addition to a 2-fold increased risk of gout,17 
Minnesota Hmong manifest gout at a younger age with more complications and have up to 
5-fold increased risk of gout-associated co-morbidities compared to non-Hmong.24,34 
Furthermore, select hyperuricemia and gout associated risk alleles are more prevalent in 
the Hmong compared to Caucasian (CEU) and Han-Chinese (CHB) populations.24,79 
Collectively, these findings strongly suggest genetics play a role in the risk for 
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hyperuricemia and gout in the Hmong, and possibly their response to medications, diet 
and lifestyle factors.  
Allopurinol is the most prescribed urate-lowering therapy (ULT) in the 
management of gout.143,181 Rapidly absorbed, allopurinol is metabolized to the active 
metabolite, oxipurinol.  Oxipurinol is renally eliminated, yet undergoes extensive 
reabsorption via the URAT1 transporter encoded by SLC22A12.253 The high variability in 
plasma oxipurinol concentrations following allopurinol dose254 suggests URAT1, 
specifically, the single nucleotide polymorphism (SNP) rs505802 T>C, to be a probable 
source of variability in response to allopurinol. In part, this variant may contribute to the 
observed high failure rates to achieve target serum uric acid (SUA) levels in patients 
treated with allopurinl.163,255 Consequently, we sought to specifically target the rs505802 
T>C within SLC22A12 as a potential contributor to the pharmacokinetics and 
pharmacodynamics of allopurinol.  
The higher prevalence of gout and gout-risk alleles in the Hmong17,79 provided the 
basis to conduct the GOUT-H study (clinicaltrial.gov, NCT02371421). Our central 
hypothesis is the rs505802 T>C within SLC22A12 affects the PK and PD of allopurinol in 
Hmong adults. The objectives of this study were to assess the effectiveness of allopurinol 
in lowering SUA in Hmong adults with hyperuricemia or gout and to quantify the impact 
of key SNPS on the urate lowering response to allopurinol. 
Materials and Methods: 
Study Design 
This genetically-guided, prospective, open-labeled, pilot study utilized the 
principles of community-based participatory research (CBPR) and capitalized on an 
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established partnership with the Hmong community.34 A ten-member Hmong Gout 
Research Board, consisting of the 3 study investigators plus 7 Hmong professionals and 
community researchers, conducted the study. The Hmong Board members gave input into 
the cultural appropriateness of study design, recruitment methods, and consent materials; 
two members actively recruited and consented participants while assisting in sample 
collection and completion of questionnaires from both Hmong and English speaking 
participants.  All study materials were approved by the Human Research Protection 
Program at the University of Minnesota Institutional Review Board (IRB #1408M53223). 
Study Participants and Study Visits 
We enrolled male and female Hmong adults ≥ 18 years old with SUA ≥ 6mg/dL, 
or history of gout documented with use of ULT, or SUA <6mg/dL with a history of 2 gout 
flares in the past 6 months. Hmong ancestry was based on self-report of both parents being 
of Hmong descent. Individuals with any of the following were excluded: active liver 
disease, eCrCl <30mL/min, pregnant women or women of a child bearing age not using 
any form of contraception, inability to discontinue any ULT for 7-days, or history of 
allergic reactions to allopurinol.  
This study was designed as a 3-visit study, including recruitment (Visit1/V1), pre-
allopurinol (Visit2/V2), post-allopurinol (Visit3/V3) [Figures 5.1-2]. Halfway through the 
study, a salivary DNA-based recruitment (Visit0/V0) was added to expedite enrollment of 
participants with the less prevalent (TT) genotype for the rs505802 T>C. Hmong adults 
responding to either media advertisements or a personal encounter with board members 
came to either V0 or V1. After obtaining consent and completing an initial screening 
survey, salivary DNA was collected and processed to identify individuals with genotypes 
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of interest. At V1, weight, height, waist circumference, heart rate, blood pressure, a brief 
medical and medication history, and blood samples (for SUA level and basic blood 
biochemistry) were collected. 
Assessment of UA disposition parameters including partial UA renal clearance 
(CLR(UA)0-6hr) , urinary UA excretion (UUE0-6hr) rate and percent UA fractional excretion 
(FEUA0-6hr %) over 6-hours was conducted before and after taking allopurinol.  
At the beginning of V2, following a 10-hour overnight fast, venous blood was collected at 
0 and 6-hours and urine was collected at 0, 2, 4, 6 hours. At the end of V2, participants 
were instructed to begin 100mg allopurinol every 12 hours for 7 days followed by 150mg 
allopurinol every 12 hours for 7 days. During V3, an assessment of oxipurinol and UA 
disposition parameters post-allopurinol conducted. Following a 10-hour overnight fast, 
venous blood was collected at 0, 2, 4, 6 hours to determine oxipurinol partial area under 
the serum concentration-time curve (AUC0-6hr).  Concomitantly, urine was collected at 0, 
2, 4, 6 hours to estimate UA disposition parameters. Following 0-hour blood draws at V2 
and V3, participants received water and traditional Hmong food for breakfast and lunch. 
The overall study design overview summary is shown in Figure5.1.  
Medication Adherence:  
All participants received at least 2 phone calls reminding them to take their 
medications, inquiring about adverse effects, and reminding them to return all used and 
unused dose-packed allopurinol. At V3, participants answered questions about their study 
medication experience, including timing of the last dose and possible adverse effects. 
Medication adherence rates for the 2-week study drug were calculated as a percentage 
(number of doses taken divided by the total number of doses expected). 
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Estimated Creatinine Clearance:  
Estimated serum creatinine clearance (eCrCl) was calculated by Cockcroft-Gault 
method: [(140-age) x (Ideal Body Weight in kg)/ (72 x Serum Creatinine)] x (0.85 if 
female). Adjusted body weight was used for overweight or obese people. 
Uric Acid Disposition Parameters:  
All UA parameters were determined over 6-hours. Absolute SUA change was 
calculated as the difference between SUA measured at the 6-hour time at both V2 and V3. 
Normalized UUE rate (mg/min/1.73m2) was calculated using urine volumes collected at 
each time point multiplied by its UA concentration over the course of 0-6 hours divided by 
1.73m2.  FEUA0-6hr (%) was expressed as the UA renal clearance relative to creatinine (Cr) 
renal clearance. This was calculated by using the total urine UA and Cr concentrations 
(mg/L) produced over 6-hours and the average concentrations (0 and 6hr) of SUA and Cr 
(mg/L). The formula used was as follows:  
FEUA0-6 hr =
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 6 ℎ𝑟𝑟 [𝑈𝑈𝑈𝑈] 𝑖𝑖𝑖𝑖 𝑈𝑈𝑟𝑟𝑖𝑖𝑖𝑖𝑈𝑈 (𝑚𝑚𝑚𝑚/𝐿𝐿) ∗ 𝑈𝑈𝐴𝐴𝑈𝑈𝑟𝑟𝑇𝑇𝑚𝑚𝑈𝑈 [𝐶𝐶𝑟𝑟] 𝑖𝑖𝑖𝑖 𝑆𝑆𝑈𝑈𝑟𝑟𝑆𝑆𝑚𝑚 (𝑚𝑚𝑚𝑚/𝑑𝑑𝐿𝐿)  
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 6 ℎ𝑟𝑟  [𝐶𝐶𝑟𝑟] 𝑖𝑖𝑖𝑖 𝑈𝑈𝑟𝑟𝑖𝑖𝑖𝑖𝑈𝑈 (𝑚𝑚𝑚𝑚/𝐿𝐿) ∗ 𝑈𝑈𝐴𝐴𝑈𝑈𝑟𝑟𝑇𝑇𝑚𝑚𝑈𝑈  [𝑈𝑈𝑈𝑈]  𝑖𝑖𝑖𝑖 𝑆𝑆𝑈𝑈𝑟𝑟𝑆𝑆𝑚𝑚 (𝑚𝑚𝑚𝑚/𝑑𝑑𝐿𝐿)X 100.  
UA/Cr0-6 hrs was calculated by comparing the amount of UA and Cr excreted in urine over 
6-hours. CLR(UA)0-6hr was calculated by measuring the amount of UA excreted in urine 
over the 6-hour time collection divided by the average SUA concentrations at hour 0 and 
6. For classifying hyperuricemia, the previously published criteria utilizing FEUA% and 
UUE rates were used to classify an individual’s hyperuricemia as either overproducers or 
underexcreters or combined.256 However, participants not meeting any of those specific 
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published criteria, FEUA% and UUE rate of > 5.5% and <25 mg/hr/1.73m2 were 
classified as normouricemia.  
DNA Extraction and Genotyping: 
DNA was extracted from peripheral blood using an Autopure LS automated 
extraction instrument and Qiagen Puregene® (Germantown, MD) reagents. In select 
participants, DNA was extracted from saliva by the ethanol precipitation method and the 
prepIT.L2P reagent for the purification of genomic DNA from the ORAgene DISCOVER 
(OGR-500) collection kit (Ontario, Canada). Finally, all DNA samples were prepared, 
labeled, and analyzed for quality and quantity. Initial genotyping for rs505802 T>C was 
conducted by a TaqMan® Genotyping Master Mix Protocol using the Polymerase Chain 
Reaction (PCR) method (Applied Biosystems, Foster City, CA, USA).  Following the 
DNA amplification, a Real-Time PCR allelic discrimination protocol was used for plate 
reads. Subsequent multiplex genotyping was confirmed using iPLEX Gold method. 
iPLEX reagents and protocols for multiplex PCR, single base primer extension and 
generation of mass spectra were used as per the manufacturer’s instructions. (iPLEX 
Application, Agena, San Diego, CA).  
Uric Acid Assay:  
Serum and urine UA concentrations were measured using a Roche COBAS 6000 
chemistry analyzer (Roche Diagnostics, Indianapolis, IN) using the enzymatic method 
with a limit detection of 0.2mg/dL. The inter-assay coefficient of variation was 1.3% at 
5.50mg/dL and 2.0 % at 9.67 mg/dL.  
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Serum Oxipurinol Assay:  
The aliquoted serum samples were stored at -80°C until quantification within the 
Clinical Pharmacology Analytical Services Laboratory (Minneapolis, MN). Detection and 
quantification of oxipurinol in serum was performed using a high-performance liquid 
chromatograph (Agilent 1200 Series, Santa Clara CA) coupled with a TSQ Quantum triple 
stage quadrupole mass spectrometer (Thermo-Electron, San Jose, CA). The assay was 
linear in the range of 50 – 25000 mg/L of oxipurinol with accuracy and total variability of 
98% and 3.9%, respectively. Details of the assay and method of detection have been 
previously published.257 
Serum Oxipurinol Exposure Calculation: 
Serum oxipurinol concentrations from 0 to 6-hours following the last dose were 
analyzed from 2-hour sampling times using non-compartmental analyses.  AUC0-6hr was 
calculated from 4 time points (0, 2, 4, 6hr) using nominal time and log linear trapezoidal 
method by Phoenix® WinNonlin® 6.4 software (Pharsight, Certara L.P.)   
Statistical Analysis: 
A sample size of 30 individuals for rs505802 T>C within SLC22A12 [13 (CC), 12 
(CT), 5 (TT)] was estimated to achieve 80% power to detect an effect size of 1 between 
mean oxipurinol AUCs across 3 genotypes using an F-test with a significance level of 
0.05. Accounting for a 20% drop out rate and using previously published estimates of 
oxipurinol AUC169 and allele frequencies within the Hmong,79 we estimated the need to 
recruit thirty-six participants. 
Continuous data variables are expressed as mean (±SD) [range] and categorical 
data as percentages. Baseline and treatment values (pre- and post-allopurinol) were 
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compared using paired t-test. For multiple testing, one-way ANOVA was used followed 
by Bonferroni t-test adjustment for post-hoc, if significant. A stepwise multiple regression 
using an additive model with F > 4.0 for inclusion and F < 3.9 for exclusion was used to 
identify which selected SNPs [Table 5.7] were associated with the absolute change in 
SUA. The base model included baseline V-2 SUA, oxipurinol AUC0-6hr, and V3 eCrCl. 
Shapiro-Wilk and Leven’s tests were used to assess normality and homoscedasticity 
assumptions of the linear model, with p<0.05 to reject the null hypothesis.  
Results  
Table 5.1 summarizes the participant’s demographics and characteristics. From 
November 2014 to December 2015, 36 study participants completed all phases of the 
GOUT-H study. Two participants were excluded from the final analyses due to poor 
(<79%) adherence to allopurinol. The mean (±SD) [range] adherence rate was 95% (±6) 
[79-100] for the 34 subjects included in the final analysis. Study participants were 
predominantly males 91% and 77% of participants were born outside the US. The mean 
(±SD) [range] age was 43.5 (+12.7) [24-67] years with 38% (13/34) <40 years of age.   
Effect of Allopurinol on Uric Acid Disposition Parameters:  
Table 5.3 summarizes the overall effects of allopurinol on UA disposition 
parameters. Allopurinol reduced the mean UUE0-6hr rate from 0.38 to 0.20 mg/min/1.73m2 
(p<0.001) [Figure 5.8], CLR(UA)0-6hr from 7.10 to 6.15 mL/min (p=0.042), FEUA0-6hr% 
from 6.49 to 4.88% (p<0.001) [Figure 5.9], urine UA/urine Cr ratio from 0.54 to 0.26 
(p<0.001). Allopurinol increased urinary creatinine excretion (UCrE) rate from 0.79 to 
0.82 mg/min/1.73m2 (p=0.419). Analysis of UA parameter changes based on rs505802 
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T>C within SLC22A12 alone did not identify a statistically significant association between 
FEUA0-6hr% either at baseline or post-allopurinol therapy.  
Effect of Allopurinol on SUA and Kidney Function 
The primary outcome was the absolute change in SUA after two weeks of 
allopurinol therapy.  The mean(+SD) SUA decreased from 9.3 (±1.5) to 5.3 (±1.1) mg/dL, 
(p<0.001) with mean (±SD) [range] absolute SUA reduction of 4.0 (±1.5) [1.4-7.1] mg/dL 
[Figure 5.4]. The mean percent reduction of SUA was 41% (±12) with a range of 23-66%. 
Additionally, 71% (24/34) of study participants achieved the target SUA <6mg/dL [Figure 
5.5]. Using the weight modified Cockcroft-Gault equation, the mean (±SD) eCrCl 
increased from 72 (±26) at V2 to 76 (±26) mL/min at V3 with a mean percent increase of 
5% (P=0.029) [Figure 5.10]. 
Hyperuricemia and Gout Classification:  
Twenty-three of 34 participants (68%) had diagnosis of gout based on self-reported 
history of using allopurinol or febuxostat. The remaining participants were enrolled based 
on SUA > 6 mg/dL. Using the published criteria for classifying hyperuricemia status,256 
38% (13/34) had UA underexcretion, 32% (11/34) had normal UA disposition, 24 % 
(8/34) had UA overproduction and 6% (2/34) had combined UA underexcretion and 
overproduction.  
Pharmacogenetics of Oxipurinol  
Thirty-four study participants completed the study, but only 33 participants had 
known serum oxipurinol concentrations due to one participant’s inconsistent timing of 
taking allopurinol. Table 5.5 summarizes the key oxipurinol PK findings. The Mean ± 
(SD) Oxipurinol AUC0-6hr was 85.9 + (34.7) (mg*hr/L) with a range of 39.9-176.6 
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(mg*hr/L) [Figure 5.11].  The mean (+SD) serum 0-hour oxipurinol concentration (C0hr) 
and oxipurinol concentration at the 6-hour were 12.6 (±6.2) mg/L and14.0 (±5.8) mg/L, 
respectively. Stratified by genotype of rs505802 T>C, the mean (±SD) SUA absolute 
change were 4.21 (±1.6) mg/dL, 3.94 (±1.2) and 3.04 (±1.0) mg/dL, for the CC, CT and 
TT, respectively (p=0.29) [Figure 5.6,14]. The mean oxipurinol C0hr, C6hr and AUC0-6hr 
were associated with SLC22A12 genotype (p<0.001) [Figure 5.15-16]. Relative to the CC 
genotype, the AUC0-6hr and C0hr were lower for CT and TT genotypes (p<0.05). Although 
the study was purposely powered for analysis of a single SNP rs505802, analysis of 
contributions from 15 SNPs across 12 genes associated with baseline SUA or gout and 
allopurinol metabolism,80,81 was conducted [Tables 5.8-10].  A base model consisting of 
baseline SUA, oxipurinol AUC0-6hr and eCrCl explained 64% of the variability in absolute 
SUA reduction. Considering 15 SNPS and using a forward stepwise multivariate analysis, 
only rs505802 T>C within SLC22A12 was found to be significantly (P=0.013) associated 
with absolute SUA reduction in addition to the base model [Table 5.6]. The final model 
explained 71% of the variability in absolute SUA reduction [Tables 5.7]. 
Allopurinol Therapy Adverse events: 
Adverse drug events reported included gout flare-ups (11/34), drowsiness (3/34) 
and nausea (2/23). One participant had urinary retention that appeared to resolve by 
reducing allopurinol dose to 250mg/day. One participant experienced drowsiness and 
remained on allopurinol 100mg every 12 hours. One case of a mild rash resolved by 
taking an antihistamine and was discontinued from the study. Blood biochemistry 
measurements taken pre-and post-allopurinol indicated no clinically important changes.  
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Discussion 
This is the first report to prospectively ascertain the impact of genetic factors on 
the pharmacokinetics and pharmacodynamics of allopurinol. Documenting a 41% SUA 
reduction facilitating 71% of participants to achieve target SUA levels < 6mg/dL with 
minimal adverse effects, provides evidence of overall efficacy and tolerability of 
allopurinol in the Hmong. Further analysis of measures of response to allopurinol based 
on rs505802 T>C within SLC22A12 suggest this SNP contributes significantly to the 
variability in urate-lowering response in the Hmong. The significance of identifying 
rs505802 T>C affecting drug response is several-fold. Not only does the risk allele (C) for 
rs505802T>C, occur more frequently in the Hmong relative to non-Hmong,79 the same 
allele has been significantly associated with baseline SUA and metabolic syndrome.80,81,258  
The physiological and biological effects of genetic variants within SLC22A12 on 
UA and oxipurinol are compelling.  The URAT1 transporter, encoded by SLC22A12, is 
responsible for reabsorbing up to 90% of the filtered UA back into circulation.182 In 
addition, evidence from in vitro data implicating the role of URAT1 in reabsorbing 
oxipurinol,253 strongly suggests that a change in either the level of activity or expression of 
transporter would be expected to influence the amount of UA and oxipurinol reabsorbed. 
The predominance of the C allele in the Hmong (65%) relative to CEU (27%) (p<0.001),79 
adds to the possible genetic basis for the Hmong’s documented predisposition to 
hyperuricemia and gout.26,79  This alignment of observations support the hypothesis that 
genetic variation  within URAT1 gene not only play a significant role in the prevalence of 
hyperuricemia and gout in the Hmong,17 but also drug response through modulating 
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oxipurinol exposure.253 Collectively, these observations support the hypothesis that 
rs505802 T>C within SLC22A12 plays a significant role in the pharmacokinetics-
pharmacodynamics of allopurinol.    
The impact of rs505802T>C within SLC22A12 on allopurinol’s pharmacokinetics 
suggests that variability in response to allopurinol may partially be attributed to an 
individual’s functionality of URAT1. From the present study, participants with the CC 
genotype had the highest oxipurinol AUC0-6hr and lowest oxipurinol renal clearance, 
resulting in a greater absolute SUA reduction compared with CT and TT genotypes 
[Figure 5.17]. This is consistent with the knowledge of the T allele (rs505802T>C) being 
significantly associated with lower SUA baseline and potentially lower oxipurinol 
exposure.80,253 Moreover, the study identifies an inverse correlation between oxipurinol 
AUC0-6hr and eCrCl (r=-0.64, p<0.001) [Figure 5.12] and a positive correlation between 
oxipurinol AUC0-6hr and absolute SUA reduction (r=0.59, P<0.001) [Figure 5.13] 
confirming the importance of kidney function and oxipurinol exposure as significant 
determinants of response to allopurinol.255  
There are other genetic factors affecting the development of gout and 
responsiveness to allopurinol. For example, previous reports retrospectively identified the 
rs2231142G>T within ABCG2, as a predictor of poor response to allopurinol.86,165 The 
mechanism by which this SNP affects the response to allopurinol remains elusive and 
underscores the need for a mechanistic-based study to examine its paradoxical effect on 
the response to allopurinol.86  In the present study, prospective enrollment based on 
rs505802T>C within SLC22A12 did not yield a significant difference in the risk allele 
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frequency of rs2231142G>T relative to  the expected frequency reported in a distinct 
cohort of Hmong[Table 5.8-9].79 This observation suggests URAT1 could play a more 
significant role than ABCG2, at least within the Hmong sample studied. Furthermore, in 
contrast to rs2231142G>T within the ABCG2, analysis focusing on rs505802 T>C within 
SLC22A12 provides a plausible mechanism for the variabilities in the pharmacokinetics 
and Pharmacodynamics of allopurinol. 
Measuring oxipurinol concentrations have been proposed as a tool to assess 
compliance and guide allopurinol dosing.163,255 For example, Emmerson et al254 suggested 
that 6-9 hour post-allopurinol measurements of serum oxipurinol concentrations of 15.2 
mg/L (100 µmol/L) are needed to achieve target SUA concentrations < 7.0mg/dL (0.42 
mmol/L).  Stamp et al 255 have suggested 6-9 hours post-dose of 15.2-22.8 mg/L or trough 
oxipurinol levels of 10.0-15.2mg/L are needed to achieve the target SUA concentration < 
6mg/dL.255 In this study, the mean (±SD) 6-hour post-allopurinol and trough serum 
concentrations of oxipurinol were 14.0 (±5.8) mg/L and 12.6 (±6.2) mg/L, respectively 
suggesting that most individuals in the present study would be expected to achieve optimal 
SUA targets. However, summarizing mean data from the population ignores important 
sources of variability in oxipurinol such as allopurinol dose, renal function and genotype. 
Specifically, with 41% SUA reduction and 71% of participants achieving SUA < 6mg/dL 
in the present study, these outcomes compare favorably relative to other published clinical 
trials achieving 33-34% SUA reduction259,160 with 45% of patients achieving SUA target 
with comparable dosing.255 Nonetheless, we recognize that this study benefited from a 
greater adherence to allopurinol, in part due to its comparatively short duration, relative to 
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others.255,259,160 However, participants achieving serum oxipurinol concentrations of < 15.2 
mg/L at 6-hours occurred in 22/33 of study participants while trough concentrations of 
serum oxipurinol of <10mg/dL occurred in 13/33 of study participants. Stratified by, 
participants with the CC genotype had more than 2-fold higher oxipurinol C0hr, C6hr and 
AUC0-6hr compared to the participants with the TT genotype [Table 5.5] [Figure 5.15-16]. 
Consequently, analysis of individuals failing to achieve target oxipurinol trough and 6-
hours had 36% and 37% SUA reduction resulting in 54% and 55% achieving target SUA 
<6mg/L, respectively.  Thus, understanding that genotype and population specific 
variability in allele frequencies may play a significant role in achieving target serum 
concentrations of oxipurinol underscores the importance of utilizing genetic knowledge in 
the context of individually guiding effective allopurinol dosage selection. Given that 
severe cutaneous reactions associated with allopurinol use is both dose and exposure 
dependent,260,261 targeting SUA levels with the benefit of knowledge of an individual’s 
genotype may provide additional rational for optimal dosage selection for allopurinol. The 
consistency of our observations with the proposed mechanistic role of rs505802 T>C 
within SLC22A12 both oxipurinol concentrations and overall response to allopurinol 
provide additional support for further studies to validate and assess the potential value of 
genetic guidance when prescribing allopurinol.  
Allopurinol is both a xanthine oxidase substrate and inhibitor. The changes in UA 
disposition parameters observed in the present study would be predictable based on this 
mechanism of action. Specifically, from Table 5.3, allopurinol reduced UA production 
without affecting its elimination. In general, most (90%) individuals with gout are 
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classified as UA underexcreters.70  In the present study, however, only 38% of study 
participants met the definition of UA underexcreters.  This observation raises questions 
about possible differences between populations in terms of the physiological basis for the 
etiology of and therefore possible differences in approaches to manage it.   
One significant barrier to using allopurinol in the Hmong relates to their 
perceptions of allopurinol’s ineffectiveness and/or perceived renal toxicity. Failure to 
overcome skepticism of Western medicine and unjust perceptions of toxicities may 
adversely affect medication adherence to allopurinol.26  Our findings of a mean increase in 
eCrCl of 5% (p=0.029) was consistent with the effect of long-term use of allopurinol on 
kidney function.262 Though it was a small improvement, it goes a long way toward 
addressing the unjust perceptions of allopurinol toxicity.  
In summary, the rs505802T>C within SLC22A12 significantly affects the 
disposition of oxipurinol and response to allopurinol in the Hmong. These findings of 
genetic basis to variability in response to allopurinol within the Hmong may translate into 
opportunities to address health disparities in prevalence and treatment of gout in the 
Hmong, while advancing precision medicine to a broader array of members of our society. 
Although validation of our findings is required, this trial demonstrated the role and value 
of forming a community partnership to uncover significant findings of genetic 
polymorphisms which modulate response to allopurinol. Once validated, such genetic 
findings may eventually form the basis for guidance of clinical decision tools to help 
manage Hmong and non-Hmong patients with gout. 
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Limitations  
Several limitations require acknowledgement. Although both men and women 
were recruited, only 3 women participated in this study. Although this limits the 
generalizability of our findings, it is not unexpected since gout is more prevalent in men 
than women and specifically Hmong men.17 As a pilot study to test the genetic basis of 
response to allopurinol, the study duration and sample collections were naturally limited. 
A short study duration precludes an evaluation of the long-term clinical outcomes 
of allopurinol therapy by genotype, yet was adequate to establish the effect of 
rs505802T>C within SLC22A12 on the pharmacokinetics and pharmacodynamics of 
allopurinol. Limitations which are common to studies of special populations, included our 
6-hour sampling scheme for blood and urine collection.  Based on other pharmacokinetics 
studies, we believe that the 6-hour window provides adequate measurement of data for our 
analysis of the principle endpoint of oxipurinol exposure by genotype while recognizing 
and respecting the guidance provided by the Hmong genomics board.  
Although we specifically designed this study to focus on rs505802T>C within 
SLC22A12, analysis of the majority of select allele frequencies in the study did not 
significantly differ from what is expected  in the Hmong population at large.79 Finally, 
while participants were encouraged to maintain a consistent diet and medication regiments 
during the study, we could not account for any dietary changes which may have occurred 
while taking allopurinol. Notably, two participants reported the use of indomethacin and 
losartan, which may affect UA disposition, however, their use of these medications were 
confirmed to be consistent. 
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Candidates who may qualify were invited to Visit 1 (V1) based on their 
response to an advertisement or interaction with a Hmong health care 
professional and or providing salivary DNA sample for genotyping 
 
Figure 5:1 GOUT-H Study Design Overview 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Candidates will be offered to participate in the study through phone calls or during clinic 
visits. Following an informed consent, targeting up to 50 participants with a maximum of 
100 will be screened for disease, genotype, and other laboratory exclusion criteria; health, 
nutrition, and medication histories will be obtained either through conducted 
questionnaires or documented health records. 
CC 
  
CT 
  
 
TT 
  
SLC22A12 (rs505802) T>C 
39 participants representing the 3 distinct genotype groups (CC, CT, TT) were invited after 
a washout period of 7-10 days of allopurinol or urate lowering drugs if applicable. Baseline 
study visit will involve estimation of baseline serum uric acid (SUA), serum oxipurinol, and 
fractional excretion of uric acid (FEUA). Two blood samples will be collected at 0 and 6 
hours and urine collected at 0 and 6 hours. We will conduct a qualitative focus group to 
ascertain their experiences with gout and gout medicines. Study medication allopurinol was 
dispensed at the end of this visit.  
Following 14 days of taking allopurinol, participants will return to clinics for 
measuring SUA, serum oxipurinol concentrations, and determining FEUA. During this 
visit, blood collections will take place at time points 0, 2, 4, and 6 and urine collections 
at 0 and 6 hours. 
Final Study Outcomes 
1. Characterize uric acid handling parameters 
in the Hmong 
2. SUA change (reduction) per genotype 
3. FEUA% per genotype 
4. Oxipurinol exposure (AUC0-6hr) per 
genotype 
SLC22A12 (rs505802) T>C 
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Figure 5:2 GOUT-H Flow Chart of Study Participants Enrollment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Community-Based 
Recruitment:  
Hmong Radio Ad, 
Word of mouth, Flyers  
  
Clinic-Based Recruitment:       
Physician guided phone calls, 
Patient-physician clinic encounter   
Screening  
   
Visit 1 
  
Visit 2 
  
Visit 0 
  
7-10 days of allopurinol or febuxostat 
  
2- eCrCl < 30mL/min 
39- Lost to contact, 
no longer interested, 
not otherwise meeting 
inclusion criteria  
1- No visit show  
1- Study drop-out   
1- Skin rash (AE) 4-7 days of allopurinol 100mg twice daily  
        
2- Poor adherence  
Final Analyses N=34 
Genotype 
 
Genotype 
 
Visit 3 
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Figure 5:3 Box plots of serum uric acid levels at enrollment (V1), pre-allopurinol (V2) and 
post-allopurinol (V3) at both 0hr and 6hr 
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Figure 5:4 Mean serum uric acid levels pre-and post-allopurinol 
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Figure 5:5 Serum uric acid pre-and post-allopurinol for all study participants 
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Figure 5:6 Serum uric acid pre-and post-allopurinol by genotype of rs505802 T>C 
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Figure 5:7 Mean absolute change in serum uric acid by genotype of rs505802T>C 
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Figure 5:8 UUA Excretion Rate Pre and Post Allopurinol 
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Figure 5:9 FEUA% Pre and Post-allopurinol    
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Figure 5:10 Box plots of estimated creatinine clearance (eCrCl) pre-allopurinol (V2) and 
post-allopurinol (V3) at 0hr using Cockcroft-Gault method 
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Figure 5:11 Oxipurinol area under concentration-time profile from 0 to 6 hours 
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Figure 5:12 Correlation of oxipurinol AUC0-6hr with creatinine clearance at V3 using 
simple linear regression 
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Figure 5:13 Correlation of absolute change in SUA (V2-V3) with 0xipurinol AUC0-6hr 
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Figure 5:14 Scatter plots of absolute change in Serum uric acid (V2-V3) by genotype of 
rs505802T>C 
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Figure 5:15 Scatter plot of oxipurinol AUC0-6hr by genotype of rs505802T>C 
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Figure 5:16 Mean (±SD) serum oxipurinol at 6-hour post allopurinol dose by genotype for 
rs505802. 
Mean (+ SD) serum oxipurionl at 6-hours post-allopurionl
SLC22A12 (rs505802T>C)
CC CT TT
Se
ru
m
 O
xi
pu
rin
ol
 m
g/
L
0
5
10
15
20
25
30
 
Analysis was conducted using One-Way ANOVA with Bonferroni correction for Post-
Hoc analysis with (p<0.05) for significance.  
 
 
 
 
P=0.005 
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Figure 5:17 Mean (±SD) renal oxipurinol clearance by genotype for rs505802. 
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𝑂𝑂𝑂𝑂𝑈𝑈𝑂𝑂𝑢𝑢𝑈𝑈𝑈𝑈𝑢𝑢𝑂𝑂𝑂𝑂 𝑅𝑅𝑢𝑢𝑢𝑢𝐶𝐶𝑂𝑂 𝐶𝐶𝑂𝑂𝑢𝑢𝐶𝐶𝑈𝑈𝐶𝐶𝑢𝑢𝑈𝑈𝑢𝑢 (𝑚𝑚𝑑𝑑/𝑚𝑚𝑈𝑈𝑢𝑢) =  𝑈𝑈𝑟𝑟𝑖𝑖𝑖𝑖𝑈𝑈 𝑂𝑂𝑂𝑂𝑖𝑖𝑂𝑂𝑆𝑆𝑟𝑟𝑖𝑖𝑖𝑖𝑇𝑇𝑇𝑇 (0−6) ℎ𝑟𝑟 (𝑚𝑚𝑚𝑚) 
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Analysis was conducted using One-Way ANOVA with Bonferroni correction for Post-
Hoc analysis with (p<0.05) for significance. 
 
 
 
 
P=0.013 
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Table 5:1 GOUT-H Demographics Results Summary (N=34) at Visit 1 
Characteristics  N (%)  Mean (±SD) Range  
Gender  
o Male 
o Female 
 
31 (91%) 
3 (9%) 
  
Age (years) 
o < 40 
o > 40 
 
13 (38%) 
21 (62%) 
43.5 (±12.7) 24 to 67 
Country of Birth 
o Laos 
o Thailand 
o US 
 
24 (70.6%) 
2 (5.9%) 
8 (23.5%) 
  
Highest Level of 
Education  
o ESL 
o High School 
o College  
o Graduate  
o Missing  
 
 
6 (17.6%) 
4 (11.8%) 
17 (50%) 
3 (8.8%) 
4 (11.8%) 
  
English Proficiency  
o Poor 
o Fair  
o Good  
o Excellent 
o Missing   
 
3 (8.8%) 
6 (17.6%) 
14 (41.2%) 
7 (20.6%) 
4 (11.8%) 
  
Immigration Year 
o 1970-1979 
o 1980-1989 
o 1990-1999 
o 2000-2009 
o Missing  
 
6 (23.1%) 
8 (30.1%) 
8 (30.1%) 
3 (11.5%) 
1 (3.8%) 
 1970 to 2009 
Years in the US  27 (±9.5) 6 to 45 
Smoking History  
o Never 
o Quit  
o Current   
 
27 (79.4%) 
4 (11.8%) 
3 (8.8%) 
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Table 5.1 Continued 
Characteristics  N (%)  Mean (±SD) Range  
Height (in)  
o < 60inches  
o > 60 inches  
 
5 (15%) 
29 (85%) 
62.8 (±2.7) 57.5 to 68 
 
 
BMI (Kg/M2) 
o < 18.5 
o 18.5 – 24.9 
o 25 – 29.9 
o 30 – 39.9 
o > 40 
 
0 (0%) 
2 (6%) 
7 (21%) 
23 (68%) 
2 (6%) 
32.5 (±5.4) 21.6 to 46.9 
Waist Circumference 
(inches)  
Males 
o < 40 
o > 40  
Females  
o < 35 
o > 35 
 
 
 
15 (48%) 
16 (52%) 
 
0 (0%) 
3 (100%) 
40.6 (±5.1) 
 
40.2 (±5.2) 
 
 
44.5 (±1.9) 
 
29.0 to 50.8 
 
29.0 to 50.8 
 
 
42.7 to 46.5 
Heart Rate (bpm)  76 (±12) 54 to 99 
Systolic Blood 
Pressure (mmHg) 
o < 140 
o > 140 
Diastolic Blood 
Pressure (mmHg)  
o < 90 
o > 90 
 
 
19 (56%) 
15 (44%) 
 
 
18 (53%) 
16 (47%) 
141 (±17) 
 
 
 
91 (±12) 
114 to 182 
 
 
 
69 to 121 
eCrCl (mL/min)  
o eCrCL > 
60mL/min 
o eCrCl < 
60mL/min 
 
23 (65%) 
11 (35%) 
74 (±26) 39 to 148 
Self-reported health 
conditions  
o Gout  
o Kidney stone  
o Diabetes  
o Hypertension 
o Hyperlipidemia  
o Heart attack  
o Stroke  
o Others 
 
 
23 (68%) 
4 (12%) 
7 (21%) 
14 (41%) 
13 (38%) 
3 (9%) 
2 (6%) 
2 (6%) 
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Table 5.1 Continued    
Participants reported medication use 
o XOI 
o Colchicine  
o NSAID 
o Opioid  
o Corticosteroids 
o ACE-I 
o ARBs 
o B-blockers  
o CCB  
o Diuretics  
o LLT 
o Antidiabetic  
o Non-insulin  
o Insulin  
o PPI 
o Sucralfate 
o Aspirin  
o Anticoagulant 
o Vasodilator  
o Antidepressants  
o Hypothyroid therapy  
o Nitrate 
o H1RA 
o *Others  
 
19 (56%) 
8 (24%) 
13 (38%) 
10 (29%) 
9 (26%) 
7 (21%) 
2 (6%) 
6 (18%) 
5 (15%) 
4 (12%) 
7 (21%) 
 
9 (26%) 
4 (12%) 
7 (21%) 
1 (3%) 
7 (21) 
1 (3%) 
2 (6%) 
6 (18%) 
1 (3%) 
1 (3%) 
2 (6%) 
19 (56%) 
  
XOI: Xanthine Oxidase Inhibitor  
NSAID: Non-steroidal anti-inflammatory drug   
ACE-I: Angiotensin converting enzyme inhibitor  
ARBs: Angiotensin receptor blockers 
CCB: Calcium channel blocker  
LLT: Lipid lowering therapy  
PPI: Proton pump inhibitor  
H1RA: Histamine 1 receptor antagonist 
*Predominantly supplements, non-western and non-FDA approved drugs  
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Table 5:2 Participants biochemical laboratory results 
Serum 
Biochemistry  
Baseline (N=34) 
Mean + (SD) 
Median [range] 
Pre-Allopurinol (N=34) 
Mean + (SD) 
Median [range] 
Post-Allopurinol (N=34) 
Mean + (SD) 
Median [range] 
ALT (U/L) 31.62 ± 18.07 
26.0 [13.0 – 89.0] 
 30.71 ± 14.78 
26.0 [12.0 – 67.0] 
AST (U/L) 24.79 ± 12.34 
21.0 [13.0 – 63.0] 
 24.44 ± 8.89 
22.50 [12.0 – 46.0] 
BILT (mg/dL) 0.48 ± 0.24 
0.4 [0.2 – 1.1] 
 0.46 ± 0.18 
0.4 [0.2 – 1.0] 
BUN (mg/dL) 17.15 ± 4.83 
18.0 [9.0 – 28.0] 
 17.41 ± 5.67 
16.0 [8.0 – 32.0] 
GLU (mg/dL) 144.76 ± 99.30 
100.5 [67.0-464.0] 
 116.59 ± 57.34 
97.5 [69.0 – 320.0] 
HCT (%) 42.27 ± 6.63 
43.1 [11.6 – 49.6] 
 42.25 ± 3.76 
42.45 [26.7 – 47.9] 
HGB (g/dL) 14.54 ± 1.51 
14.8 [9.1 – 16.6] 
 14.13 ± 1.52 
14.25 [7.4 – 16.3] 
PLT (x10e9/L) 228.97 ± 51.40 
233.0 [68.0 –332.0] 
 232.62 ± 51.57 
226.00 [159.0 – 385.0] 
WBC (x10e9/L) 7.21 ± 2.00 
7.65 [2.80 – 10.30] 
 8.63 ± 2.23* 
8.65 [4.90 – 13.60] 
K (mmol/L) 4.01 ± 0.36 
4.10 [3.10 – 4.60] 
 4.17 ± 0.33 
4.20 [3.50 – 4.80] 
Na (mmol/L) 138.15 ± 2.81 
139.0 [131.0 –143.0] 
 139.44 ± 2.58 
139.0 [135.0 – 144.0] 
SCR (mg/dL) 1.08 ± 0.24 
1.03 [0.60 – 1.59] 
  
SCR (mg/dL) 0hr  1.10 ± 0.30 
1.00 [0.70 – 2.30] 
1.04 ± 0.24 
0.99 [0.63 – 1.72] 
SCR (mg/dL) 6hr  1.10 ± 0.3 
1.0 [0.7 – 2.2] 
1.06 ± 0.28 
0.99 [0.62 – 1.94] 
SUA (mg/dL) 9.05 ± 1.92 
9.25 [4.70 – 13.0] 
  
SUA (mg/dL) 0hr  9.40 ± 1.70 
9.70 [5.80 – 13.00] 
5.81 ± 1.16* 
5.95 [3.60 – 7.80] 
SUA (mg/dL) 6hr  9.30 ± 1.50 
9.60 [5.80 – 12.80] 
5.32 ± 1.09* 
5.60 [3.10 – 6.90] 
eCrCl (mL/min) 74 ± 26 72 ± 26 76 ± 26* 
* Indicates statistical significant (p<0.05) between V1 and V3 or V2 and V3 
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Table 5:3 Uric acid parameters pre-and post-allopurinol therapy (N=34) 
Parameter Pre-Allopurinol (V2) (0-6) 
hr 
Post-Allopurinol (V3) (0-6) 
hr 
P-value 
Mean + (SD Mean + (SD) 
UUE Rate 
(mg/min/1.73 m2) 0.38 + (0.14) 0.20 + (0.08) <0.0001 
UCrE Rate 
(mg/min/1.73 m2) 0.79 + (0.22) 0.82 + (0.26) 0.419 
CLR(UA) (mL/min) 7.10 + (2.61) 6.15 + (2.04) 0.042 
FEUA % 6.49 + (3.60) 4.88 + (2.14) <0.0001 
Urine Spot Ratio 
(UUA/UCr) 
0.54 + (0.22) 0.26 + (0.13) <0.0001 
UUE= Urinary Uric Acid Excretion  
UCrE= Urinary Creatinine Excretion   
FEUA= Fractional Excretion of Uric Acid 
CLR(UA)= Uric Acid Renal Clearance 
UUA= Urine Uric Acid 
UCr= Urine Creatinine  
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Table 5:4 Pharmacodynamics summary of allopurinol by genotype 
SLC22A12 
(rs505802T>C) 
Count Mean SUA (mg/dL) (±SD) 
Pre-allopurinol  Post-allopurinol  Absolute Change 
CC  14 9.80 (±1.45) 5.19 (±1.19) 4.21 (±1.6) 
CT  14 9.26 (±1.54) 5.32 (±0.98) 3.94 (±1.2) 
TT 5 8.96 (±0.47) 5.92 (±1.01) 3.04 (±1.0) 
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Table 5:5 Pharmacodynamics summary of allopurinol by genotype 
SLC22A12 (rs505802) 
Genotype 
Mean ± (SD) Range 95% CI P-value* 
 Oxipurinol AUC0-6hr (mg*hr/L) 
CC (n=14) Reference 107.1± (36.0) 64.1-176.6 89.5 to 130.9  
CT (n=14) 77.5± (23.9) 43.3-118.2 63.7 to 91.3 0.032 
TT (n=5) 49.7 ± (10.5) 39.9-65.6 36.6 to 62.8 0.002 
 Oxipurinol C0hr (mg/L) 
CC (n=14) Reference 15.7 ± (6.7) 5.8-28.0 11.8 to 19.6  
CT (n=14) 11.0 ± (3.9) 4.3-17.5 8.7 to 13.3 0.046 
TT (n=5) 6.9 ± (1.7) 5.2-9.4 4.8 to 9.0 0.005 
 Oxipurinol C6hr (mg/L) 
CC (n=14) Reference 17.3 ± (6.3) 8.5- 28.4 13.7 to 20.9  
CT (n=14) 12.7 ± (4.0) 6.4-19.5 10.4 to 15.0 0.064 
TT (=5) 8.5 ± (2.3) 6.7-12.3 5.6 to 11.4 0.006 
 Oxipurinol Renal Clearance (mL/min) 
CC (n=14) 12.8 ± (5.2) 3.9-24.2 9.8 to 15.8 0.01 
CT (n=14) 13.8 ± (3.6) 9.0-20.0 11.7 to 15.6 0.03 
TT (n=5) Reference 19.9 ± (3.6) 15.9-23.6 15.4 to 24.4  
*One-Way ANOVA followed by Bonferroni t-test for Post-hoc analysis with P<0.05 for 
significance  
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Table 5:6 Stepwise multiple Linear Regression summary model 2 
Independent Variable Beta Coefficient P-value R2 Adjusted R2 
Constant -4.828 0.001 
0.71 0.67 
V2 SUA6hr 0.34 0.004 
Oxipurinol AUC (0-6) hr 0.04 <0.001 
V3 eCrCl (mL/min) 0.021 0.009 
SLC22A12 (rs505802T>C) 0.68 0.013 
Note: SNP rs505802 was analyzed using an additive model. The rs505802 T>C was coded 
in the following manner: TT=0, CT=1 and CC=2 
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Table 5:7 Base-model and final model Summaries 
Model R R2 Adjusted 
R2  
Std. Error of 
the Estimate 
Change Statistics 
R2 
Change 
F 
Change 
df1 df2 Sig. F 
Change 
1 0.797a 0.636 0.596 0.8781 0.636 16.275 3 28 0.000 
2 0.843b 0.711 0.668 0.7966 0.075 7.021 1 27 0.013 
a. Predictors: (Constant), eCrCl V3(mL/min), V2 SUA6hr, Oxi_AUC (0-6) hr 
b. Predictors: (Constant), eCrCl V3(mL/min), V2 SUA6hr, Oxi_AUC (0-6) hr, SLC22A12_ rs505802 
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Table 5:8 Uric acid disposition genes included in the analyses of GOUT-H study 
Gene Chromosome Protein Function Reference 
SLC22A12 11q13.1 URAT1 Uric acid reabsorption 80,191,205,263 
ABCG2 4q22.1 BCRP Uric acid secretion 86,165,208,264 
SLC2A9 4p16.1 GLUT9 Uric acid reabsorption 80,190,265 
PDZK1 1q21.1 PDZK1 Scaffolding protein 80 
SLC22A11 11q13.1 OAT4 Uric Acid reabsorption 80,85 
SLC17A1 6p22.2 NPT1 Uric acid secretion 80,204,205 
SLC16A9 10q21.2 MCT9 Uric acid reabsorption  
XDH 2p23.1 Xanthine 
Dehydrogenase 
Uric acid production 
and allopurinol 
metabolism 
266 
AOX1 2q33.1 Aldehyde Oxidase1 Uric acid production 
and allopurinol 
metabolism 
266 
MOCOS 18q12.2 Molybdenum 
Cofactor Sulfurase 
XDH and AOX1 
cofactor 
266 
LRRC16A 6p22.2 CARMIL1 Actin capping protein 
inhibitor 
80,209 
GCKR 2p23.3 Glucokinase 
Regulator 
Glucose metabolism 80,193,205 
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Table 5:9 SNP frequency comparisons of serum uric acid transporter genes 
Gene (SNP) Genotype 
GOUT-H 
Study 
Hmong Reference 
Cohort79 P-value 
N % N % 
SLC2A9 
(rs1014290) 
CC 
CT 
TT 
Total 
2 
10 
22 
34 
5.9% 
29.4% 
64.7% 
 
16 
107 
104 
227 
7.1% 
47.1% 
45.8% 
 
0.115 
SLC2A9 
(rs3733591) 
AA 
GA 
GG 
Total 
6 
21 
7 
34 
17.6% 
61.8% 
20.6% 
 
77 
112 
38 
227 
33.9% 
49.3% 
16.7% 
 
0.164 
SLC16A9 
(rs2242206) 
GG 
GT 
TT 
Total 
5 
22 
7 
34 
14.7% 
64.7% 
20.6% 
 
55 
114 
62 
231 
23.8% 
49.4% 
26.8% 
 
0.236 
SLC17A1 
(rs1183201) 
AA 
AT 
TT 
Total 
1 
5 
28 
34 
2.9% 
14.7% 
82.4% 
 
6 
61 
162 
229 
2.6% 
26.6% 
70.7% 
 
0.272 
SLC22A11 
(rs173007410) 
AA 
AG 
GG 
Total 
32 
2 
0 
34 
94.1% 
5.9% 
0% 
 
202 
27 
1 
230 
87.8% 
11.7% 
0.4% 
 
0.471 
SLC22A12 
(rs505802) 
CC 
CT 
TT 
Total 
15 
14 
5 
34 
44.1% 
41.2% 
14.7% 
 
100 
93 
34 
227 
44.1% 
41.0% 
15.0% 
 
1.00 
ABCG2 
(rs2231137) 
AA 
AG 
GG 
Total 
6 
16 
12 
34 
17.6% 
47.1% 
35.3% 
 
64 
119 
46 
229 
27.9% 
52.0% 
20.1% 
 
 
0.110 
ABCG2 
(rs2231142) 
AA 
CA 
CC 
Total 
8 
14 
11 
33 
24.2% 
42.4% 
33.3% 
 
32 
101 
98 
231 
13.9% 
43.7% 
42.4% 
 
0.266 
ABCG2 
(rs2725220) 
GG 
CG 
CC 
Total 
27 
7 
0 
34 
79.4% 
20.6% 
0% 
 
181 
47 
3 
231 
78.4% 
20.3% 
1.3% 
 
1.00 
P<0.05 for statistical significance  
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Table 5:10 SNP frequency comparisons of serum uric acid non-transporter genes 
Gene (SNP) Genotype GOUT-H Study 
Hmong Reference 
Cohort79 P-value 
N % N % 
PDZK1 
(rs12129861) 
AA 
AG 
GG 
Total 
7 
7 
19 
33* 
21.2 
21.2 
57.6 
 
27 
97 
105 
229 
11.8 
42.4 
45.9 
 
0.048 
XDH 
(rs4407290) 
GA 
GG 
Total 
2 
32 
34* 
5.9 
94.1 
 
9 
218 
227* 
4.0 
96.0 
 
0.641 
AOX1 
(rs3731722) 
TC 
TT 
Total 
4 
30 
34* 
11.8 
88.2 
 
21 
208 
229* 
9.2 
90.8 
 
0.544 
MOCOS 
(rs594445) 
AA 
CA 
CC 
Total 
1 
7 
26 
34 
2.9 
20.6 
76.5 
 
5 
36 
187 
228 
2.2 
15.8 
82.0 
 
0.495 
LRRC16A 
(rs742132) 
AA 
GA 
GG 
Total 
19 
13 
2 
34 
55.9 
38.2 
5.9 
 
171 
55 
4 
230 
74.3 
23.9 
1.7 
 
 
0.041 
GCKR 
(rs780094) 
CC 
TC 
TT 
Total 
12 
16 
6 
34 
35.3 
47.1 
17.6 
 
117 
96 
18 
231 
50.6 
41.6 
7.8 
 
0.089 
* Indicates SNP was not in a Hardy-Weinberg equilibrium 
P<0.05 for statistical significance 
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Chapter 6  
Concluding Summary and Futures Direction 
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Overall Conclusions: 
The Minnesota Hmong community is a migrant minority group that came from the 
southern parts of China, Laos, and Thailand after becoming allies with the US during the 
Vietnam war. The Minnesota Hmong presents with a differential prevalence of select 
health conditions than non-Hmong pressing clear health disparity concerns within the 
community. The Hmong population is an ideal population for genetic-based studies due to 
their apparently low admixing rates and high cultural identity due to their strong social 
norms and highly structured clan system. Additionally, the high prevalence of certain 
health conditions in the Hmong community further augments the opportunity to identify 
genetic signatures or patterns associated with the manifestation of those health conditions. 
This expanded knowledge of disease-gene relationship can serve as a proof of concept for 
study designs that can be applied to other populations and ultimately addressing such 
health disparities in this unique populations.  
The Hmong in Minnesota present with a differential prevalence of some health 
conditions relative to the average US population, particularly hyperuricemia and gout, as 
explored in this dissertation. While the prevalence of these health conditions can be partly 
due to a genetic predisposition for these conditions cannot be ignored. Some of these 
factors could be related to cultural concepts of health, perception of illness, concepts about 
disease management, prior reactions to Western medicine, religious beliefs, such as 
reincarnation, and historical immigration to the US as refugees, which may all play roles 
in affecting disease rates and influencing people’s behaviors towards Western 
biomedicine. As these layers of social and cultural determinants of health affect the 
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Hmong residing in Minnesota, research conducted within this unique community involves 
careful and delicate design to account for such factors that are as important as 
understanding the genetics and non-genetic factors that increase their risk for these 
conditions. 
Community-based participatory research (CBPR) model serves as an ideal 
approach to addressing pressing health needs in the Hmong community, identifying means 
to reduce health disparities and strengthening the partnership between the Hmong 
community and researchers at the University of Minnesota. Moreover, this approach 
empowers the community to influence the trajectory of the research track within the 
community while providing guidance on the cultural appropriateness of the study design 
and engaging community stakeholders to ensure the inclusivity of the community at large.  
Applying the principles of CBPR and guided by an established Hmong Gout Research 
Board, the Hmong community identified gout as a health condition worthy of study due to 
its significant impact on their community. In fact, the Hmong do not only have a 
significantly higher prevalence of gout than non-Hmong but also present with the more 
severe forms of gout and more gout comorbidities. The impression by members of the 
community is confirmed with studies that reported the high prevalence of gout in Hmong 
compared to non-Hmong (6.5 vs 2.9%) and especially Hmong men compared to non-
Hmong counterparts (11.5 vs 4.1%).  Thus, they expressed interest in collaborating with 
researchers to better understand what makes them different and how we may collaborate 
to help reduce patient suffering from this condition.  
Collectively, the national and global prevalence of gout is trending upward, which 
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may be in part due to trends such as an increase in life expectancy, higher global 
consumption of alcohol and fructose corn syrup and other factors. In addition, trends 
identifying an increased prevalence of obesity and metabolic syndrome which appear to be 
associated with increased incidence of gout. While select drugs, diet, and lifestyle play a 
major role in the development of hyperuricemia and gout, genetic variations in the 
pathway of uric acid production and disposition substantially contribute to these 
conditions, which explain their high degree of heritability.  
Genetic explorations of the prevalence of risk alleles associated with certain 
diseases and drug responses in the Hmong have allowed us to conclude that the Hmong 
are a unique population that is genetically distinct from other Asian groups while being 
radically different from Caucasians. In earlier chapters, we document that the Hmong to 
have a higher prevalence of the risk alleles associated with hyperuricemia and gout as well 
as different allele frequencies of clinically established drug-gene pairs.  The observations 
of hyperuricemia and gout risk alleles in the Hmong parallel the documented higher 
prevalence of these two conditions in the Hmong community than the rest of the US 
population. Additionally, our genetic analysis results further distinguish the Hmong from 
Caucasians and highlights a distinction between the Hmong (who are generically 
described as Chinese descendants) and the Han-Chinese, the most concordant racial and 
ethnic group to the Hmong.  
Studying special populations through clinical research is critical to the 
advancement of precision medicine and reaching the goal of tailored therapy to optimize 
treatment outcomes. Engaging the Hmong in genetic and pharmacogenetic-based studies 
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is a key first step to not only advance the precision medicine initiative but also provide the 
means to reduce, if not close, the health disparities gaps (disease prevalence, access to 
healthcare, healthcare literacy, healthcare quality) between the Hmong and non-Hmong in 
Minnesota.  
In general, the response to drugs is marked with a substantial intra and inter-patient 
variability. While important sources of variability in response to drugs could be affected 
by the individual’s lifestyle (smoking, alcohol consumption, physical activity, dietary 
restriction), concomitant use of other drugs and existing health conditions, it is well 
characterized that genetic factors may also play a significant role in this variability.  For 
example, response to clinically relevant drug therapies can be significantly affected by an 
individual’s genotype for select genes affecting its disposition and elimination. 
Consequently, the absence of pharmacogenetic knowledge about the Hmong presents as a 
healthy disparity of knowledge that could lead to sub-optimal management of their health 
conditions or super-therapeutic dosing that could lead to adverse events. Of course, this 
would be true only if there were substantive differences between the Hmong and other 
populations for allele frequencies of very important pharmacogenes. Indeed, this appears 
to be the case in Minnesota Hmong.  Preliminary assessment of the pharmacogenes in the 
Hmong suggests the Hmong present as a distinct patient population that would require 
different dosing requirements for the drug warfarin relative to Caucasians based on 
CYP2C9 and VKORC1. The genetic variations within the warfarin response genes in the 
Hmong are clearly distinct from Caucasians and indicate that some Hmong patients may 
well require a lower starting dose than Caucasians counterparts. Additionally, the 
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prevalence of the CYP2C19*2/*3 indicates that approximately 58% of the Hmong would 
not be candidate for using clopidogrel. Collectively, the absence of this information can 
negatively and disproportionally widen the gap of health disparities between the Hmong 
and non-Hmong. 
The Genetics Of HyperUricemia Therapy in Hmong (GOUT-H) study represents 
the epitome of a partnership between the Minnesota Hmong community and University of 
Minnesota researchers to address a community-identified health disparity in the Hmong 
community. It also provides a proof of concept for the feasibility of conducting a 
pharmacogenetic-based pilot study involving a culturally unique population that is 
minimally represented in clinical and genetic research using CBPR. Using the candidate 
gene approach, GOUT-H provides proof of concept for the role of genetic polymorphisms 
in the pathway of uric acid disposition.  Not only do these key genes predict the risk of 
hyperuricemia and gout, but also the therapeutic response to allopurinol, which is 
extensively used to treat both conditions. 
We have shown that allopurinol is an effective urate-lowering therapy in the 
Hmong with hyperuricemia or gout. Using comparable allopurinol dosing, the Hmong had 
a higher average of serum uric acid reduction (41%) than other reports within other 
populations (32%), despite achieving lower serum oxipurinol levels compared to the 
suggested therapeutic levels. This observation highlights the role of genetic polymorphism 
in the URAT1 gene (SLC22A12) transporter, which is a major transporter for oxipurinol 
reabsorption back to into circulation. This further supports the contribution of the URAT1 
gene as it does not only modulate the risk for developing hyperuricemia and gout, but it 
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also serves as a marker for the response to allopurinol. Evidently, the work conducted on 
determining the therapeutic range of oxipurinol levels to achieve the target serum uric acid 
did account for the genetic polymorphisms in the URAT1 transporter gene, which explains 
higher serum uric acid reduction despite lower serum oxipurinol. Furthermore, the 
populations studied for determining optimal oxipurinol levels were mostly Caucasians 
who are known to have a higher prevalence of the T allele for the rs505802 T>C within 
the SLC22A12, which is associated with lower exposure to oxipurinol. This validates our 
central hypothesis of the C allele for rs505802 T>C within the SLC22A12 is associated 
with different oxipurinol pharmacokinetics (PK) and pharmacodynamics (PD) than the T 
allele. This is consistent with our findings of individuals of the TT genotype to have the 
oxipurinol AUC and lowest reduction of serum uric acid but the highest renal clearance of 
the oxipurinol compared with the CT and CC genotype.  
Although the GOUT-H study provided a genetic-based evidence to the differential 
response to allopurinol, the relatively short duration of our study (2 weeks of therapy) 
precludes us from making solid predictions regarding the long-term outcomes of 
allopurinol therapy across the different genotypes of patients with the rs505802 T>C. 
However, we believe that achieving the target serum uric acid < 6mg/dL is a strong 
predictor of positive treatment outcomes and based on our short-term observations, the 
likelihood is high that it may be maintained.  
Finally, one of the major barriers to achieving optimal management of gout across 
all populations is the patients’ potential lake of adequate understanding of the 
pathogenesis of gout and need for chronicity of uric acid lowering therapy to prevent 
 207 
subsequent gout attacks.  Failure to comprehend that vulnerable patients are chronically at 
risk for hyperuricemia and subsequent acute gout attacks unless changes in lifestyle and 
diet are implemented as well as chronically taking their urate lowering drugs will render 
gout a sub-optimally controlled disease. Specifically, many Hmong and non-Hmong 
patients with gout do not fully appreciate the importance of preventative steps to avoid 
acute gout attacks. Rather, patients with gout not taking chronic preventive medicine often 
become desperate and focused on resolution of acute gout attacks rather than preventative 
urate-lowering therapies. In doing so, they tend to use different analgesic drugs, OTC 
items, dietary supplements, or alternative medicine products that promise to “naturally 
alleviate” their pain. In fact, some GOUT-H Hmong participants reported they would 
rather deal with the acute gout attack than taking a drug daily, especially when they are 
asymptomatic.  This was discovered to be in part, due to the negative perception that using 
a long-term medication could damage their bodies, especially their kidneys.  Dispelling 
such a belief plays a significant role in effectively managing gout in this community. 
Hesitancy to use chronic medications out of fear that they may cause kidney 
damage further complicates the management of gout in the Hmong population. Therefore, 
education on management of chronic diseases is critical and may, in fact, change the 
adherence to patient’s medications or study drug in our example. In the GOUT-H study, 
we implemented different techniques to help adherence and educate patients on the role of 
the chronic use of allopurinol vs. acutely to better manage their gout. These techniques 
included a medical presentation about gout by a Hmong primary care provider, targeted 
focus groups on the perception and management of gout and delivering patient reminders, 
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all of which may explain the high mean adherence rate observed in our GOUT-H study. 
Future directions 
Patient and physician education remain an area for a substantial improvement. 
From a primary care perspective, many physicians are apprehensive to initiate urate-
lowering therapies in patients who have experienced their first gout attack. In fact, most 
patients are only started on chronic urate-lowering therapies by their second or third 
experience of a gout attack. Patient and clinician education about the optimal management 
of gout is needed.  This is particularly true as gout often co-presents with multiple 
comorbidities such as hypertension, declining kidney function and metabolic syndrome all 
of which substantially contribute to morbidity and mortality if sub-optimally treated. 
Therefore, a study to compare the effect of early vs. delayed sustained initiation of urate-
lowering therapy on the long-term gout treatment outcomes is warranted.  
Gout is generally preceded by chronic hyperuricemia. However, treatment of 
asymptomatic hyperuricemia is not done clinically. Nonetheless, hyperuricemia has been 
shown to result in multiple comorbidities such as hypertension, chronic kidney disease, 
obesity and metabolic syndrome. Moreover, lowering serum acid in pre-hypertension 
adolescents using allopurinol 200mg twice daily has shown to significantly reduce systolic 
and diastolic blood pressure. Similarly, we noted a mild improvement in kidney function 
following 2 weeks of allopurinol therapy. These reports are suggesting that reducing 
serum uric below saturation levels (< 6.8mg/dL) can reap health benefits in some high-risk 
patients. Therefore, a long-term prospective randomized controlled trial can provide the 
answer to the risk/benefit ratio of treating individuals with serum uric acid higher above 
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saturation levels.  
Allopurinol remains the mainstay for the treatment of gout though it has been 
associated with rare but severe allergic reactions such as severe cutaneous adverse 
reactions (SCAR) or Steve-Johnson Syndrome. Although these reactions have been 
strongly linked to genetic polymorphisms within the HLA-B58:01, preemptive testing for 
this polymorphism is rarely done especially in populations with such low allele 
frequencies. Furthermore, some reports have also linked the starting dose of allopurinol 
and reduced kidney function as significant covariates in for the development of these 
adverse reactions. From the GOUT-H study, specifically, the role of the genetic 
polymorphism of rs505802T>C in the SLC22A12 as oxipurinol exposure modulator, 
suggest that URAT1 genotype may contribute to the overall risk of SCAR. This may 
represent a plausible hypothesis for SCAR risk stratification as “elevated or lowered” in 
individuals with different genotypes, which are significantly associated with oxipurinol 
exposure, a major predictor for SCAR.  
GOUT-H was conducted prospectively using a candidate gene approach and its 
effect on allopurinol response in the Hmong, however, others have used the GWAS 
approach to identify genetic variations associated with response to allopurinol mainly in 
Caucasians and Hispanics. While the nonsynonymous   rs2231142 ABCG2 A>C (Q141K) 
was found to associated with response to allopurinol, the same group failed to provide a 
physiological or in-vitro model to support this association and did not provide any PK 
information to support their findings. GOUT-H study, however, is the first to investigate 
the role of rs505802 T>C within the SLC22A12 on oxipurinol PK and PD. This effect 
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needs to be validated in different population cohorts to tease out other population-specific 
genetics from the true effect of rs505802 T>C on the response to allopurinol. Ultimately, 
these validations will provide the evidence to whether this SNP could serve as a genetic 
marker for the selection of allopurinol in patients with gout.  
While GOUT-H showed PK and PD differences in the response to allopurinol 
based on the SLC22A12 genotype for the rs505802 T>C, a long-term study about the 
effect of those differences on the management of gout is needed. This could address the 
question of whether genetic-based differences in response to allopurinol are also 
associated with different patient treatment outcomes, such as frequency of gout flares and 
new onset of comorbidities that are commonly associated with long-standing 
hyperuricemia and gout.  
Although the assessment of the effect of Hmong diet on the high prevalence of 
gout in the Hmong is lacking, some reports have shown that the traditional Hmong diet 
may be considered as uric acid-prone diet.  A systematic evaluation of the typical Hmong 
diet in the context of hyperuricemia and gout is critical in assessing the contribution of 
diet and lifestyle to the overall prevalence of gout in this unique population. This 
assessment will also help address the interaction between the high prevalence of 
hyperuricemia and gout risk alleles in the Hmong and their respective diet.  
Finally, a comparative efficacy assessment between the most commonly used 
urate-lowering therapies based on genetics and gout phenotype in the Hmong community 
will help advance the precision medicine of hyperuricemia and gout for the Hmong, as 
well as advance our approach for managing a very long known heath condition in other 
 211 
populations. The impact of these present and future research endeavors will ultimately 
help the Minnesota Hmong reach their full potential as an integral of the community, 
reduce burden of health disparity on the society and improve the health wellness of the 
public at large.  
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Criteria for the diagnosis of gout 267 
I Monosodium urate crystals identified in joint fluid, or 
II Tophus containing monosodium urate crystals, or 
III Any 6 of the following 12 criteria: 
 1. more than one attack of acute arthritis 
2. maximal inflammation developed within 1 day 
3. mono-arthritis 
4. redness observed over joint 
5. first metatarso-phalangeal joint painful or swollen 
6. unilateral first metatarso -phalangeal joint attack 
7. unilateral tarsal joint attack 
8. suspected tophus 
9. hyperuricemia 
10. asymmetric swelling of joint on X-ray 
11. subcortical cysts without erosion on X-ray 
12. joint fluid culture negative for organisms 
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Uric acid parameters pre-and post-allopurinol therapy (N=32) 
Parameter Pre-Allopurinol (V2) 
(0-6) hr 
Post-Allopurinol (V3) 
(0-6) hr 
P-value 
Mean + (SD) Mean + (SD) 
UUE Rate 
(mg/min/1.73 m2) 0.37 + (0.14) 0.20 + (0.08) <0.0001 
UCrE Rate 
(mg/min/1.73 m2) 0.80 + (0.21) 0.82 + (0.26) 0.419 
CLR(UA) (mL/min) 6.94 + (2.45) 6.13 + (2.10) 0.078 
FEUA % 5.75 + (2.03) 4.63 + (1.73) <0.0001 
Urine Spot Ratio 
(UUA/UCr) 
0.50 + (0.16) 0.26 + (0.13) <0.0001 
This table summarizes the analysis of only 32 participants of GOUT-H study after 
excluding the two participants who were taking losartan and indomethacin. As shown in 
the table, the renal clearance of acid is no longer significant between pre-and post-
allopurinol. See table 5.3 for comparison.  
 
UUE= Urinary Uric Acid Excretion  
UCrE= Urinary Creatinine Excretion   
FEUA= Fractional Excretion of Uric Acid 
CLR(UA)= Uric Acid Renal Clearance 
UUA= Urine Uric Acid 
UCr= Urine Creatinine  
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UUA Excretion Rate Pre and Post Allopurinol (N=32)
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These box plots summarize the distribution urinary uric acid excretion of only 32 
participants of GOUT-H study after excluding the two participants who were taking 
losartan and indomethacin. See figure 5.9 for comparison   
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FEUA% Pre and Post Allopurinol (N=32)
Pre Allopurinol Post Allopurinol
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These box plots summarize the distribution fractional excretion of uric acid of only 32 
participants of GOUT-H study after excluding the two participants who were taking 
losartan and indomethacin. See Figure 5.11 for comparison.   
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  Oxipurinol Concentration 0-hr 
<10mg/L (n=13) >10mg/L (n=20) 
SUA Absolute change (mean + SD) 3.3 (1.2) mg/dL 4.6 (1.4) mg/dL* 
% SUA reduction (mean + SD) 36.2 (10.0) % 44.9 (11.7) % 
Genotype counts 5 TT, 6 CT, 2 CC 8 CT, 12 CC* 
N (%) with SUA < 6mg/dL 7 (54%) 16 (80%) 
 Oxipurinol Concentration 6-hr 
 <15 mg/L (n=22) > 15 mg/L (n=11) 
SUA Absolute change (mean + SD) 3.6 (1.4) mg/dL 5.1 (1.1) mg/dL* 
% SUA reduction (mean + SD) 36.9 (10.4) % 50.5 (8.4) % 
Genotype counts 5 TT, 11 CT, 6 CC 3 CT, 8 CC* 
N (%) with SUA < 6mg/dL 12 (55%) 10 (91%) 
* Indicates statistical significance p<0.05 
Oxipurinol Parameter      
(mean + SD) 
Participants with SUA < 
6mg/dL (V3) (n= 23) 
Participants with SUA > 
6mg/dL (V3) (n= 10) 
AUC
0-6hr
 (mg*hr/L) 94 (36) 67 (23) 
0-hr Concentration (mg/L) 13.7 (6.3) 9.4 (3.7) 
6-hr Concentration (mg/L) 15.3 (6.1) 11.1 (3.6) 
 
SLC22A12 
(rs505802T>C)  
Participants with SUA < 
6mg/dL (V3) (n= 23) 
Participants with SUA > 
6mg/dL (V3) (n= 10) 
TT 2 (9%) 3 (30%) 
CT 11 (48%) 3 (30%) 
CC 10 (44) 4 (40%) 
Fisher’s exact test with p= 0.37 
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Absolute SUA Change Stepwise Regression Models beta-coefficients* 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t-statistic Significance 
Beta Std. 
Error 
Beta 
1 (Constant) -3.326 1.286  -2.587 .015 
V2 SUA6hr .335 .121 .340 2.769 .010 
Oxi_AUC (0-6) hr .031 .006 .784 4.819 .000 
CrCl V3(ml/mi) .019 .008 .357 2.267 .031 
2 (Constant) -4.828 1.297  -3.722 .001 
V2 SUA6hr .342 .110 .348 3.117 .004 
Oxi_AUC (0-6) hr .040 .007 1.011 5.925 .000 
CrCl V3(ml/mi) .021 .008 .402 2.797 .009 
SLC22A12_ 
rs505802T>C 
.680 .257 .341 2.650 .013 
*Dependent Variable: SUA6hr (V2-V3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
